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iAbstract
Research into the causes and roots of inflammation has provided a vast literature 
from which to draw. In spite o f this data, major human diseases such as rheumatoid 
arthritis or the effects o f sepsis following injuiy continue to cause suffering and 
sometimes death.
Research has led to several main contenders for the title o f “protein at the top of 
the inflammatory cascade ” but again, reading the vast knowledge that others have 
uncovered, it is plain to see that there are redundancies, and a legion of control 
mechanisms operating to join all the major cytokines and cell types that constitute the 
mammalian inflammatory response. Amongst one of the recently pro-inflammatory 
proteins is Interleukin-15. (EL-15)
IL-15 was discovered in 1994 and has since been associated with up-regulation of 
inflammation and postulated as a controller of tumour necrosis factor alpha. The EL-15 
protein is similar in structure to the EL-2 protein in several mammalian species. However 
in spite o f its structural homology, there is little or no sequence homology with IL-2.
The experiments here are performed in the murine models of human diseases. The 
murine EL-15 shares approx 73% sequence homology with the human EL-15.
Thus this project set out to clone what at the time, was commercially unavailable, namely 
murine recombinant EL-15 and to raise antibodies against this protein. It was the intention 
to use these antibodies as therapeutic agents in three murine models of inflammation; the 
Collagen Induced model, the LPS shock model o f sepsis and finally the septic arthritis 
model.
i
Recombinant murine IL-15 was cloned, purified and used to raise rabbit anti- 
muIL-15 antibodies. These anti sera were used in the CIA model. Furthermore, the 
cloning process uncovered a mutant form of murine IL-15 which had the native binding 
characteristics but had no ability to activate T cells. This protein was also used 
therapeutically in the CIA model as a putative therapeutic agonist to IL-15. Neither 
experiment produced clear indications that the anti -IL-15 anti bodies or the mutant 
agonist were successful in abrogating the symptoms of CIA however there was a trend 
for early and subtle amelioration o f symptoms.
The difficulties with purification of recombinant protein and particularly 
solubility indicated a change to the original protocol. Instead o f using the recombinant 
IL-15 & its antibody to continue the investigation in the remaining two models, the more 
readily purified soluble EL-15 Receptor alpha (EL-15Ra) was used as the therapeutic 
agent.
In both the LPS shock model and the septic arthritis model, the therapeutic 
inoculation o f the mice with IL-15Ra, seemed to modify the mortality associated with 
high dose LPS shock in the LPS model; severity and incidence o f sepsis in both models. 
There was also a trend for reduced incidence and severity of arthritis in the septic arthritis 
model.
Furthermore, EL-15Ra therapy appeared to alter the distribution o f S. aureus in 
the soft tissues o f the septic arthritis mice. In this instance, S. aureus was found in the EL- 
15Ra treated group tissues but not in the control group, suggesting IL-15 removal had 
some effect on the ability o f the tissues examined to clear the bacteria. This finding was 
also either time dependant or related to the cessation o f therapy as the differential
distribution generally disappeared following the cessation o f therapy and then resembled 
the controls. IL-15Ra administration also appeared to affect the ability o f the spleen cells 
from mice in the septic arthritis mice also to react to the mitogens, SEA and CON-A, 
with the treatment mice showing less activity than the control mice during the treatment 
period.
In the many determinations o f the effects o f EL-15 throughout this study, there have not 
been any constantly obvious and statistically significant differences, however, an overall 
conclusion can be drawn that there is a persistent trend for the amelioration o f sepsis and 
arthritis in the CIA, LPS and Septic arthritis models when EL-15 depleting agents such as 
anti-EL-15 antibodies, EL-15 antagonist and soluble receptor are administered 
therapeutically. This study therefore, may provide the basis for better defined 
experiments to be carried out, perhaps with better power and sampling and reagents, 
strengthening this trend into a fact.
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1Chapter 1 
The role of IL-15 in murine models o f inflammation.
l i l
Inflammation
The Latin words, rubor, calor, tumor and dolor describe the results o f the biological 
process o f  inflammation. Redness, heat, swelling and pain are the physical symptoms 
accompanying the stimulation o f immune system components by either foreign bodies such 
as microbes, or aberrant reactions to normally innocuous antigens derived from self or the 
environment. The processes involved in the generation o f the inflammatory response can 
loosely be divided into three areas ( 1):
♦ Recognition o f the antigen followed by activation o f  components o f the immune system. 
(Can be non-specific or Antigen specific).
♦ Amplification o f the immune response through development o f immune-effector cells and 
immune-active molecules and their recruitment to the site(s) o f inflammation.
♦ Outcome o f the response. E.g. Pathology, fatality or eradication/control o f the pathogen 
etc.
The inflammatory response is a normal and necessary reaction enabling defence o f the 
body against pathogens and foreign bodies. The recognition o f antigen, initiation o f the 
inflammation response and the removal o f the pathogen are all processes mediated by 
specific cells and soluble factors o f the immune system. Before discussing inflammation in 
terms o f disease situations, it is important to present an overview o f the mechanism o f the
inflammatory response in the context o f a healthy immune system. For instance: A 
macrophage in tissue near the site o f a skin wound encounters an invading bacterium. The 
bacterium is ingested by the macrophage by phagocytosis. The macrophage may then enter 
the lymph capillary system that drains the tissue o f interstitial fluid and cellular debris; 
Alternatively, a skin wound occurs and becomes infected by bacteria, for example S. aureus. 
As the infection proceeds, some o f  the bacteria migrate into the interstitial spaces o f the lower 
dermis. Fragments o f dying bacteria enter the draining lymph capillaries and travel with the 
lymph to a draining lymph node, usually found locally with respect to the injury site. Within 
the lymph node, the bacterial antigen might be engulfed by one o f the resident macrophages.
Either o f  the macrophages described above would enzymatically digest the protein 
components o f  the bacterium and display some o f the products on their surface membranes, 
in conjunction with specialised Major Histo-Compatibility class II molecule (MHC-II). This 
macrophage is now functioning as an Antigen Presenting Cell (APC).
The lymph node is a site o f interaction between antigen presenting cells and T-cells, 
where these and other cells o f  the immune system can monitor the presence o f antigens 
entering the lymph. These antigens may be processed by antigen presenting cells prior to 
arriving in the lymph node or may arrive independently with the lymph. If no antigen is 
detected by the T cells, antigen presenting cells return to the circulation or tissues. However 
if antigen such as those derived from the ingested bacterium are detected, the following set o f 
events may occur, recognising the antigen and initiating an immune response.
Naive CD4+ve T cells regularly exit the blood circulation and migrate through the 
lymphoid organs and nodes. However, a CD4+veT cell specifically able to recognise a 
bacterial peptide may encounter the APC displaying its specific antigen and a T cell driven 
inflammatory response may be initiated. (Generally, the T-cells cannot recognise antigen 
unless it is displayed by an APC e.g. macrophage.) (1)
The T cell Receptor (TCR) is specific for its antigen. The TCR binds the antigen/MHC 
complex on the APC. Adhesion molecules such as LFA/1 and ICAM/1 (2) (3) followed by 
“Co-stimulatory5’ molecules e.g. CD28 and B7 (T cell and APC respectively) draw the two 
cells together and allow cell-cell “communication”. This set o f  signals starts the antigen 
recognition process, which in turn activates the formerly quiescent naive T cell.
The activated T cell now begins to express the mitogenic cytokine IL-2 and IL-2 receptor 
alpha protein. The IL-2a receptor protein migrates within the plane o f  the membrane to join 
with the beta and gamma IL-2 receptor subunit to form a high affinity IL-2 receptor. The 
newly synthesised IL-2 acts via this receptor allowing clonal expansion o f the T cell. At this 
stage, the naive T cell moves into a proliferative state. The new clone o f T cells formed by 
this proliferation is also reactive to the bacterial antigens presented by the APC, but no longer 
requires co-stimulatory signals such as the CD28/B7 interaction.
The activated or “primed” T-cell clones re-enter the circulation and can develop in 
several ways. Activated CD4 cells may differentiate as T helper (Th) cells o f  which there are 
generally held to be two types, Thl and Th2 (4). The direction o f differentiation depends 
upon the cytokine milieu existing in the tissues in which the T cell clones find themselves. (5)
Some pathogens induce macrophages and natural-killer cells to produce IFNy and IL-12 
and this causes T cells to mature into Thl type cells. Thl cells have pro-inflammatory 
activities, inducing more IFNy and IL-12, resulting in a pro-inflammatory cycle. These 
cytokines activate macrophages and more T cells are activated by the macrophages’ increased 
antigen presentation and enhanced non-specific phagocytic events. Furthermore, this 
activation o f macrophages by the Thl cells enables them to produce more TNFa and TNF 
receptor. TNFa acts in an autocrine fashion in synergy with IFNy from the T cells to induce 
production/release o f antimicrobial molecules such as Nitric Oxide (NO) and Oxygen 
radicals such as O'.
4In the presence o f cytokines such as IL-4, Th2 type cells may develop from the new 
clone. These cells, although having some pro-inflammatory activity, tend to eventually 
express cytokines such as TGF-p and IL-10, which can damp down the inflammatory 
response.
B cells often require T cell help to generate antibodies against their specific antigens 
(6 ) (T cell independent activation is possible by antigen cross-linking o f  receptors) (7). 
Antigen is identified by its specificity to the B cell surface Immunoglobulin. The 
immunoglobulin and the antigen are internalised and antigenic peptides are displayed on 
MHC class one molecules. An activated Th2 cell, reactive to the peptides displayed on the B 
cell MHC, can bind the MHC/antigen via its TCR. CD40/CD40-ligand costimulatory contact 
may then occur between these cells and, when supported by Th2 cell derived cytokines, the B 
cell may develop into a plasma cell producing antibodies against the antigen.
A further subset o f  the activated T cell clones may become memory cells, an 
expanded population o f cells within the body, able to recognise the antigen that initially 
invoked the clonal expansion. These cells are identified by protein markers on their cell 
surfaces (for example CD45RO) which are different from those o f the naive T cell.
Thus, the immune response can be seen to have an antigen recognition stage and this 
is followed by an initiation o f inflammation by cellular action (macrophage activation and 
soluble factors such as pro-inflammatory cytokines) ( 1).
The last stages o f the healthy immune response include the production o f antibody. 
This allows the mopping up o f antigen by non-specific mechanisms, such as complement and 
increased phagocytosis. This is often accompanied by the production o f inhibitory cytokines 
such as TGF-p and IL-10 that act against the pro-inflammatory cytokines leading to reduction 
of proliferation events and inflammatory cytokine production. The residual reactive memory
T cell clones can also be considered as an outcome o f  the healthy immune response, ensuring 
a rapid response against any further encounter with the original antigen. (1)
1.1a Cytokines defined and their diversity o f action.
Cytokines are often defines as chemical messengers. They are diverse and numerous and not 
limited to production by cells o f  the immune system alone. Janeway and Travers (1) describe 
cytokines as “ small soluble proteins produced by one cell that alter the behaviour or 
properties o f  another cell”
Cytokines is a term referring to all these chemical messengers however, those termed 
interleukins are those derived from T cells. E.g. IL-15. However, we know that IL-15 is 
found in many tissue types so it is probably best to stick to the general term o f cytokine and 
accept the name interleukin for convenience! The table (i) below (adapted from (1)) 
highlights some o f  the diversity o f cytokines and their origin and targets.
6  Y
Cytokine Produced by Eflects on
B Cells T Cells macrophages Haemopoetic cells
Interleukin-4
(IL-4)
Th2 Activation,
growth
Growth & 
survival
Inhibits
activation
Growth o f  mast 
cells
IL-5 Th2 Differentiation
IgA
production
Eosinophil 
differentiation and 
growth
IL-6 Th2 Growth and 
differentiation
Co-
stimulator
- Induces colony 
stimulating factor
11-10 Th2 Upregulates 
MHC class 2
Inhibits Thl - Inhibits 
cytokine 
release
Costimulates mast 
cell growth
IL-2 Thl growth growth - Stimulates NK 
cell growth
Interferon y Thl Differentiation 
and Ig2a 
sythesis
Kills activation Activates NK 
cells
Tumour
necrosis
factor
Thl, Th2 Activates and 
induces NO 
production
Granulocyte
macrophage
colony
stimulating
factor
Thl & Th2 differentiation Inhibits
growth
activation Stimulates
production o f  
granulocytes and 
macrophages
Table (i) adapted from Janeway and Travers (1) showing a selection o f common cytokines, their 
originating cell types and their effects on other cells in the immune system.
The effects o f  cytokines on the effector cells o f the immune system are very important
in disease. It can be seen that there is a target for therapeutic intervention through either
supplementing or blocking o f cytokines. Monoclonal antibodies against tumour necrosis
factor such as that marketed as Remicade by Schering Plough , have increasingly wide
indications in human treatment for immune disease. The licensed indications for Remicade
f  .
(generic name infliximab) currently include Rheumatoid arthritis, ^dikylosing spondylitis,
Chfpris disease and just recently psoriasis.
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The discovery of IL-15 and its characterisation
This thesis concerns the cytokine IL-15 and the role it may play in the immune 
response, explored through three murine models o f inflammatory disease.
The discovery o f IL-15 is documented in the literature in May 1994. Burton et al, (8 ) 
demonstrated that the conditioned culture supernatant from HuT-102 cells (an adult 
leukaemia T cell line) could induce the proliferation o f the normally IL-2 dependant cell line 
CTLL. This factor was designated IL-T. In the same journal edition, Bamford reported (9) 
that the IL-2receptor p chain was not only used by IL-2, in stimulating the Kit 225 cell line 
but also by the novel IL-T. In the same month, May 1994, Kenneth Grabstein et al, (10) 
cloned a cytokine, purified from the supernatants o f the simian kidney cell line CV-1/EBNA. 
These supernatants had demonstrated proliferative activity on the IL-2 dependent, murine cell 
line CTLL. Purification by molecular weight and charge characteristics revealed this activity 
resided in a protein with mobility o f 14-15kDa on SDS PAGE. N-terminal amino acid 
sequencing led to cloning and publication o f the IL-15 cDNA sequence in several 
mammalian species. The murine IL-15 shares 73% homology with the human in both nucleic 
and amino acid sequence. ( 11)
The IL-15 and IL-2 molecules share a number o f biological functions. The gene 
coding for IL-15 exists as a single copy gene (11) & 12); because o f the single gene status 
and the absence o f homology with the IL-2 gene sequence implies that there is unlikely to be 
any evolutionary link to IL-2 via gene duplication and subsequent mutation from or to the IL- 
2 gene. However, IL-15 undoubtedly has an important relationship to IL-2, as not only is it 
encoded on the same chromosome, but also shares to a remarkable degree the same biological
8functions. These include T cell stimulation (8 ), B cell proliferation and differentiation (13) 
and induction o f  natural killer cell proliferation. (14)
When the IL-15 secondary structure (inclusive amino acid sequence o f  IL-15) was 
processed by 3D-analysis software, (10) a “4-alpha helix bundle” structure was predicted, 
similar to the structure o f IL-2. In addition to molecular shape, IL-15 and IL-2 share some 
important biological activities, as noted earlier. These similarities are likely, in part, to be a 
function o f the redundancy o f  the IL-2 and IL-15 receptor subunits. Within the trimeric IL-2 
receptor, only the IL-2 receptor alpha (IL-2Ra or CD-25) subunit is exclusive to IL-2 
activity. The IL-2 gamma-subunit (also known as Gamma C or Common) is a component o f 
the receptors o f  IL-4 and 7 (15) and IL-15. In addition to the gamma subunit, the IL-15 
receptor also utilises the IL-2 beta subunit (16)
The distinction o f  the IL-15 receptor from the IL-2 receptor lies in the IL-15 receptor 
alpha (IL-15Ra) subunit. The IL-15Ra receptor subunit protein is related in tertiary structure 
to the IL-2Ra, but has little sequence homology. However IL-15/IL-15Ra exhibits 1000 
times the binding coefficient o f IL-2/IL-2Ra. The tissue distribution o f IL-15Ra by mRNA 
analysis shows that, compared to the IL-2Ra, the IL-15Ra is ubiquitous, whereas the former 
is largely restricted to T cell containing tissues (17).
Although sometimes described as a macrophage-produced cytokine, the tissue 
distribution o f IL-15 reflects that o f its receptor alpha subunit. Grabstein (10) details IL-15 
mRNA expression in diverse tissues, including kidney epithelia, placenta, heart, lung and 
liver cells. However, this ubiquity o f IL-15 mRNA is not readily demonstrated by IL-15 
protein. IL-2 is produced by T-cells, whereas IL-15 is not. This may be an example o f an 
extremely tight biochemical control mechanism, perhaps functioning to prevent widespread 
induction o f unwanted IL-15 action in major body organs and tissues. The IL-15 mRNA is 
present, but not readily translated to protein. A mechanism for this regulation has been
9suggested by the work o f  Bamford et al (18) who discovered that the HTLV-1 virus 
transformed T-cell line HuT-102 produced IL-15 active protein at 51pg/ml (between 6-10 
fold more protein than non-transformed cells) when assayed by Enzyme Linked 
Immunosorbent Assay (ELISA). However, further investigation revealed that between 214 
and 216 base pairs (bp) o f the 5’ untranslated IL-15mRNA had been replaced with viral DNA 
derived from the Long Terminal Repeat (LTR) section o f  the HTLV viral gene sequence. 
Within the native IL-15 UTR lie 10 AUG motifs o f  which 8 had been deleted by the viral 
insertion. These AUG motifs were found to influence IL-15 production. This was shown 
when these elements were serially deleted and transfected as constructs into COS cells. 
Increases o f  up to 4.3 fold IL-15 production were demonstrated when the AUGs were 
deleted.
In addition to the AUG translation inhibition control mechanism, alternative splicing 
o f  the mRNA is also reported. An example o f this is described by Meazza (19) who reported 
the inclusion o f an additional exon o f 119bp found in 9 o f 11 small lung cell cancer cells. 
This exon conferred a new open reading frame to the elongated mRNA and translated into a 
shorter signal peptide sequence. Bio-active IL-15 was not reported in connection with this 
variant IL-15mRNA by either ELISA (sensitivity 50ng/ml) nor the highly sensitive IL-15 
CTLL bioassay) leading to speculation that effect o f the added exon may be a negative 
control mechanism
The literature mentions several other variant forms o f IL-15mRNA, including three 
described by Nishimura (20) where an alternative exon 5 insertion leads to a slightly 
increased RNA/protein-translation efficiency. The discrepancy between observed levels of 
IL-15mRNA and detected protein and the variations in the efficiency o f translation are 
indicative o f complex trancriptional and translational and post-translational control 
mechanisms that are at present unclear. However, recently Musso et al (127) have shown that
differential forms o f  the leader sequence upstream o f the coding region o f the mRNA for IL- 
15 have can lead to expression o f either a secreted form or a membrane-bound form o f  IL-15 
in normal human monocytes. The membrane bound form could not be eluted by either 
Trypsin or acetate buffers, indicating that the IL-15 was an integral membrane protein. The 
membrane bound form o f IL-15 was noted to be up regulated by IFNy. Musso speculates that 
this location o f the protein may prevent association with the IL-15R complex but furthermore 
that the membrane for was biologically active and was able to stimulate in-vitro proliferation 
o f T lymphocytes. Differential production o f membrane and cytosolic IL-15 isoforms was 
also reported by Kurowska M et al (128) in human foetal brain tissue.
These reports may indicate the reason for apparent ubiquitous distribution o f mRNA for IL- 
15 yet often low detection by ELISA.
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Rheum atoid arthritis and cytokines
The pro-inflammatory effects o f IL-15 suggest it may have a role in inflammatory 
disease. This is exemplified by a series of experiments focusing on Rheumatoid Arthritis 
(rheumatoid arthritis) and models o f this common disease. In order to examine any role o f IL- 
15 in rheumatoid arthritis, it is necessary to describe the immunological events believed to 
lead to the establishment and progress of the disease. The diagram below Figure (i) shows a 
normal, joint on the left side and the right side shows the rheumatoid arthritis joint, including 
an enlarged section showing the site o f immune cell infiltration and development o f pannus 
as described in the text immediately below.
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Figure 1: Diagram of a prototypical
outputs and major cell types m ode
from activity in the area near the
junction. indicated by the dotted
(figure i, adapted from Malaysian Arthritis foundation review, 7, May, 2005)
Rheumatoid arthritis is a disease where the initiating event is unclear. The major 
focus o f  the disease pathology is on the destruction o f the joints (although there are a range o f  
non-joint effects associated with rheumatoid arthritis). The destruction begins with the 
infiltration o f the normally sparsely cellular synovium (some macrophages and fibroblasts) 
with activated cells o f the immune system. These include CD4 and CD8 T-cells, dendritic 
cells and macrophages. In later stages o f the joint inflammation, B-cells and mast cells are 
detected in the synovium. These activated cells produce destructive enzymes, such as 
collagenases, that destroy the joint cartilage and a cytokine milieu that promotes aggressive 
attacks on the cartilage and bone within the joint. The healthy synovial membrane is very 
thin, principally comprising o f  fibroblasts and fibrous tissue and a lining layer, often just one 
cell thick. In rheumatoid arthritis, the synovial membrane changes. The lining layer is often
10 cells thick and containing many macrophages. Many immune cells, including T cells, 
infiltrate and swell the stroma. During rheumatoid arthritis, this expansion o f the synovium 
eventually impinges on the surface o f the cartilage in the joint. This mass o f cells develops a 
dense region, in juxtaposition to the cartilage known as “Pannus”. Cartilage and joint 
destruction leads to impaired joint function (21)/(22).
The orchestration o f  the above events is conducted by cytokines, the messengers o f 
the immune system which function through both auto and paracrine action. As with the 
immune system as a whole, they can have beneficial or derogatory effects. For example, 
Granulocyte /Macrophage-Colony Stimulating Factor (GMC-SF) can up-regulate MHC class
11 molecules in a pro-inflammatory action. However, it can also induce up-regulation o f IL-1 
receptor antagonist, leading to a down regulation o f an IL-1 driven inflammatory response 
(21). Investigations into the cytokines found within the rheumatoid joint indicate a profile 
including IL-1 (23) GM-CSF, (24) IL-6 (25) IL-8 (26) and TNF-ct (27)/ (28).
Chu et al (29) emphasise the importance o f these cytokines by localising them to the 
site o f  joint destruction, i.e. the Cartilage/Pannus Junction (CPJ). The elucidation o f cytokine 
types and their localisation to the joint stimulated discussion regarding the type o f cells 
responsible for initiation and propagation o f  the inflammation in the joint. The relative 
absence o f IL-2 and Interferon gamma (IFNy), traditionally held as the primary T-cell 
activators, from the synovial cytokine profile has led to differing opinions regarding the main 
cellular players in the aetiology o f  rheumatoid arthritis. For instance, Firestein et al (30) argue 
for the ascendancy o f the macrophage in the progression o f  the disease because o f the 
absence o f IL-2 and the presence o f  GM-CSF. Panayi et al (31) have proposed the T-cell as 
the prime initiator and propagator o f the synovial inflammation citing direct T-cell Receptor 
(TCR) activation and Fibronectin binding events in the context o f T-cell activation within the 
joint.
The discovery and characterisation o f IL-15 has allowed a further arm o f the 
discussion to be developed where a macrophage-produced cytokine similar to IL-2 could 
account for the recruitment, activation and propagation o f an active population o f T-cells 
within the rheumatoid joint. Several experiments in this laboratory have illuminated aspects 
o f  IL-15 action and presence in rheumatoid tissue samples and models o f this disease.
The generation o f synovitis would require recruitment o f T-cells into the joint. IL-2, 
signalling through the IL-2 receptor along a chemical gradient, is a very potent chemo- 
attractant o f T-cells (32). Wilkinson and Liew (33) demonstrated that IL-15 exhibited similar 
activity when T-cell locomotion and polarity were assessed bn collagen gel matrices. 
Compared to M IP la  and IL-8 (both T-cell chemo-attractants believed to be present in the 
synovium), IL-15 had greater weight for weight chemo-attractant activity.
Mclnnes et al (34) reported the presence o f IL-15 in the joint tissues o f rheumatoid 
arthritis patients when detected by ELISA. This cytokine was localised by immune-
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histochemical staining to macrophages, i.e. cells counter-stained with CD68 and also amongst 
T-cell aggregates (counter-stained with CD3). It was proposed that this IL-15 was either 
macrophage generated in close proximity to the T-cells or that it was IL-15 receptor bound on 
the T-cell surface.
The in-vitro chemotactic evidence was reflected in-vivo when DBA/1 mice were 
sensitised with heat killed C. parvum prior to a 500ng, recombinant, simian-IL-15 injection, 
administered intradermally to the footpad. This led to a vigorous T-cell infiltration to the site 
o f  the IL-15 inoculation (34).
Later, Mclnnes et al (35) proposed a mechanism relating the presence o f IL-15 within 
the joint to the macrophage production o f TNF-a. In this hypothesis, T-cells became exposed 
to IL-15 and, following IL-15 exposure, cell-cell contact with macrophages induced TNF- 
alpha production. In vitro cell contact experiments using dual chambered slides indicated 
soluble factors were not likely to be responsible for this and that the cell contact was indeed 
necessary. Levels o f up to 400pg/ml TNF-a production were induced in this manner in 
peripheral blood monocytes (PBMCs) when they were placed in contact with the same 
patients’ synovial T-cells (35).
The cytokines involved in inflammation are believed to act in a cascade mechanism 
where the initiating events are controlled by one or two cytokines at the apex o f the cascade. 
This is reviewed by Feldmann (36). Here, TNF-a was described as exerting dominant control 
over IL-1 and other pro-inflammatory cytokines. The work o f Mclnnes et al (35) noted 
above, indicates that IL-15 may indeed be another dominant regulator in context o f its ability 
to control the production o f TNF-a via T-cell/macrophage cell/cell contact and induction, and 
therefore possibly involved in the initiation o f inflammatory events relating to rheumatoid 
arthritis.
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Animal models of inflammation
1.4 Collagen Induced Arthritis model
The collagen induced arthritis model (CIA) has been developed from experiments in 
the rat (37). The CIA model has frequently been used in mice. Use o f DBA/la genetic 
background mice for this model has become a standard technique. The DBA/la type mice 
show no immunologically aberrant behaviour and, therefore are widely accepted as suitable 
tools for inflammation research. (The methodology is described in the materials and methods 
section below). As described by Sewell & Trentham (38), the CIA model demonstrates: 
sustained proliferative synovitis; pannus formation; and cartilage and bone destruction. These 
are all salient features o f the human rheumatoid disease, although CIA is in most cases 
transient, resolving after a few weeks, compared to rheumatoid arthritis which tends to be 
chronic over very long periods o f time.
This model has several features that imply that T-cells are involved in the 
pathogenesis o f the attendant joint disease. In their review, Staines and Wooley (39) describe 
how the adoptive transfer o f either T-cells or anti-collagen antibodies from a mouse with CIA 
to genetically similar mice with no disease will independently induce CIA in the recipient 
mouse. This implies that T-cells reactive against collagen are involved, possibly by direct 
recognition o f collagen as antigen, (activated Thl type reaction) or by Th2 cell induction o f 
anti-collagen antibodies by collagen reactive B-cells.
Another line o f evidence o f T-cell involvement in pathogenesis o f CIA is the 
dependence on the MHC for disease incidence within an experimental species. Staines and 
Wooley also note that the B10.R111 (H2r) strain o f mouse is completely resistant to CIA 
induced by chicken collagen, but is reactive to deer, bovine and porcine collagen. The DBA/1
H2q mice will react to all tested collagens. This differential susceptibility is suggestive o f 
collagen reactive T-cells’ ability to recognise collagen antigenic epitopes being controlled by 
differential expression o f MHC class II proteins Le. the phenotypic expression o f  the genetic 
background o f  the mice H2q vs. H2r.
A third line o f evidence suggesting a central role for T-cells is the ability to modify 
the CIA disease progression by anti-T cell antibodies such as anti-CD4 (40) and CD40-ligand 
which is the molecule synthesised by T-helper cells in order to induce B-cell proliferation 
(41).
Immune cells do not work in isolation but utilise soluble factors such as cytokines to 
influence their activities. The cytokines may form a more defined target for therapy 
possibilities and researchers have been attempting to reveal such a target as described in the 
discussion o f  the immunology o f rheumatoid arthritis above. TNF-a has been a focus due to 
its position as a  dominant regulator o f the pro-inflammatory response. Williams et al (42) 
clearly demonstrated a role for TNF-a in the CIA when they administered neutralising anti- 
TNF-a monoclonal antibodies, before and after the induction o f  arthritis. The therapy was 
clinically effective in established arthritis two days after treatment commenced.
As noted above, Mclnnes (35) proposes a control mechanism whereby IL-15 exposed 
T. cells drive macrophages to produce TNF-a. Therapeutic anti-TNF therapy o f the CIA 
model and the recent success o f clinical trials using anti-TNF in human rheumatoid disease 
indicate the pre-eminence o f TNF-a in the pathology o f rheumatoid arthritis and its model 
CIA. Ruchatz et al (43) tested the hypothesis that IL-15 might control TNF-a production 
through modification o f CIA. A soluble form o f IL-15 receptor alpha subunit (rIL-15Ra) was 
administered as a preventative agent that resulted in the reduction o f arthritis development 
during the therapy period. Proliferative responses to the collagen type II antigen were also
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reduced. This provided evidence that IL-15 may play a role in the collagen induced arthritis 
and by inference in rheumatoid arthritis.
1.5 Lippopolvsaccharide shock model
In humans, septic shock (also known popularly as blood poisoning or LPS shock) is a 
major cause o f  death in hospitals after cardiogenic shock. Typically, septic shock is caused by 
infections such as peritonitis occurring as a result o f  instrumental abortion, intestinal wounds 
and ruptures or via the infection o f the genital tract. Gangrene or urinary infections are 
another common cause. Patient symptoms include high fever, significant vaso-dilation 
throughout the whole body increased cardiac output (in response to the vaso-dilation), blood 
“sludging” and clotting. The clotting causes blockages in the small capillaries and venules o f  
the major organs. The result o f  the vasodilation is blood pools in the veins. Perfusion o f the 
essential organs fails, leading rapidly to death. Endotoxic shock is similar in pathogenesis to 
these and a frequent cause in humans is when a portion o f the gut becomes strangulated and 
the coli-form bacteria o f the gut multiply out o f  control. These mostly gram-negative 
bacteria, frequently E. coli, release endotoxin into the tissues and subsequently the blood, 
initiating the septic shock response described above. It is highly likely that cytokines are 
involved in the evolution o f  the septic shock. The dependence o f the pathogenesis o f 
endotoxic shock on these mediators is discussed below (44). The role o f the 
lipopolysaccharide (LPS) itself is demonstrated by the fact that the symptoms o f the 
endotoxic shock can be reproduced by LPS injection into mice. Furthermore, these symptoms 
can be abrogated by the prior administration o f anti-LPS antibodies in primates as 
demonstrated by Tracey et al (45).
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Septic shock is a self-propagating disease where the vasodilatory effects on the 
circulation and cytokine production lead to further shock i.e. more vasodilation and cytokine 
release, and rapidly lead to death. Standiford et al (46) studied the regulatory effect o f IL- 
lONeutralisation o f this cytokine increased lethality in murine models o f septic shock. This, 
along with investigations into TNF-a discussed below, point to the importance o f the 
cytokines in the progression o f septic shock
Therefore, septic shock occurs in humans when endotoxins are released from invading 
bacteria, usually gram negative (70%) and sometimes gram-positive species. Endotoxins are 
called so because they consist o f a chain o f oligosaccharides linked to a lipid moiety and 
reside within the membrane o f many gram-negative species. The most commonly studied 
endotoxin is lipopolysaccharide (LPS) and this is released by bacteria into the surrounding 
tissues/serum. (47)
The symptoms seen in the model following LPS administration are dose dependent 
and often lethal. Fever, diarrhoea, lethargy, mucus encrustation around the eyes, cyanosis and 
weight loss are frequently seen. TNF-a and IL-1 are commonly attributed as principal 
mediators o f  endotoxin induced inflammation (48), (49) & (50).
Beutler et al (51) injected 200ul rabbit anti-TNF-a enriched immune serum by the 
intra-peritoneal (IP) route into BALB/c mice, both 3-6 hours prior and post IP injection o f 
400ug LPS. Significant protection from LPS induced lethality was attained when the anti- 
TNF-a enriched sera were injected prophylactically, but no protection was evident if the anti­
sera were administered post or concurrent with the LPS injection. Interestingly, the antisera 
did not have any marked effect on the symptoms o f shock. This led the author to propose that 
lethality and some o f the other sub-lethal effects o f LPS shock might be under differential 
regulation.
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Freundenberg et al (52) suggested that the majority o f the septic shock pathologies 
were mediated by macrophages. They transferred endotoxin sensitive macrophages into mice 
previously insensitive to LPS, which then succumbed to endotoxic shock. As macrophages 
are a major producer o f  TNFa, this is not inconsistent with many papers over the last decade, 
which indicates TNFa as a major factor in Endotoxic shock. Several authors have used 
neutralising anti-bodies or gene deletions to elicit the roles o f TNF-a, IL-1 a  and p, IL-6, and 
IFNy and some consensus views can be gained from a study o f the results o f these 
investigations. One such study, investigating sub-lethal Euthyroid syndrome, illustrates the 
cytokine pattern induced by LPS insult. Following IP injection o f 75ug E. coli LPS into 25g 
(average weight) Swiss mice (a sub lethal dose), Boelen et al (53) reported that TNF-a, IL- 
l a  &p, IL-8 and IL-6 production is increased. Boelen’s study also monitored the weight loss 
associated with LPS induced illness and found that although TNF-a production was inhibited 
by prophylactic anti-TNF-a neutralisation, neither IL-6 production nor weight loss 
parameters were affected. Zanetti (54) also studied the relationship between cytokines and 
shock induced by either LPS or gram negative bacteria. Following Intra-Venous (IV) 
injection o f  LPS (range 10 -500ug/mouse LD = 200-500ug), serum levels o f TNF-a peaked 
at up to 45ng/ml at 1.5-2 hours post LPS injection. Levels then fell below detectable levels in 
survivors (at 0+6hrs) and maximum lOOpg (at 0+6hr) in mice that eventually died. TNF-a 
was not detectable in serum at the time o f death. IL-1 and IL-6 also increased in level, 
peaking after the TNF-a but remaining detectable [in survivors] until 0+15 and 9 hrs 
respectively. These cytokines were also detectable in serum at the time o f death. When bolus 
injection o f E. coli by IP route was used to induce shock, the level o f TNF-a production was 
50-100 fold lower than that seen during IV-lipopolysaccharide induced shock. In this case 
(IP), the TNF-a production did not peak and fade as with the intravenous LPS or E. coli
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induction o f shock, but persisted at a lower level until death. Treatment o f  these groups with 
anti-TNF-a neutralising antibodies showed a dichotomy as the IV challenged group were 
completely protected from death but no protection was exhibited in the IP-live group. The 
anti-TNF-a significantly reduced IL-1 and IL-6 in the IV-LPS challenged mice, but no such 
reduction was seen in the IP E. coli experiment. There are limitations here as one group (IP) 
are using a single dose o f LPS and the other a challenge o f live bacteria, constantly producing 
more pathogenic antigens. Furthermore, the IP 1000xLD50 LPS/anti-TNF-a group were 
sensitised by co-injection o f 15mg D-galactosamine with the LPS (D-galactosamine reduces 
liver metabolism giving another variable). (55)
The live E. coli experiment is perhaps more akin to physiological disease than the 
bolus LPS shock experiment. If  the same antigen (LPS) is injected by different routes or 
produced by a live organism rather than a single injection, the immune response may also 
operate in subtly different ways. Doherty (56) also demonstrated protection from LPS 
induced lethality by anti-TNF-a administration 6 hours prior to a 40mg/Kg LPS injection by 
the IP route, as did Smith et al (57), when 90% protection was conferred by pre-treatment 
with anti TNFa in LPS challenged mice. Tracey et al (45) reported that complete protection 
from lethal septic shock, induced by intravenously injected E. coli in baboons, was conferred 
by prophylactic injection o f anti-TNF-a antibodies. This reflects the IV results o f Zanetti 
noted above (54). Tracey et al (50) demonstrated that recombinant TNF-a could produce all 
the symptoms o f  Endotoxic shock. When this evidence is placed alongside the evidence for 
the modification o f the LPS induced responses described briefly above, there can be no doubt 
as to the importance and pre-eminence o f TNF-a in septic shock, irrespective o f the route o f 
disease induction.
The focus on TNF-a as a presumptive controller o f lethality may now move towards 
some other cytokine(s) and more specifically that the control o f IL-1 and 6 production may
not necessarily be directed by TNF-a in the live bacterial infection. For example, other 
variations are seen in the septic shock cytokine pattern, specifically IL-6 and IFNy. IL-6 is 
often reported as increased during LPS sepsis. Zanetti (54) reports LPS induced IL-6 
decreased in response to anti-TNF-a treatment (in the IV LPS model but not IP), but Boelen 
(50) reports no effect on IL-6 when anti TNF-a treatment is used in IP low dose LPS induced 
shock. Amiot et al, (58) when injecting mice with disrupted TNF-a and lymphotoxin genes 
with LPS, found no difference in the IL-6 production between wild type and TNFa-/-.
Another complication relevant to the Endotoxic shock story is the fact that mice can 
be pre-sensitised to LPS by priming them with heat killed bacteria, e.g. C. parvum (59), BCG 
(60), or Actinomycin D (61). These priming steps lower the lethal dose by many times and 
the LPS induced cytokine pattern in these experiments may be altered in comparison to LPS 
induction o f  shock without priming. Both Wysocka (60) (via IL-12 in response to LPS) and 
Smith (59) (C. parvum) report that priming induces IFNy and claim roles for IFNy in shock 
pathogenesis by synergy with other cytokines or as a means o f potentiating TNF-a 
production (59). A role for IFNy was also demonstrated by Doherty, (56) who found anti- 
IFNy completely protected against recombinant TNF-a and endotoxin induced shock. 
Doherty also suggests the possibility that IFNy may enhance the lethal effects o f  endotoxin or 
LPS. Furthermore, Doherty et al (62) demonstrated murine-IL-15 production by macrophages 
can be induced by IFNy priming and incubation in LPS independently o f T cells in a non­
specific manner. Therefore, both IFNy and TNFa, which from the evidence discussed above 
can be seen to have a major role to play in the pathogenesis and lethal effects o f septic shock, 
could also be associated with IL-15 activity through its ability to up-regulate TNFa via 
activated T cells. This thesis attempts to explore such a role for IL -15 in septic shock through 
the septic shock model whose methodology is described in chapter 2.
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l.<6 The septic arthritis model
A logical continuation in the investigation o f the role o f  IL-15 in inflammation was to 
investigate IL-15 action in the murine model o f septic arthritis. The human disease has two 
components: development o f a rapid and aggressive arthritis; and a risk o f mortality from 
septic shock induced multiple organ failure. In a review, Goldenberg, (63) describes how 
bacteria enter the joint spaces from the blood having migrated from elsewhere in the body, 
e.g. an infected wound or skin infection site. Within the hours following entry o f  the bacteria 
into the joint, inflammatory synovitis occurs. The synovial membrane thickens by cell 
proliferation and inflammatory cells invade the synovium. These cells then secrete pro- 
inflammatory cytokines and proteases. Subsequent to these events, cartilage and then bone 
are destroyed in the afflicted joint. The bacteraemia causing such arthritis also may lead to 
shock like symptoms similar to those described in the section on LPS shock above. The gram 
positive nature o f the most common cause o f septic arthritis, S. aureus, means that the major 
toxins causing shock to occur are super-antigens such as Staphylococcal Enterotoxins A and 
B (SEA & SEB) and Toxic Shock Syndrome Toxin (TSST).
75% o f  septic arthritis in humans is caused by Staphylococcus species Goldenberg, 
(64). Patients receiving injected, intra-articular therapy such as Glucocorticosteroids may be 
at higher risk as bacteria can be accidentally introduced directly into the joint with the 
injection. Furthermore, the introduction o f immune-suppressive drugs into the joint 
environment may add a risk factor for septic arthritis development simply because o f the 
immunosuppressive nature o f the drugs. Ostensson and Geborek (65) studied patients 
undergoing treatment for rheumatoid arthritis and concluded that there was one septic 
arthritis incident associated with every 2000 injections within their study group. One patient 
in their study (patient 1) received an injection o f  crystalline glucocorticosteroid into a
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rheumatoid shoulder. Within two days, high fever had developed as had septic arthritis in the 
original shoulder and furthermore, acute and severe arthritis occurred in one knee and ankle 
within one day. Septic arthritis can be a serious threat to human health. For example, a study 
by Gupta et al (129) followed 75 patients over 2 years following diagnosis o f Septic arthritis 
by positive identification o f S. aureus within synovial fluid culture. Joint disease was reported 
in 46% o f this group. Fever and leg ulcers were also represented in these patients. 11% o f the 
patients died. The poor prognosis has led to a further prospective study in Septic arthritis 
patients Gupta et al (130) recommending the treatment o f patients exhibiting clinical signs 
suggestive o f  Septic arthritis to be treated as such even in the absence o f actual S. aureus 
culture isolate.
A murine model o f the human septic arthritis has been developed by Bremell et al. 
(66) Bremell describes how bolus injections o f live S. aureus are administered into the blood 
via the tail vein o f Swiss mice. Symptoms o f bacteraemia and arthritis appear after a few 
days. Bremmell later characterises some aspects o f  the model with description o f  the 
histological evidence o f arthritic joint destruction, accompanied by mononuclear cell 
infiltration o f the joint. He also describes serological changes such as increased IL-6 
production and massive induction o f IgG, indicating B cell activation (67). Many o f the early 
papers focus on histological changes in the model relating to the arthritis seen in human 
disease. More recently many investigators have studied the more life-threatening aspects o f 
the disease and its model, for example sepsis, shock and the host response to the pathogenic 
bacteria.
The role o f IL-15 demonstrated by Ruchatz (43) in the modification o f Collagen 
Induced arthritis in mice, invites the question as to whether IL-15 plays a similar modulating 
role in septic arthritis. Furthermore, the symptoms of sepsis exhibited by the mice in the 
septic model are not dissimilar to those displayed by the mice in the LPS induced shock
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model. (High fever, lethargy, eye secretions etc.). Serologically, TNF-a and IFNy are up 
regulated (68). Bremmell (67) reports increased IL-6 and Zhao et al (69) reports increased 
TN F-a and IL-1.
There appears to be, as in the LPS shock model o f  sepsis, a picture o f pro- 
inflammatory cytokines mounting a co-ordinated attack on the pathogen. This may be a host 
response to the spread o f toxins from the bacteria, entering the bloodstream with resultant 
shock and multiple organ failure. However in this disease, there are also the consequences o f 
joint destruction due to the localisation o f the bacteria to the joint cavity and the local 
inflammation.
If IL-15 does have a place in the regulation o f the host response via cytokine cascade 
control, then the negative effects o f  the immune response to the bacteria and their toxins may 
be ameliorated by the therapeutic intervention o f IL-15Receptor-a (IL-15Ra). However, 
even if there is a reduction o f TNF-a driven immune responses, there may also be a 
concomitant reduction o f the ability o f the host to mount sufficient immunity against the 
invading pathogen. In this case bacteria might continue to colonise the host unchecked with 
eventual death or severe disease from shock and only a temporary respite from the initial 
effects o f sepsis. Indeed, Docke et al (70) note that monocyte function may be down- 
regulated during septic shock citing evidence that sepsis patients were unable to produce high 
amounts o f TNF-a and IL-1. They also correlate with this inability o f patients to produce 
pro-inflammatory cytokines resulting in increased morbidity and mortality. Within a mouse 
model for septic arthritis, mice deficient in TNFa and Lymphotoxin (LT) were injected with 
toxic shock strain o f S. aureus. Mice deficient in TNFa/LT were observed to have 67% 
mortality and this was associated with reduced phagocytosis. In comparison, control mice 
(wild type) were able to clear S. aureus from the bloodstream. Control mice (wild type) were 
also observed to have far more severe arthritis symptoms. (131) Thus the implication for
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TN Fa having a role in the pathogenesis o f Septic arthritis is promoted by these data but the 
amelioration o f  the arthritis by therapeutic intervention may come at a risk o f greater sepsis 
and possible mortality.
Interestingly, the evidence for a lead role for TNFa and IL-1, the main ‘‘usual” 
inflammatory protagonists is queried by the report by Kimura et al (132) Here, anti TNFa 
antibodies and IL-1R antagonist, when co injected with heat killed S. aureus, reduced 
leukocyte infiltration by 80% in rabbits compared to controls. This effect was temporary and 
progressive cartilage destruction was not ameliorated by a subsequent injection o f  antiTNFa/ 
IL-lRantagonist at 20 hrs post S. aureus injection. Therefore, although TNFa was involved 
actively in the early stages o f infiltration, TNF alpha was not the main inflammatory 
protagonist 20hours following the S. aureus inoculation.
Verdrengh et al (133) investigate the role o f  Macrophages (putative IL-15-secreting 
cells in inflammation) in the pathogenesis o f septic arthritis and sepsis. Mice were either 
inoculated with S. aureus or a buffered saline control. Within these mice, monocytes and 
macrophages were depleted by treatment with etoposide. The monocyte /macrophage 
deficient mice were noted to exhibit less arthritis symptoms when compared to the non­
depleted mice. However, the mice exhibiting milder arthritis symptoms were also associated 
with higher S. aureus infection linked mortality. Furthermore, the mice with increased sepsis 
linked mortality also had reduced serum levels o f TNFa and IL-6. This indicates that 
Macrophages while playing a destructive role in the pathogenesis o f S. aureus induced 
arthritis were likely to be providing a protective role in clearing S. aureus from the blood and 
kidneys. Thus removal o f Macrophages was detrimental to survival, and the concomitant link 
to reduced TNFa and IL-6 indicate that these cytokines may also have a similar protective 
role. TNF alpha, seems to have an early destructive role in promoting inflammatory cell 
infiltration but only to a much lesser extent 20 hours later.
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Therefore, the septic arthritis model presents the conundrum; how to reduce 
inflammation associated with Arthritis while not reducing the host inflammatory response 
against the pathogen?
With the experiments described above in mind, it is interesting to speculate how IL-15 
receptor alpha based on its arthritis reducing activity shown by Ruchatz (43) in the collagen 
induced arthritis model might influence the septic arthritis model. I f  IL-15 neutralisation was 
to occur and TNF were reduced, might infection o f  the mice continue and mortality increase? 
These experiments in all these murine models start from the premise that IL-15 somehow 
influences TNFa, previously shown to have a controlling role in all these disease models.
1.7 Aim
The pro-inflammatory effects o f IL-15 are unlikely to be associated only with 
rheumatoid disease. This thesis attempts to further explore the role o f IL-15 in inflammation 
through the Collagen Induced Arthritis (CIA) model o f  rheumatoid disease, the role o f IL-15 
in the Lipopolysaccharide (LPS) Shock model and the Septic Arthritis murine models o f 
bacterially induced inflammation. The aim o f  these experiments is to detect any modification 
o f the normal disease outcomes o f the models o f inflammation described above, caused by 
the removal o f IL-15 by therapeutic intervention o f either anti-IL-15 anti-body, IL-15 
antagonist or IL-15-Receptor-alpha protein to mice.
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Chapter 2 
Materials and methods
Table ii Summary of steps for experiments in murine models of
inflammation
Raise antibody to 
recombinant EL-15
nrnfpin
Clone mouse IL-15 
gene into bacteria
Isolate IL-15 protein 
from large scale 
colony of
transformed bacteria
Use purified anti-IL15 
antisera to test effect 
in 3 models of 
inflammation
Following failure to generate usable IL- 
15-antisera, use purified recombinant EL- 
15soulble receptor as therapeutic agent in 
murine models o f inflammation.
2.1 Cloning of the murine IL-15 gene
In order to produce recombinant muIL-15, it was first necessary to clone the gene 
from murine cells.
2.2 Cell culture
A mouse macrophage cell line, J774 was cultured according to standard techniques. 
Cells were cultured to confluent density in Coming 75cm^ (Coming Costar, Cambridge, MA, 
USA) plastic tissue culture flask in RPMI (GIBCO, Life Technologies, Paisley, Scotland.) 
medium containing Penicillin, Streptomycin, L-glutamine and 10% foetal calf serum (All 
additives from Gibco).
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Induction o f  IL-15 mRNA was reported in murine macrophage cells in response to 
IFNy and LPS stimulation. (62) Based on this method, J774 cells were washed in RPMI 
medium and seeded at lx l 0? cells per 75cm^ flask as described above then rested overnight. 
IFNy @10ng m H  (final concentration) was added followed by LPS 4 hours later at 2pg/ml 
(final concentration). The cells were harvested after six hours by scraping and then pelleted 
by gentle centrifugation (4°C, 1500rpm, five minutes) The supernatant was discarded and 
the cells frozen at -70°c.
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2.3 RNA preparation
The cell pellet was thawed on ice and RNA extracted using Trizol reagent (Gibco Life 
Technologies, Paisley, Scotland) according to the manufacturer’s recommendations.
lml o f  Trizol reagent was added to the cell pellet and homogenised by repeated 
pipetting and then incubated for five minutes at 22°C. A 20% volume o f chloroform (Sigma 
Poole, Dorset, UK) was added and after 15 seconds vigorous shaking, incubated at room 
temperature for three minutes. The two-phase solution was separated by centrifuging at 
12000 rpm for fifteen minutes at 4°C. (MSE, Micro Centaur, Phillip Harris, Aberdeen, 
Glasgow UK). The upper, aqueous phase containing the RNA was then transferred to a fresh 
eppendorf and precipitated by adding 0.5ml isopropanol (BDH Chemicals LTD, Poole, 
England).
After incubation at room temperature for ten minutes, the RNA precipitate was 
pelleted by centrifuging (MSE, Micro Centaur, Phillip Harris, Aberdeen, Glasgow UK) at 
12000 rpm for fifteen minutes at 4°C. The supernatant was discarded and the pellet washed 
in 70% ethanol (BDH Chemicals LTD, Poole, England).
Then, after mixing, the tube was spun at 7500rpm for five minutes at 4°C. The pellet 
was air dried for three to five minutes and dissolved in 30ul o f Diethyl Pyrocarbonate 
(DEPC) (Sigma Poole, Dorset, UK) DEPC treated water and incubated at 60°C for ten 
minutes to ensure solubilisation o f the RNA. The quality and quantity o f the recovered RNA 
were tested by comparing the amount and ratio o f UV light absorption by the sample in the 
260 and 280nm wavelengths. (Spectrophotometer, LKB, Pharmacia, Upsala, Sweden) The 
samples were analysed at 1/500 dilution. After correction for the dilution factor, the amount 
o f RNA recovered was calculated by reference to the classical formula; Absorbance o f 1.0 
@260nm indicates 40 fig/ml RNA. The RNA quality was estimated to be most free from 
protein contamination when the ratio o f A260/280nm was equal or close to 1.8. (71)
2.4 Amplification o f muIL-15 bv RT-PCR
Isolated RNA was transcribed to cDNA by Reverse Transcriptase-PCR (RT-PCR) 
according to the standard protocol (Superscript RT-PCR kit Gibco, Paisley, Scotland)). In 
summary; a random primer/RNA template reaction was prepared; 5pg total RNA from J774 
cells cultured as described previously, was added to 3ul random primers (50ng/ul) and 
adjusted to 12pl final volume with DEPC treated water, mixed and incubated at 70°C for ten 
minutes. A first strand synthesis reaction was prepared; 2pl 10X PCR buffer, 2 pi 
MgCl2(25mM), lp l dNTP mixture (10 mM) and 2pl Dithiothreitol O.lM(DTT) (All supplied 
with Superscript kit, Gibco). Seven pi o f this reaction was added to the RNA/Primer reaction
and incubated for five minutes at room temperature (25°C) 200Units o f  Reverse 
Transcriptase (Gibco, Life Technologies, Paisley, Scotland.) were added to the reaction, 
mixed and followed by a further incubation o f ten minutes at room temperature. The reaction 
was transferred to a water-bath (Grant Instruments, Cambridge, England) and incubated at 42
degrees for fifty minutes followed by termination by heat inactivation at 70°C for fifteen 
minutes in a Heat Block (Grant Instruments, Cambridge, England). Oligonucleotide primers 
were designed to define the mature coding region o f the IL-15 mRNA according to the IL-15 
gene sequence published by Krause et al (72)
Two cloning strategies were used to attain recombinant IL-15. In the first instance, 
primers were designed to enable a PCR product to be cloned directly into the TA- cloning 
vector (Invitrogen, 9351 NV Leek, The Netherlands) followed by sub-cloning to the Qiagen 
Protein expression vector . It was therefore important that the first set o f primers captured the 
entire coding portion o f the IL-15 gene. It was also necessary that the ligated ends o f the gene 
would match the sequence o f the “sticky ends” required to correctly orientate the sequence
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into the plasmid for transformation o f the e coli. The second primers were also stringent in 
their requirement to match the expression vector ends. Furthermore, the start codon needed to 
be captured by the upstream primer, thus the sequences below were chosen.
TA cloning vector primers
Primer 1 5' A GGA TCC ATG TGG ATA GAT GTA AGA TAT 3'
Primer 2 3' GCAGTCAGGACGTGTTGATG 5'
Primers for direct insertion to pQE 60 expression vector
Primer 1 5' G GCC ATG GGC ATA GAT GTA AGA TAT GAC CTG G 3'
Primer 2 3' GTC AGG ATC CGT TGA TGA ACA TTT GGA CAA TG 5'
These primers were diluted to a working stock o f luM. These were included in the following 
PCR reaction mixture. This is detailed in Table 1 below.
Reagent/sample Amount
04 )
10 X PCR buffer 10
MgCl2 (25mM) 6
DNTP mix(lOmM) 2
Primer 1 5
Primer 2 5
Taq polymerase 1
3 2
CDNA 2
Sterile water 69
Table 1 PCR reaction mixes in a total volume of lOOul were mixed to this formula.
PCR reactions were carried out on a Techne (Techne (Cambridge) Ltd, Cambridge, England) 
thermal cycler without a heated lid. Therefore all reactions were overlaid with mineral oil 
(Sigma, Poole, Dorset, UK.) The PCR reaction mixture omitted Taq polymerase prior to
addition o f mineral oil. Reaction samples were heated to 95°C for two minutes. Whilst 
cooling, Taq polymerase was added, followed by oil. The tubes were loaded into the thermal
cycler and denatured for three minutes at 95°C then 35 cycles of;
♦ Denaturation...... one minute @ 95°C
♦ Annealing............two minutes @ 56°C
♦ Extension............three minutes @ 72°C
♦ One final cycle extension step o f ten minutes at 72°C.
These conditions were also used for P-Actin control reactions using primers synthesised 
according to published murine-p-actin sequence data. The results were analysed on 1% 
agarose gels under UV light and Ethidium Bromide staining.
2.5 PCR Product Purification for direct cloning in to vectors
PCR products o f the correct size were purified in the following manner. As reactions 
were usually carried out in duplicate, the two positive reactions were pooled and 200ul 
Phenol/Chloroform (Sigma, Poole, Dorset, UK.) added, shaken hard for 15 seconds. The
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tubes were centrifuged for two minutes at 13000 rpm @ room temperature. The upper 
aqueous phase was transferred to a fresh tube and re-extracted with 200ul chloroform. The 
upper aqueous phase was transferred to a fresh tube and 20ul 3M Na- Acetate pH7 and 440pl 
100% Ethanol. After incubation for ten minutes in liquid nitrogen, the tubes were centrifuged 
at 15000rpm for thirty minutes at 4°C. The supernatant was discarded and the PCR product 
pellet washed in 75% ethanol and re-centrifuged for ten minutes at 4°C and 12000rpm. The 
pellet was then dried under negative pressure for five minutes at 55°C and re-suspended in 
30pl distilled water.
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2.6 Ligation o f the muIL-15 product into pCR 2.1 TA cloning Vector
The TA cloning vector (Invitrogen, 9351 NY Leek, The Netherlands) provides a 
convenient system for rapid incorporation o f a gene o f interest from PCR amplified form into 
a  plasmid. This is achieved because the linearised plasmid has 3' Thymidine residues in 
multiple “A” cloning-site. A consequence o f PCR amplification using Taq polymerase with a 
10-minute final extension step is the addition o f an Adenine (A) residue at the 5' end o f  each 
o f  the double strands o f DNA. During ligation, these “A”s form “Watson and Crick” 
complimentary base pairs with the Thymidine (T) residues o f the plasmid strands. It was 
decided to persue this strategy in the first instance prior to insertion o f the gene into a protein 
expression system using the following method.
A 50pl PCR reaction using the Primers designed for TA cloning (primers 1&2 
described above), produced a product o f 356 base pairs, visualised by agarose gel analysis. In 
line with Invitrogen's recommendations, the PCR cycles were restricted to 30. Ligation into 
pCR2.1 (the code name for TA cloning vector) was carried out according to the 
manufacturer’s protocol This plasmid carries both Ampicillin and Kanamycin resistance 
gene open reading frames in the plasmid sequence, allowing negative selection o f 
transformants when the plasmid is transformed into non-ampicillin or non-Kanamycin 
resistant strains o f host bacteria in the presence o f one, or a combination o f these antibiotics. 
3pl o f fresh PCR product was added to lp l 10X ligation buffer, 2pl o f pCR2.1, 3ul sterile 
water and 1 pi o f T4 ligase (4 units) with all reagents supplied by Invitrogen (Invitrogen, 
9351 NV Leek, The Netherlands). (This reaction gives approximately a 1:1 ratio o f PCR 
product to vector) The reaction was gently mixed and placed in a 14°C water bath overnight.
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2.7 Transformation
A 50fil aliquot o f Competent E. coli strain "One shot Top IN V aF " (Invitrogen) were 
thawed on ice. 2pl o f  0.5M B-mercaptoethanol was added to the competent cells with veiy 
gentle mixing by sterile pipette tip. 2pl o f  the overnight ligation reaction was then added with 
further gentle mixing over ice and then incubated on ice for thirty minutes. After the 
incubation the Transformation reaction was heat shocked for exactly thirty seconds in a 42°C 
water bath with the reaction then being placed onto ice for two minutes. 450jrl o f SOC 
medium (2% tryptone, 0.5% yeast extract, lOmM NaCl, 2.5mM KCL, 10mMMgCl2, 
10mMMgSO4 and 20mM glucose at room temperature) was added to the reaction and then
shaken horizontally (Gallencamp, Dorset, UK) for one hour at 37°C @ 225rpm followed by 
storage on ice.
LB agar plates were prepared. 50jig/ml ampicillin (Sigma Poole, Dorset, UK.), 
40pg/ml 5-Bromo-4chloro-3-indolyl-p-galactopyranoside 15pg (X-Gal), (Boeringher- 
Mannheim, Lewis, East Sussex, UK) and Isopropyl-B-D-thiogalactopyranosamide (IPTG) 
(Bioline, UK) were added as the plates cooled. The plates were pre-wanned to 37°C and 50pl 
o f the transformation reaction was pipetted and then spread onto the plate surface. After
absorption o f  liquid into the agar, the plates were inverted and incubated overnight at 37°C. 
The plasmid used here contained the Lac Z gene, (which allows bacteria incorporating this to 
metabolise the plate constituents), described above to form a blue product. If there has been 
successful insertion o f the IL-15 sequence into the plasmid, the Lac Z gene is disrupted and 
therefore the host bacterium cannot metabolise the chromogenic substrate in the plate and as 
a consequence will remain white instead o f blue.) Therefore, 12 white colonies were selected 
and inoculated into 2ml 2xYT medium with lOOng/ml ampicillin and grown in shaken
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suspension overnight. The cells were harvested by centrifugation at 1500 rpm for two 
minutes at room temperature.
2.8 Plasmid Mini-prep
A standard mini-prep protocol was used to isolate plasmid DNA from the host E. coli 
for analysis. All medium was removed by pipette and cells were re-suspended in 200pl GTE 
buffer, (18g Glucose, 4ml 0.5M EDTA, 5ml 1M Tris, add sterile water to 500ml). (Chemicals 
by BDH Chemicals LTD, Poole, England.) 400pl o f  freshly prepared lysis buffer (8ml sterile 
water, 1ml 2M NaOH, 1ml 10%SDS (BDH Chemicals LTD, Poole, England.) was added, 
shaken and incubated on ice for five minutes. After exactly five minutes, 300pi o f 
neutralising solution (K-acetate) was added followed by further 5-minute incubation on ice. 
The samples were centrifuged at 13000rpm for five minutes at 4°C. The supernatant was 
transferred to a fresh tube and the pellet discarded. 900pl o f 100% ethanol was added to 
precipitate the plasmid DNA, mixed well then centrifuged as previously. The supernatant was 
discarded and the pellet washed in 75% ethanol and re-centrifuged. The supernatant was
O
discarded again and the pellet dried under reduced pressure at 55 C for five minutes. The 
pellet was re-suspended in 40pl o f  distilled water with 1 pi DNase free RNase (Boeringher- 
Mannheim, Lewis, East Sussex, UK)
2.9 Restriction Digest analysis of cDNA
To identify any clones positive for IL-15cDNA sequence, analysis was initially 
performed by restriction enzyme digest o f the plasmid DNA. This method was also used to 
check orientation o f the insert within the plasmid. (Because the nature o f T/A cloning 
insertion is not orientation specific)
Restriction-Digest reactions were set up to determine orientation and aid identification
o f clones positive for an IL-15 insert. For example, 3pl o f plasmid DNA was added to 2 pi o f
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restriction enzyme buffer B (Boeringher-Mannheim, Lewis, East Sussex, UK), 14pl dH20
and 1 jj.1 BamHl (Boehringer-Mannheim, East Sussex, UK) This was incubated at 37°C for 2 
hours. Samples o f  the same plasmid DNA were also analysed in a similar reaction containing 
the enzymes, EcoRl and Rsal (Boeringher-Mannheim, Lewis, East Sussex, UK), 1 pi o f  each 
in 2pl o f buffer A, 13pi o f water and 3 pi o f  DNA. Several samples o f  IL-15 PCR product 
were prepared for sequencing using the Qiagen mini-prep system according to the 
manufacturers instructions (Qiagen. Crawley, England). O f the 3 inserts sequenced, 1 was 
identical for the sequence o f  muIL-15 (No 6) and another was identical except for a 48 base 
pair, in-frame deletion. Further transformations and plasmid DNAs were produced and 
digested followed by sequencing using the manual Sanger Di-deoxy Nucleotide method, 
described below.
2.10 Di-deosv DNA sequencing
The di-deoxy Sequencing method (also known as the Chain Termination Method) 
devised by Sanger et al (73). A standard mini-prep (See above) was carried out on 2ml 
overnight cultures o f the transformant colonies, believed to carry the IL-15cDNA insert. 9pl 
o f Plasmid/TE buffer was added to lp l o f 2M NaOH and incubated for fifteen minutes at
37°C to remove contaminating RNA and denature the DNA. Sequencing primers were 
constructed according to the sequence recommended by the plasmid suppliers allowing 
sequencing o f the plasmid from 200 base pairs 5 prime to the insert, through the insert and 
then ending around 200bp downstream o f the insert. See below for primer sequences.
4 M l3 Reverse Primer CAG GAA ACA GCT ATG AC
4 M13 Forward primer(-20) GAC CGG CAG CAA AAT G
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A priming reaction was set up. lp l o f each primer was added to the denatured samples 
and mixed by vortex. 3pl o f  3M K-acetate (pH4.8) was then added to neutralise the alkali 
denaturant. The DNA was then precipitated with 75pl 100% ethanol and collected by 
centrifugation at 13000 rpm at room temperature for ten minutes. The supernatant was 
discarded and the pellet washed in 75% ethanol. After centrifugation, the supernatant was 
again discarded and the pellet re-suspended in 8pl sterile water. The sequencing then 
followed the protocol recommended by the suppliers o f the sequencing reagent (Sequenase 
version 2.0 DNA sequencing kit, Amersham Life science), 10 pi o f the priming reaction was 
added to lp l DTT, 0. 2pl diluted labelling mixture, 0.5pl dATP, 2 pi diluted Sequenase- 
polymerase. A 96 well-U bottomed plate (Coming Costar, Cambridge, MA, US) was 
labelled with A, C, G and T for both the forward and reverse primed reaction. As suggested 
by Sambrooke, Fritsch & Maniatis (71), 2.5 pi o f each o f these nucleotides were then 
dispensed to the bottom o f  each o f the wells as per the labelling scheme. 3.5pl o f the 
labelling/template reactions were added to the top o f the wells, taking care not to allow the 
two reagents to meet. The plate was then briefly spun in a centrifuge (Mistral 3000 MSE, 
Micro Centaur, Phillip Harris, Aberdeen, UK) to start the reactions simultaneously. The 
reaction was incubated for five minutes at room temperature and meanwhile 4pl o f the 
formamide stop solution was added to the opposite side o f each well. A quick spin 
precipitated the stop formula into the reaction allowing all the reactions to be stopped 
simultaneously. The sequences were analysed on 6M-urea polyacrylamide denaturing gels 
using standard procedure (71).
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2.11 Transformation into Qiagen Expression Vectors
Two expression vectors were used to transform M l 5 strain E. coli with murine IL-15 
cDNA to enable expression o f  IL-15 recombinant protein. These vectors differ in the 
orientation o f the 6-histidine residue affinity purification tag with respect to the cDNA insert. 
The 6-Histidine tag is added to the recombinant protein at the 5 prime end when the pQE-30 
is used and 3 prime end when the pQE60 is used. The secondary structure o f the recombinant 
protein may dictate that one orientation o f the tag may affect bioactivity less than the other 
orientation and therefore both vectors were used here to explore any advantage conferred by 
this facility.
The pQE-series o f plasmids carry a P-Lactamase sequence open reading frame that 
confers ampicillin resistance in successful transformants. In turn the host E. coli species used 
here; M l5 is selected for pREP4, which expresses Kanamycin resistance activity. Thus these 
two antibiotics can be used for accurate selection and to reduce high background cloning 
events.
2.12 Sub Cloning TA Vector insert to pQE 30-expression vector
From the pCR2.1 transformed bacteria (confirmed by digest pattern and sequence 
analysis) one clone IL-15 coding for the correct IL-15 sequence and another clone, IL-15, -48 
which coded for IL-15 with a 48 bp deletion were selected for sub cloning into the expression 
vector pQE-30. (Qiagen, Crawley, England) These clones were inoculated into 2 ml o f  LB 
broth with ampicillin and cultured overnight in shaken suspension at 37°C. A mini prep 
(described above) was used to isolate plasmid DNA. A digestion reaction was set up in total 
volume o f 70pl including 7pl Restriction enzyme buffer B, 5pi BamHl (Boeringher- 
Mannheim, Lewis, East Sussex, UK), 3 3pi sterile water and 25 pi o f plasmid DNA. 
Concurrently, 2pl o f the vector pQE-30 was digested in a volume o f 60pl o f the same 
reaction mix. The plasmid reactions were incubated to completion at 1.5 hours @37°C in a 
water bath whilst the vector was digested for 3 hours in a 37°C water bath.
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To prevent self-ligation o f the vector, 55 pi BamHl digested vector was de- 
phosphorylated with lp l CIP (Alkaline Phosphotase) (Boeringher-Mannheim, Lewis, East 
Sussex, UK), lOpl CIP buffer and 34pl Tris lOmM pH8.3. Incubated at 37°C for 2 hours and 
the reaction stopped with 1 pi 0.5M EDTA with heating to 75°C for ten minutes. Meanwhile, 
the BamHl digested IL-15-cDNA fragments were gel purified by running out on a 1% 
agarose gel Following electrophoresis, bands o f the predicted size were visualised under UV 
light and cut from the gel. DNA was extracted by the “Freeze Squeeze” method, briefly, the 
gel fragments containing the excised bands were placed into freeze squeeze buffer (0.3M Na- 
Acetate in ImM EDTA pH 7.0) in separate eppendorfe and incubated in the dark for ten 
minutes at room temperature. The buffer was discarded and the tubes containing the gel 
fragments placed into a (dry ice C02/ethanol bath (-80°C) until frozen. The frozen gel
fragments were transferred to a Spinex (Coming Costar, Cambridge, MA, USA) 0.2um filter 
tube and spun at 13000 rpm for ten minutes at room temperature. The gel fragments were 
discarded and the liquid residue containing the IL-15 fragments made up to 400pl per sample 
with TE buffer. The IL-15 and the de-phosphoiylated vector were then Phenol-chloroform 
extracted and ethanol precipitated as described earlier for PCR purification. The vector pQE- 
30 was re-suspended into 20pl sterile water and the DNA inserts into 15pl each. 3pi o f each 
o f these were run out on an agarose gel to determine concentration ratios for ligation (ideally 
a 1:1 ratio).
A ligation reaction was set up as described for pCR2.1 above resulting in the 
production o f the IL-15/pQE-30 and IL-15-48/pQE-30 constructs. A control self-ligation with 
no insert was also incubated and used for transformation control. Transformation of E. coli 
strain M l 5 (Qiagen) with these constructs was carried out to the manufacturer’s protocol 
summarised here. A lOOpl aliquot o f thawed transformation competent M l5 (Qiagen. 
Crawley, England) cells were added to lOpl o f ligation reaction and incubated on ice for 
twenty minutes. The cells were heat shocked for 90 seconds at 42°C in a water bath and 
following this incubated in 500pl o f Psi broth. (LB bacterial growth medium (Gibco Life 
Technologies, Paisley, Scotland) with 4mMMgS0 4  and lOmM KC1. (BDH Chemicals LTD,
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Poole, England). Samples were then placed into shaken suspension at 37°C for ninety 
minutes. 50pl o f  each o f  the transformation reactions were plated out on agar plates 
containing 100pg/ml ampicillin (Sigma Poole, Dorset, UK.) and 25 jig/ml Kanamycin (Gibco, 
Life Technologies, Paisley, Scotland.) The plates were incubated overnight at 37°C and 
positive colonies selected (negative selection) for protein expression screening.
In the case o f transformation with expression vector pQE-60, the procedure was 
exactly the same as above except the IL-15 PCR product was generated to include the 
restriction enzyme sites, N col and Bgl II (Boeringher-Mannheim, Lewis, East Sussex, UK). 
These were inserted into the 5’ and 3’ primer sequences (primer sequences noted on page 28). 
A construct was prepared by linearising the pQE-60 vector by digestion with these enzymes 
in a two-stage digestion reaction followed by ligation with the similarly digested PCR 
product. Sequencing o f the insert to confirm IL-15 sequence integrity was performed directly 
on the pQE-60/IL-15 constructs (as compared to the pCR.2.1 sequencing that was carried out 
prior to sub cloning into the pQE-30 vector).
Small-scale expression cultures were set up to identify transformants (selected by 
sequencing), which were able to express recombinant IL-15. Single colonies were picked 
from agar plates o f successful transformants (including vector controls) and cultured 
overnight in LB broth with antibiotics (Penicillin and Kanamycin as described above). A 
fresh flask with 10ml medium was inoculated with 500pl overnight culture and grown at 
37°C for thirty minutes and then periodically measured by spectrophotometry until OD 
@600nm was approx. 0.6 indicating log growth phase had been attained and cultures were at 
similar densities. Cultures were prepared in duplicates enabling one to be induced with 
isopropyl-p-D-thiogalactoside (IPTG) (Bioline London, England) to a final concentration o f 
2mM and one to serve as non-induced control. Following induction o f recombinant protein 
expression, cultures were grown for 3 - 6 hours and then harvested by centrifugation at 
lOOOOrpm for 1 minute at 4°c. (Centrifuge, Becton-Dickinson ultracentrifuge & JA 10 rotor, 
Oxford UK). The cells were then lysed in Lysis buffer B (8M urea @pH8.0) The lysate was 
centrifuged at 13000rpm /room temperature for ten minutes and the pellet o f cell debris
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discarded. The supernatant was transferred to a fresh tube. 40pl o f  a slurry o f  Ni NTA 
agarose resin (Qiagen) (Qiagen. Crawley, England) (pre-equilibrated in buffer B) was added 
and rotated for thirty minutes at room temperature. Centrifiiging for 10 seconds at 13000 rpm 
pelleted the resin. The unbound fraction was removed and stored on ice for analysis. The 
resin was washed 3 times with buffer C (buffer B at pH6.4) and the washings kept for 
analysis. 20ul buffer C with lOOmM EDTA was added and mixed with the resin to elute any 
protein and incubated at room temperature for two minutes. After a 10 second spin at 13000, 
the supernatant was transferred to a fresh tube and mixed with 5 pi o f  5X-PAGE sample 
buffer (5ml Glycerol, 2.5ml Mercaptoethanol, 1.5g SDS 6.25ml 0.5M TRIS, made up to 25ml 
with KfeOand ph6.8). Following heat denaturation (100°C water bath) for seven minutes the 
samples were loaded onto a 15% polyacrylamide SDS gel and separated by gel 
electrophoresis. The proteins eluted were visualised by Coomassie blue staining.
2.13 Protein production
Transformed bacteria established by Coomassie gel analysis to be expressing 
recombinant IL-15 proteins were grown in large-scale cultures. IL-15 protein was purified 
and characterised to further establish its identity by anti-IL-15 binding, and ability to bind the 
IL-15 specific receptor subunit, recombinant IL-15Receptor alpha. (IL-15Ra) Bioactivity 
was also tested in the Cytokine dependent CTLL murine T cell line.
2.14 Large scale production and purification of recombinant IL-15
Glycerol treated stocks o f IL-15 expressing bacteria were stored at -80°c. Large-scale 
culture was established by inoculating 100ml LB broth/antibiotics with a loop o f bacterial 
stock, grown overnight with shaking at 37°C. 900ml (or multiples o f these amounts) o f pre­
warmed broth were inoculated with 100 ml overnight culture and growth continued for 2 
hours (OD@ A600nm=aPProx 0.6). This log phase culture was then induced by addition o f
IPTG to final concentration o f 2mM. Induction was continued for 4 hours. Cells were 
harvested by centrifugation at 4000rpm at 4°C for twenty minutes (Beckman JA 10 Rotor). 
The supernatant was discarded and the pellets re-suspended with 30ml Buffer B (8M urea,
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0.1M NaH2P0 4 , O.OIM Tris.Cl, pH8.0) per cell culture in sterile 50 ml tubes. Lysis was 
achieved by rotation at room temperature overnight. Cell debris was pelletted by centrifuging 
at 14000rpm for thirty minutes at room temperature (Becton-Dickinson ultracentrifuge & JA 
17 rotor, Oxford UK). The supernatant was transferred to a fresh 50ml tube and 500ul 
NiNTA resin was added per original litre o f culture. Then followed by incubation at room 
temperature with gentle rotation for periods in excess o f one hour. The resin was collected by 
brief centrifugation and the “unbound” portion discarded. The resin was washed in 40 ml 
buffer B and loaded into a Qiagen 10 ml affinity purification column. The filter collected the 
resin as the wash buffer/resin system was poured into the column. As the washing buffer 
voided from the column fresh buffer B @ pH8.0 was added to the column to about 10 column 
volumes. Periodically, (i.e. every 2-column volume), samples o f the washings were measured 
for protein by Absorbance @260nm. When the OD was <0.01, buffer C (As buffer B but at
pH6.4) was added to the column and further OD observations made. At ODO.Ol the protein 
was deemed to be purified to a greater degree and after a pre-wash o f Buffer C with 50mM 
Imidazol, the remaining resin-bound protein was eluted in 4ml Buffer C/300mM Imidazol. 
Samples were taken and analysed for molecular weight and purity. Dialysis against PBS 
induced precipitation o f the protein subsequently; PBS with 30% glycerol was used for 
dialysis.
Constant problems with precipitation and low yield resulted in the purification 
strategy being changed to more severe conditions. The revised protocol included Lysis and 
solubilisation in Buffer A (6M Guanidine hydrochloride) (Qiagen. Crawley, England), two 
extra washing buffer steps; Buffer D and E (As buffer B but pH 5.9 and 4.5 respectively) and 
elution in buffer F, (6M Guanidine Hydrochloride/acetic acid 0.2M = approx. pH 2.8). 
Analysis by electrophoresis required dialysis against PBS/30% glycerol. This was because 
guanidine was precipitated as crystal salts by SDS in reducing-polyacrylamide gels. (See 
Western Blotting, section 2.17 below)
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2.15 Production of murine IL-15 receptor alpha
5 Litres o f LB medium with antibiotics (25ng/ml Kan & lOOng/mlAmpicilin) were 
inoculated 10% overnight culture o f E. coli (M l5 strain, transformed with truncated murine 
IL-15 receptor alpha cDNA in pQE 30 expression plasmid; kindly donated by Holger 
Ruchatz). After 2 hours growth at 37°C protein production was induced by 2mM IPTG added 
to the log phase culture. Growth was continued for two more hours at 37°C with shaking at 
225rpm. Cells were pelleted by centrifugation (4000 rpm @ 4°C for thirty minutes) in a J10 
rotor in a Beckman ultracentrifuge) media discarded and the cell pellet frozen at -70°C 
overnight.
Pellets were directly lysed by 8M urea (buffer B) (Qiagen) @30ml per 1L culture o f 
cells. Lysis achieved by rotation for 4 hours. A cleared lysate was prepared by centrifugation 
(14000rpm@25°C for forty minutes J17 rotor). Cell debris discarded. 0.30ml o f  Ni-NTA 
agarose was added to each 30ml-cleared lysate and incubated with rotation for lhour. The 
lysate/Agarose slurry was centrifuged at 2500rpm and the glutinous, unbound fraction o f 
lysate discarded. The remainder was diluted with 30ml buffer B and re-centrifuged to pellet 
the agarose. The unbound fraction was again discarded. The resin/slurry was then added to a 
Qiagen column. The column was washed with approx. 200ml buffer B followed by 200ml 
buffer C (Qiagen) (i.e. A280 <0.01) The column was washed with 10ml buffer C/20mM 
Imidazol followed by a wash with 5ml o f bufferC/50mM Imidazol. The column bound 
fraction was then eluted with 8ml Buffer C/ 300mM Imidazol. The eluate was then placed in 
dialysis tubing and dialysed against High salt PBS buffer at 25°c for 30 hours with 1 change 
of buffer. (PBS pH7.2/2% NaCl)
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2.16 Protein assay
Protein concentration was determined by either o f two methods.
The Coomassie protein assay
A standard curve o f BSA diluted in dialysis buffer with concentration range 1.5mg -
0.1 mg/ml was constructed. (74) lOOpl o f each standard and each dialysed sample was mixed 
with 5ml Coomassie reagent (Pierce, Rockford, Illinois, USA). Absorbance was read 
immediately at A5 9 5 nm and protein content o f the samples determined in relation to the 
standard curve absorbencies. As the curve was most linear at values o f 0 to 500pg/ml, 
dilutions o f the samples were made to enable readings in this section. This method is less 
susceptible to solvent interactions and could be used well for quick determinations e.g. 
success o f purification.
BCA protein assay.
This assay may be affected by Guanidine in excess o f 4M but is very reproducible 
and useful for accurate protein determinations such as Bioassay or western blotting 
preparation. 10 ml Bicinchoninic acid (Sigma Poole, Dorset, UK.) was mixed with 200pl 4% 
CuSC>4 (aq) according to the manufacturers recommendations. In volumes o f 500pl,
standards were prepared with double dilution o f BSA in whatever sample buffer was being 
used, in concentrations from 200ul and down. The sample was diluted 1/10 and sample and 
dialysis blank prepared. 500pl o f reagent was added to each sample/blank/standard tube, 
mixed and incubated for thirty minutes at 37°C. Absorbance was read at 562nm and sample
concentration determined against that o f the standards.
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2.17 Western Blotting
It was necessary to confirm the identity o f the recombinant protein by an affinity 
method as well as the mobility evidence o f Coomassie stained gels. A 15% polyacrylamide/ 
SDS gel was prepared. Samples o f dialysed recombinant IL-15 were denatured in 2X sample 
buffer and amounts corresponding to lpg  protein loaded onto the gel. Rainbow, pre-stained 
molecular weight markers (Amersham, Little Chalfont, Bucks, England) were run and when 
the markers indicated the 14kDa proteins had travelled approximately 3/4 o f  the gel surface, 
the current was stopped. The stacking portion o f the gel was discarded and the gel washed 
briefly in Tris/glycine/methanol transfer buffer. The separated proteins were transferred onto 
pre-wetted nitro-cellulose membrane (Biorad) by liquid-transfer at 200-300 milli-amps 
overnight. The nitro-cellulose membrane was incubated in blocking buffer (PBS 0.1% Tween 
20 and 5% dried milk (casein) for one hour with orbital shaking at room temperature
conditions for all incubation and washing steps).
The membrane was washed in PBS 0.1%Tween 20 (PBS-T) for fifteen minutes and 
then three times with fresh PB-T for five minutes. The primary detection monoclonal 
antibody; biotinylated-rat anti-murine IL-15 (Pharmingen, San Diego, California, USA) was 
diluted 1/1000 v/v into blocking buffer and the membrane incubated for 2.5 hours. Washing 
was then as before. Extravidin HRP conjugate (Sigma, Poole, Dorset, UK) was diluted in PB- 
T and the membrane incubated for one hour. The membrane was washed as before with 1 
extra 5-minute wash. The blot was transferred to a darkroom with detection by the ECL 
method (ECL, Amersham, Little Chalfont, Bucks, England). The membrane was dried o f 
excess wash buffer. Equal volumes o f the detection reagents were mixed together (0.125ml 
per cm^ membrane) and poured over the membrane and incubated for 60 seconds in a clean 
petri dish. The membrane was dried o f excess detection reagent and placed protein side down 
over Clingfilm. The Clingfilm was folded in an envelope around the membrane and the 
protein side placed face up into an auto radiograph cassette. Autoradiography film (Kodak, 
Ilford, Essex, England) was placed over the membrane/envelope and exposed for variable 
amounts o f time.
2.18 ELISA
The bioactivity o f the recombinant protein was tested initially by its ability to bind the 
IL-15 specific receptor subunit IL-15 Receptor alpha (IL-15Ra) in an ELISA based assay. A 
96 well plate (Immulon) was coated with 50pl per well with IL-15 Receptor alpha @ lpg/ml 
in 0.1 M NaHCQ3 pH8.2 and incubated at 4°C overnight. The plate was washed 3 times in 
PBS-Tween20 (0.05%) and non-specific binding blocked by incubation at 37°C for one hour 
with 200pl per well 10% Foetal Calf Serum in PBS. The plate was washed 4 times and 
samples o f recombinant IL-15 and a Human commercial IL-15 standard curve, both diluted 
into 10% FCS/PBS added with serial dilution across the plate. After 3 hours incubation at 
37°C, the plate was washed four times and rat anti-mouse IL-15 biotinylated monoclonal 
anti-body (Pharmingen, San Diego, California, USA) diluted to l/2000v/v in 10% FCS/PBS 
was added at 50 pi per well. This was incubated for one hour at 37°C. the plate was washed 
four times and a 1/1000 dilution o f Extravidin peroxidase (Sigma Poole, Dorset, UK.) in 10% 
FCS/PBS was then added at 50ul per well and incubated for forty five minutes at 37°C. The 
plate was washed six times and the chromogenic substrate, TMB-Microwell added at lOOpl 
per well. After ten minutes development time, the plate was read for absorbance at 405nm 
enabling calculation o f IL-15 and an assessment o f binding which in turn infers a degree o f 
bioactivity.
2.19 CTLL assay
This T cell line, originally cloned from a C57bl/6 mouse (1977) is IL-2 dependent. 
However proliferation o f  this cell line is also supported by IL-15 (10). It was possible 
therefore, to assess bioactivity o f the recombinant protein murine IL-15 by measuring 3H
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thymidine uptake by CTLL cells in a proliferation assay. Briefly, cells were cultured in the 
presence o f IL-2 (lOng/ml) for 3 days in RPMI/10% FCS and antibiotics. The cells were
harvested, washed twice in RPMI (No IL-2) and re-suspended at l x l0^ cells/ml. In a 96 well 
culture plate, a standard curve o f Human IL-15 or IL- 2 was constructed using serial dilutions 
o f  cytokines in RPMI. Samples o f dialysed recombinant protein were diluted in the same
manner. CTLL cells were added to the plate and incubated overnight at 37°C. A pulse o f
tritiated thymidine, (luC i per well) was added with incubation at 37°C for 6 or more hours.
Cells were harvested on a Wallac cell harvester and thymidine uptake determined by 
scintillation counting on a Wallac Betaplate scintillation counter.
2.20 Generation of Polyclonal anti-murineIL-15 anti-body
A New Zealand White rabbit (Harlan, Olac, Huntingdon, Cambridge) was bled for 
pre-immune serum sampling. Then it was inoculated with 92pg o f  recombinant IL-15 in 250 
pi o f PBS/glycerol diluted into Freunds complete adjuvant (Difco) with a total volume o f 
500pl Nineteen days later, a booster injection o f 140pg recombinant IL-15 in Freunds 
incomplete adjuvant (Difco, USA) was given. Two subsequent booster injections were given 
at similar intervals. Serum-levels o f anti-IL-15 antibody were measured by ELISA. A 96 well 
plate was coated 50pl/well, half with lpg/ml recombinant IL-15 and the remainder with 
recombinant IL-18 (negative control) and incubated overnight. Following the washing regime 
described above, a 1/100 Rabbit serum sample was added and then serially diluted across the 
plate and incubated for 2 hours at 37°C. The plate was probed with 1/1000 Sheep/anti-rabbit 
HRP conjugate (SAPU, Scottish Antibody Production Unit, Law, Scotland) and anti-body 
titre analysed by spectroscopy at 405nm as previously described. Anti-body was purified 
from serum by protein A column chromatography (Sigma Poole, Dorset, UK), following the 
manufacturers’ recommendations (except eluted anti-body fraction was not dialysed against
49
Azide). The Anti-body was dialysed against PBS and total IgG recovered measured by 
Coomassie assay (Pierce, Rockford, Illinois, USA) as described earlier.
Murine models of Inflammation
To investigate the role o f IL-15 in inflammatory diseases, three models were used.
2.21 Collagen Induced Arthritis
Male DBA/1 mice (Harlan, Cambridge, England) at 6-8 weeks old (75) were 
inoculated intradermally with 200ug bovine collagen type II (Sigma Poole, Dorset, UK) in 
complete Freunds Adjuvant (Difco, USA). The mice were challenged 21 days later by Intra- 
peritoneal (IP) injection o f 200ug collagen in Freunds incomplete adjuvant (Difco, USA). 
Therapeutic doses o f  anti-IL-15 polyclonal anti-body or -48 IL-15 mutant were administered 
daily starting one day after challenge.
Following the collagen challenge, the mice were monitored daily for weight change, 
signs o f arthritis including paw thickness (calliper measurement o f paw diameter) and 
incapacitation. Arthritis was assessed by the following severity score system, 0 = normal paw 
appearance, 1= erythema, 2= erythema and swelling 3 = severe swelling and /or loss o f 
function. Incidence o f arthritis was also recorded daily.
2.22 LPS induced Endotoxic shock model
LPS shock was induced in 10-week-old Balb/c mice (Harlan, Cambridge and In-house 
bred mice) by intraperitoneal injection o f  18mg/Kg LPS in PBS (Sigma Poole, Dorset, UK) 
(48). Immediately following induction the mice were treated with either IL-15 receptor alpha 
or PBS. The therapeutic dose regime varied in time and amount according to the exact 
experiment, (See results). Frequent observation was used to assess the effect o f the treatment 
using the indices o f septicaemia shown in the table (Table 2) below. Initially mortality was
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the only informative parameter. In later experiments, biochemical analysis o f Serum samples 
were obtained by exanguination o f the mice following dislocation o f the neck. Serum was 
diluted 1/10 in 7% BSA (Sigma Poole, Dorset, UK) and levels o f  serum enzyme indicators o f 
liver damage determined (kind assistance o f  Glasgow Royal Infirmary, Routine 
Biochemistry). A general matrix o f indicators o f  sepsis was also derived and used to 
determine severity. In some experiments in this model, BALB/c mice o f  the same age were 
primed with 1 mg/mouse heat killed C. parvum suspended in PBS and injected by IV route. 
Seven days later doses between 0 and 5 mg/Kg LPS were injected by IP route and therapeutic 
IP injections o f IL-15 receptor alpha (or control) were initiated. The observation and post­
mortem analysis o f  the procedure was identical to that for that described above.
Healthy Unhealthy
Actively running around 0 Moving slowly
1
Inquisitive 0 Not Inquisitive
1
React to touch 0 No reaction to touch
1
Moving around at 60 hours 0 No spontaneous movement at 60 Hours
4
Normal stools 0 Diarrhoea
1
Clear eyes 0 Encrusted eyes
1
Skin warm to touch/relaxed 0 Skin coId/Hunched aspect
1
Weight loss <30% 0 Weight loss >30%
7
No shivering when picked 
up
0 Shivers uncontrollably on picking 
up 5
Mobile at 72 hours 0 Immobile at 72 Hours
7
Table 2 Table of scoring system used to m onitor mice during this experiment 
based on previous results and M orton-Griffith index and the Rodent Protection 
Document. AH animals scoring -7  were scored and humanely killed. The data 
was recorded on an “ intention to trea t” basis.
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2.23 Septic arthritis model
S. aureus LS-lstrain the TSST producing strain o f  StaphylococcuS. aureus previously 
used in Bremell’s murine model o f septic arthritis (66) were cultured on blood agar plates at 
37^C and re-suspended to 5x10** bacteria/ml determined by spectrophotometry. 4-6 week old 
MF1 mice were inoculated with 5x10? bacteria per animal In one experiment, 40pg o f  IL- 
15-receptor-alpha was injected immediately following and three days after the bacterial 
inoculation by the IP route. In a later experiment IL-15 receptor treatment was given daily for 
7 days following the bacterial inoculation The mice were carefully observed (where possible 
by a blinded observer) for symptoms o f incidence and severity o f Arthritis by the scoring 
system described above and septicaemia by definition o f lack o f spontaneous mobility, 
presence o f ocular discharge, starey coat and hunched position Weight loss/gain, mortality, 
and the incidence and severity o f  sepsis were also recorded. Observations were continued for 
periods up to two weeks.
Whole blood obtained by exanguination was analysed for S. aureus colony forming 
units. 1/10 serial dilutions o f whole blood were plated out on blood agar and incubated 
overnight at 37^C. S. aureus colonies were kindly identified by Professor C Gemmell.
At post-mortem, spleens were removed from each carcass, pooled per 
treatment/control group and forced through nylon mesh with a syringe plunger into a single 
cell suspension, lg  o f tissue suspension was weighed out and serial dilutions at 10"2* 10"^, 10 
"4, 10-5, 10"6 & 10-7 ^ 0  sterile PBS were made. lOOpl o f each o f these dilutions were 
spread onto pre-warmed blood agar plates and incubated overnight at 37°c. S. aureus 
colonies were counted the following day. Kidneys and liver were obtained and treated the 
same way.
Hind limbs were removed above the ankle joint. The paw was cut across the foot 
midway between the heel and toes. The freshly cut face was then streaked across the surface 
of a pre-warmed blood agar plate. After over night incubation at 37°c, the number o f S. 
aureus colony forming units were counted.
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Spleen cells from the suspension described above were re-suspended in RPMI at 
l x l c e l l s  /ml and plated out in a round bottomed 96 well culture plate. Spleen cells were 
stimulated with dilutions o f Staphylococcal Enterotoxin-A (SEA) (Sigma), Toxic Shock 
Syndrome Toxin (TSST) Sigma, Concanavalin-A (Sigma), Simian IL-15 (Immunex) or 
medium alone. Incubations were for 24 or 48 hours at 37°C. Detection o f  proliferation was by 
3hThymidine pulse 6 hours prior to cell harvesting followed by scintillation counting on a 
Wallac Beta counter.
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2.24 Statistical analysis
In order to assess significance o f the experimental results, the following tests have been 
used.
1. Mann Whitney U
2. Chi square
3. Kruskal Wallace
These tests were performed on raw data using a PC supplied by Gateway Computers, 
UK and using the statistical analysis programme, “Minitab” provided by the University o f 
Glasgow. To confirm significance, a p value o f less than 0.05 was required.
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Chapter 3 
Results
3 .1 Generation of murine IL-15 and murine -48  IL-15 mutant
A PCR primer pair (listed in chapter 2 page-26) was synthesised 
corresponding to parts o f the published sequence o f murine IL-15 and predicted a 
product o f 355bp (gene-bank accession number U14332). Following PCR 
amplification using these primers, products with mobility o f approximately 360bp 
were identified by agarose gel electrophoreses. Fig 1 shows a photograph o f such a 
gel.
Fig 1 PCR products amplified from J774 m acrophage total cDNA using IL-15 
and P-actin specific prim ers. Lane 1; 1Kb ladder lane 2,3 and 4; IL-15 cDNA 
including signal sequence product 510bp, lanes 5,6 and 7 m ature coding 
sequence. Lanes 7,8 and 9; p-actin. Lane 12 1Kb ladder (Ethidium bromide 
stained 1% agarose gel illuminated by UV light)
5 6
These PCR products were ligated into the TA cloning vector, pCR2.1 and 
transfected into E.coli according to the protocols listed in the previous chapter (page 
33). Plasmid DNA was extracted from overnight cultures o f successful transformants 
by the mini-prep method described earlier. Two restriction enzyme digest reactions 
were carried out to further confirm the identity o f  the PCR products as IL-15 derived. 
A single restriction enzyme BamHl (Boehringer Mannheim, Germany) digest 
confirmed that the insert was reverse orientated within the plasmid and had a mobility 
o f around 400bp (including some 3’ plasmid sequence). The murine IL-15 cDNA 
sequence has a naturally occurring Rsal restriction enzyme cut site at 770bp. When 
the plasmid DNA was digested with both EcoRl and Rsal, a pair o f products o f 199 
and 170 bp were predicted. Figure 2 below indicates the locations o f these restriction 
sites and their digestion product sizes.
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5’pCR2.1
 p ~
BamHI
Rsal
primer
t=L
TJ
EL-15 PCR product insert 4
BamHl 
5’primer
3’pCR2.1
J
EcoRl EcoRl
Figure 2 Schematic representation of the pCR.l/IL-15 plasmid and insert with 
locations of restriction enzyme sites listed.
Fig 3 below shows the products o f a digestion with EcoRl/Rsal. As predicted, lanes 
numbered 6 and 7 give products o f 190 and 170bp. However the lane labelled 8 has 
one product at 190 and a smaller one at approximately 130 bp. This alternative 
digestion product size suggested that as well as IL-15, a mutant had possibly been 
cloned as a result o f a PCR artefact or an alternative IL-15 mRNA transcription event. 
This alternative fragment was called IL-15-48 for the purposes o f this thesis.
Fig 3 Agarose gel (2% ) stained with Ethidium bromide and illuminated with UV 
light. Lanes 11 and 12 show predicted digestion products of 170 and 190bp when 
pCR2.1/IL-15 is digested with restriction enzymes EcoRl and R sal. The 
characteristic “double banding” is visible. Lane 6 and 13 contain a product at 
190bp and one below at approximately 130bp (IL-15-48).
3.2 Sequencing
The clones contained in the plasmids labelled 6, 7 and 8 in figure 3 above, were 
sequenced by automated sequencing (Strathclyde University, Glasgow) (Sequencing 
gel not shown).
Clone 6 and 7 were confirmed as 100% homologous with the published sequence for 
murine IL-15. Clone 8 was found to be identical to murine IL-15 sequence except for 
an in-frame deletion o f 48 base pairs, corresponding to 16 amino acids from (bp)99 to 
147 inclusive hence IL-15-48. Figure 4 below shows the sequence o f clone 6 which is 
homologous to the murine 11-15 sequence published by Anderson et al (Accession 
number to gene bank= U 14332). The recombinant clone excludes the 5’ un-translated 
region (UTR) found in the natural gene product. The figure also shows in red and 
brackets, the in frame deletion o f 48 bp corresponding to 16 amino acids from the 
normal mature protein.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
ATG tgg ata gat gta aga tat gac ctg gag aaa att gaa age ctt att caa
Met tip ile asp val arg tyr asp leu glu lys ile glu ser ile gin ser
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
tct att cat att gac acc act tta tac act gac agt gac ttt cat {ccc agt tgc
ser ile Iris ile asp tin thr leu tyr tin asp ser asp phe his pro ser cys
36 37 38 39 40  41 42 43 44 45 46 47 48 49  50 51 52
aaa gtt act gca atg aac tgc ttt etc ctg gaa ttg cag} gtt att tta cat
Ivs val thr ala met asn cys phe leu leu glu leu gin val ile leu his
53 54 55 56 57 58 59 60  61 62 63 64 65 66 67 68 69
gag tac agt aac atg act ctt aat gaa aca gta aga aac gtg etc tac ctt
gin tyr ser asn met thr leu asn glu thr val arg asn val leu tyr leu
70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86
gca aac age act ctg tct tct aac aag aat gta gca gaa tct ggc tgc aag
ala asn ser thr leu ser ser asn lys asn val ala glim ser gly cys lys
87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103
gaa tgt gag gag ctg gag gag aaa acc ttc aca gag ttt ttg caa age ttt
glu cys glu glu leu glu glu lys thr phe thr glu phe leu gin ser phe
104 105 106 107 108 109 110 111 112 113 114
ata ege att gtc caa atg ttc ate aac acg tcc tga------------plasmid-----------
ile arg ile val gin met phe ile asn thr ser Stop
Figure 4
cDNA sequence o f clone 6 showing amino acid translation, homologous to gene 
bank sequence number U 14332. The translation to amino acids is indicated by 
green, small standard abbreviations below cDNA sequence 
Bases and amino acids highlighted in red indicate the deletion found in the cDNA 
sequence of clone 8 This deletion, between amino acids 33 and 48 inclusive, is in­
frame with both the recombinant start codon and the natural sequence.
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3.3 Hydro path icitv
In figure 5 below, a Kyle and Doolittle predictive plot o f Hydropathicity o f  the 
primary structure o f the cloned product sequence shows that the amino acids deleted 
from the standard IL-15 approximately correspond to a major hydrophobic domain.
The significance o f this deletion is unknown. It may be an artefact o f the cloning 
process which happened to be in frame and coincide with a hydrophobic domain o f 
the primary protein structure. However, it is interesting to speculate, as later 
experiments described below show, that the translated deletion mutant retained the 
ability to competitively bind the IL-15receptor in an antagonistic mode when in 
competition with the native protein. The lower Hydropathicity o f IL-15-48 mutant 
may lead to greater solubility compared to that o f the native sequence.
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K y te  a n d  D o o l i t t l e  H y d r o p a t h ic i t y  P l o t
H y d r o p h o b ic
< peuref> J?  -w e
1101009050403010
Figure 5
Doolittle plot of the relative hydrophobicity of the protein predicted by the 
sequence derived from clone 6
3.4 Protein expression
Sequenced clones containing IL-15 or the IL-15-48 were directionally sub­
cloned into the Qiagen expression vector pQE30 and transformed into E.coli (Ml 5 
strain) by the methods described in chapter 2. Following the manufacturer’s protocol 
for fast colony screening (see chapter 2), cultures were selected which could be 
induced to produce recombinant protein o f the expected molecular weight range for 
recombinant IL-15, i.e. 14-15 kDa. The small overnight cultures were pelleted and 
lysed in SDS sample buffer and run out on a 15% polyacrylamide gel. Figure 6 below 
shows a coomassie stained 15% polyacrylamide gel with five cultures. These cultures 
were sampled pre-protein production-induction with IPTG and then two and four 
hours after induction. The fifth culture is a control culture transformed with empty 
pQE30 vector. It can be seen that there is heavy induction o f proteins after 2 hours at 
approximately 13kDa in the IL-15-48 cultures and at approximately 15kDa in the IL- 
15 cultures when compared to the non-induced samples o f these cultures. The fifth 
culture, the vector control shows no such induction. Treatment o f the samples is 
described above in the materials and methods. Briefly, pellets were dissolved into 
0.5ml SDS sample- buffer and heated for 7 minutes at 100°c. Samples were loaded at 
20ul per well into a 15% polyacrylamide gel. Gel was stained with coomassie blue 
and vacuum dried
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Fig 6 Polyacrylamide gel electrophoresis separation of total protein from five 
pQE30 transformed E.coli cultures including a vector control transformation. 
Lanes 1 & 17 Molecular weight markers. Lanes 2-4 & lanes 5-7 two cultures 
transformed with pQE30/IL-15-48. Lanes 8-10 & 11-13 cultures transformed 
with pQE30/lL-15 and lanes 14-16 control culture transformed with an empty 
pQE30 vector. The first lane in each group was sampled before protein induction 
by 2mM IPTG and the second and third lanes of each group are sampled at 2 
and 4 hours post induction respectively. Protein was induced at 2 and 4 hours in 
all IL-15-48 and IL-15 cultures at approximately 13 and 15 kDa respectively. No 
protein induction is seen in the vector control transformant culture. 2ml culture 
samples were taken and pelleted by centrifugation and pelleted by brief 
centrifugation.
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Having identified colonies producing inducible protein in the predicted 
molecular weight range, larger size colonies o f both IL-15 and IL-15-48 
mutant expressing cultures were established to gain sufficient protein for 
further analysis and characterisation. The protocols and volumes used are 
described in chapter two. It was found that the protein yield when using the 
Ni-NTA affinity purification system was much lower that expected from the 
intensity o f the staining in induced cultures when protein was extracted by 
SDS page buffer. (Fig 5) It was considered that the recombinant IL-15 was 
only slightly soluble in the 8M urea “Buffer B” o f the standard protocol and 
therefore a more stringent lysis and washing procedure was adopted using the 
Guanidium Chloride “Buffer A” system described in chapter 2.
This increased the protein yield from below 1 OOpg/ml to levels 
exceeding 300pg/ml. Purity was also increased but solubility was only 
achieved in Phosphate Buffered Saline (PBS) at pH 7.4 when 30% glycerol 
was added to the dialysis buffer. The IL-15 -48 deletion mutant, however, was 
soluble in the urea buffer at 400pg/ml and remained soluble when dialysed 
into PBS/Glycerol 30%. This again, perhaps due to the observed missing 
hydrophobic domain seen in the kyle Doolittle plot on pg 60. Because glycerol 
and traces o f urea are believed to interfere with some protein assays, such as 
the Bicinchoninic Acid (BCA) Assay, the wider spectrum Coomassie Plus 
assay, (Pierce Reagents USA) was used to determine protein concentrations o f 
recombinant IL-15 and -48 mutant. An example o f this assay is shown below 
in figure 7
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Fig. 7 A typical concentration determ ination o f recom binant IL-15 and IL-15 -48 m utant. A standard curve  
was constructed by serial dilution o f Bovine Serum  A lbum in in PB S/30%  glycerol d ialysis buffer. lOOpI o f  
dialysed sam ple was added to 5000pl Coom assie plus reagent, vortex m ixed and O ptical D ensity (O D) 
m easured by spectrophotom etry at 595nm  against a reagent/buffer control.
3.5 Western Blotting
In order to confirm further the identity o f the putative recombinant IL-15 or its 
variant IL-15-48, a western blot was made using IL-15 and IL-15-48 samples and 
appropriate controls. Below in figure 8A, the samples were run out on one o f a pair o f 
duplicate 15% polyacrylamide gel. The other o f these gels, figure 8B, (Same batch o f 
gel mixture and samples run simultaneously in a dual gel apparatus) was transferred 
and western blotted according to the protocols described in chapter two. When the gel 
was blotted with a commercial anti murine IL-15 monoclonal antibody, the 
characteristic double bands, as noted in all the IL-15 purification performed in 
relation to this thesis, stained intensely when visualised by ECL-auto-radiography. 
There was no staining o f the control samples and it was concluded that the antibody 
was detecting recombinant murine IL-15 and a mutant IL-15-48, clearly seen to have 
a lower molecular weight in both the coomassie and western blotted gels. Due to time 
elapsed between write up and experiment, the gels no longer were readable and were 
discarded therefore no data can be shown other than the recorded observations above.
3.6 Recombinant murine IL-15 Binding assay
The western blot evidence in conjunction with the coomassie-blue stained gel 
molecular weight evidence (Fig 6) strongly suggested that the purified recombinant 
protein was murine IL-15.
To further confirm the identity o f the presumptive recombinant IL-15 and 
mutant IL -15-48 molecules, an ELISA type assay was designed to establish any 
binding activity o f the recombinant molecules to a soluble murine IL-15 receptor 
alpha protein cloned and expressed by this laboratory.
Half o f the wells in an Immulon 4 (Coming Costar, Cambridge, MA , USA), 
96 well plate were coated at 10pg/ml with recombinant IL-15Ra and the remainder 
with recombinant murineIL-18 at the same concentration. After overnight incubation 
and washing and blocking as described in the ELISA protocol, a duplicate set o f wells 
in the receptor and IL-18 coated part o f the plate, were incubated with serial dilutions 
o f either recombinant IL-15 or IL-15-48 mutant. These were added at a starting 
concentration o f 1 mg/ml and serially diluted across the plate and incubated @37°c for 
2.5 hours. The presence o f IL-15 or mutant IL-15-48 bound to the bound IL-15- 
receptor alpha or IL-18 control was detected by a sheep anti-IL-15Ra antibody 
(SAPU, Scotland) and development o f the assay with the chromogenic substrate 
TMB-microwell (KPL, Gettysburg, Maryland USA).
Figure 9 below reveals binding o f IL-15 and IL-15-48 to the receptor but little binding 
was evident in the IL-18 control wells.
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Figure 9 Shows results of ELISA to determine binding affinity o f purified 
samples of rmuIL-15 and rmuIL-15-48 mutant to the soluble IL-15Receptor 
alpha Rmu IL-18 was used as a control molecule. The recombinant IL-15 
and 11-15 mutant exhibited strong binding to IL-15Ra at all concentrations 
tested However a weak binding of these molecules was observed to the 
control The significance of this was not realised at the time but with 
hindsight it may have indicated some LPS contamination of the samples 
following purification
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Having demonstrated that the recombinant IL-15 and mutant were both able to 
recognise the IL-15 receptor, it was necessary to ascertain if the recombinant protein 
had IL-15 bioactivity.
7 2
Characterisation of Bio-activitv of recombinant murine IL-15
3.7 CTLL proliferation assay.
The CTLL assay is based upon a murine Cytotoxic T Lymphocyte Line cell 
line, which is commonly used as an IL-2 bioassay (82). This is because these cells 
have an absolute dependency in a cell culture medium for exogenous IL-2 for 
proliferation and survival. However, this cell line is also responsive in the same way 
to IL-15 as demonstrated by Grabstein et al (10), as IL-15 and IL-2 share many o f the 
same cell proliferative activities.
CTLL cells were cultured for three days following recovery from frozen 
storage (-80°c), in RPMI with penicillin and streptomycin, 10% foetal calf serum and 
L-glutamine and in the presence o f lOng/ml recombinant IL-2 (Genzyme, UK). The 
cells were then cultured for a further three days in the absence o f IL-2 and washed 
twice in fresh RPMI pipetted onto a 96 well plate at 5x104 cells per well. Prior to 
addition o f the cells, recombinant murine IL-15 and IL-2 were serially diluted, 
starting from 10 and 250 ng/ml final concentration, across the triplicate, 6-well 
sections o f the plate in volumes o f lOOpl/well. The recombinant-mutant molecule, 
murine IL-15-48, was added to three o f the IL-15 groups o f wells at 60, 125 and 
250ng/ml in each o f the selected wells. These were pre-incubated with the IL-15 
dilutions. In one set o f wells, IL-15-48 mutant was added alone. Cells were cultured 
in 5% CO2 @37°c overnight and then pulsed with lpCi tritiated-thymidine per well. 
Cells were harvested and proliferation activity was measured by beta scintillation 
counting in counts per minute (Wallac Beta Counters, USA). The induction o f
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proliferation o f the CTLL cells by murine IL-15, murine IL-2 and murine IL-15-48 
mutant is shown below in figure 10.
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Figure 10
When CTLL cells were incubated with recombinant murine IL- 
15 or IL-2, a dose dependent proliferation curve is seen. If the 
murine IL-15 is pre-incubated with m utant murine IL-15-48 
before adding to the cells, a reduction of proliferation activity is 
seen. The m utant molecule itself dem onstrated negligible 
proliferative activity.
Figure 10 shows that the CTLL cells were induced to proliferate by the recombinant 
murine IL-15 in the absence o f IL-2, indicating that it had IL-15 bioactivity and 
therefore, further confirming the recombinant molecule as murine IL-15. I has been 
suggested that the identity o f this molecule as IL-15 could have been strengthened by 
the addition o f further controls such as IL-2 receptor or neutralising antibody in the 
assay. The mutant molecule, IL-15-48 had a defined, in-frame deletion mutation o f 16 
amino acids. It was interesting to see if this deletion affected the ability o f the mutant 
to bind its receptor or indeed had any IL-15 bioactivity. In the previous section, the 
ELISA assay (figure 9) demonstrated that the mutant could bind to the IL-15 soluble 
receptor with similar affinity to the standard recombinant murine IL-15. Here in 
figure 10 however, where the normal IL-15 could induce proliferation measured by 
cpm >30000, the mutant molecule induced little or no proliferation above the cell 
only background count o f 150cpm.
This implied that the site o f interaction between IL-15 and its receptor could be 
affected by the deletion.
In order to investigate the possibility that IL-15-48 could act as an antagonist to IL- 
15, a sample o f IL-15-48 was added to murine IL-15. In this assay, 250ng/ml 
recombinant IL-15 had induced proliferation > 27000cpm. However in wells where 
the dilutions o f IL-15 were pre-incubated with mutant IL-15-48 protein prior to cells 
being added, there was a suppression o f proliferation. This suppression was present at 
60ng/ml IL-15-48 and at 125ng/ml. At 125ng/mlIL-15-48 mixed with 250ng/mlIL-15, 
there was almost 50% suppression. At higher ratios o f IL-15-48 to recombinant 
murine IL-15 (500 or 250ng/ml IL-15-48 with dilutions o f muIL-15 250ng/ml), the
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suppression effect was lost. (Not shown in figure 10) This may have been due to 
precipitation o f the IL-15-48 protein at these concentrations in the glycerol free RPMI 
cell growth medium. However, suppression was demonstrated when the cells were 
incubated by IL-15-48 at concentrations o f  60 and 250ng/ml.
The low stimulation activity o f recombinant IL-15 relative to human and commercial 
products was investigated in the following experiment. Briefly, 200ng o f recombinant 
murine-IL-15 was diluted into 1ml o f either RPMI or PBS. Then 12ul o f each o f these 
suspensions was removed following mixing and settling and loaded into a PAGE gel, 
as described in the materials and methods. The relative amount o f recombinant muIL- 
15 remaining in each o f the samples was compared by transfer o f the electrophoresed 
proteins to a western blot The blot showed that there was relatively little recombinant 
IL-15 in the RPMI compared to the PBS/glycerol sample. If  the murine IL-15 was 
indeed precipitating in physiological solution, this might explain the disparity noted 
above between the activities o f the recombinant IL-15 produced here and the 
commercial muIL-15 product in the CTLL cell bioassay. Due to degradation o f  the 
gel autoradiograph, this data is not illustrated.
7 7
3.8 The generation of anti-IL-15 antibodies.
Polyclonal, anti-murine IL-15 antibody generation was carried out according 
to the protocol described in the methods and materials section 2.20. Briefly, a white 
New Zealand rabbit was immunised with recombinant murine IL-15. Subsequent 
booster injections o f mu-IL-15 were made at 3-week intervals, as described in the 
methods and materials section 2.6. The anti-IL-15 antibody titre o f the test-bleeds was 
determined two weeks after each IL-15 booster injection by coating a 96 well culture 
plate with wells containing 50pl o f either murine IL-15 or murine IL-18 at a 
concentration o f 1 mg/ml. The plate was then incubated overnight at 4°C. A serial 
dilution o f a 1/100 dilution o f IL-15 injected rabbit serum was then added across the 
plate. Detection o f antibody binding was by incubation with 1/1000 anti-rabbit HRP 
conjugate, washing and then with 1/2000 anti rabbit HRP conjugate, followed by 
washing and incubation with 1/2000 Extravidin peroxidase. The assay was developed 
with TMB-microwell (KPL, Gettysburg, Maryland USA). An example o f an ELIZA 
demonstrating binding o f the Rabbit anti-serum to mu-IL15 and not to IL-18 is shown 
below in figure 1 IB below where 1/100 dilution o f the serum was made into PBS, as 
described in section 2.20 o f materials and methods and briefly above.
1/1 1/2 1/4 1/8 1/16 1/32
cfiludon x10-2
Figure I IB Rabbit polyclonal anti sera was found to have binding affinity for muIL-15 but only  
background readings for IL-18 when tested by ELIZA . Duplicate results only thus no error bars 
can be shown. Initial dilution o f  the anti sera was 1/100 (dilution I) and subsequent dilutions  
w ere  doubling dilutions. Polyclonal anti-m u-IL -15 titre indicated  at con vergen ce  with  
background at 1/1600 A pre bleed serum was taken prior to inoculation o f  the rabbit with m ulL-  
15 there is no data available  for this serum sam ple. However, the graph dem onstrates  dose 
d ependant binding effect approach ing  a s im ilar level o f  anti IL-15 versus IL-18 which indicates  
specific ity for its ligand. A second rabbit was inoculated but did not develop a s ignificant  
antibody titre.
After the fourth booster, the serum anti-IL-15 titre was indicated as 1/500000 
(not shown) and this crude serum was IgG enriched by affinity purification on a 
Protein A column (Sigma, Poole , Dorset, UK) and recovered by dialysis against PBS. 
The manufacturer’s recommendations were followed, as described in materials and 
methods section 2.20, only omitting the addition o f azide as the anti sera was to be 
used in an in-vivo experiment.. The anti-IL-15 activity o f the purified serum was 
measured by the method described above and the results are shown below in figure 
12. From this figure the anti-IL15 titre o f the serum was estimated as 1/32000.
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Fig 12 Anti IL-15 titre of the fifth bleed. Serum titre =1/32000 following purification 
against Protein A column. This is reduced from 1/50000 prior to IgG enrichment
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The anti-IL-15 IgG rich sera were then tested for protein concentration using the 
Bicinchoninic Acid Assay (Pierce) described in materials and methods section 2.16. 
Briefly, a Bovine Serum Albumin (BSA) standard curve was constructed and 
duplicate samples o f the purified anti IL-15 serum were measured against the standard 
curve. The concentration o f the IL-15 serum IgG samples was 140pg/ml. protein A 
purified samples were loaded onto a PAGE gel apparatus to determine molecular 
weight o f the antibody fraction. Figure 13 shows that a clean major band in the region 
o f 50kDa could be observed. This is the molecular weight expected for IgG 
molecules, confirming a successful purification o f  IgG. It has been learnt 
subsequently that silver sataining could enhance the definition and sensitivity o f this 
gel.
\ L ( % ftfk  ft Puri fie /
Fig 13b Two (A & B) samples of Protein A purified rabbit anti­
m urine EL-15 serum separated on a 15% polyacrylamide gel. The 
majority of protein in the samples corresponds to the expected 
weight for IgG molecules on denaturing gels of around 50kDa.
3.9 Purification and assay summary
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3.9 Purification and assay summary
The restriction enzyme digestion analysis, Sanger sequencing, Western 
blotting and molecular weight evidence noted above indicated that the products 
obtained from cloning were indeed recombinant murine interleukin 15 and a novel 
variant, IL-15—48.
Commercial muIL-15 (Immunex, Seattle, USA), which became available 
following the start o f these experiments, was able to induce maximal stimulation o f 
the CTLL cell proliferation indicated by 390000 counts per minute (cpm) as a 
result o f adding just O.Olng/ml IL-15. The recombinant muIL-15 produced for this 
thesis was also assayed and CTLL stimulation was attained, indicating bioactivity 
o f this non-commercial recombinant muIL-15 molecule. However, it required 
concentrations between 125ng/ml and 2.7pg/ml to induce comparable stimulation 
(370000 counts per minute, a decrease in activity o f at least 10000-fold). This 
indicated that there was much lower bioactivity in the muIL-15 produced here 
when compared to the Immunex product. One possibility is that this may be 
attributable to the reduced solubility o f the laboratory recombinant muIL-15 in the 
physiological solution used in the assays.
The CTLL assay testing stimulation o f recombinant muIL-15 also demonstrated 
that the 11-15-48 mutant had no proliferation induction activity and, moreover, IL- 
15-48 was able to competitively suppress proliferation o f CTLL cells when it was 
co-incubated with the recombinant muIL-15 at the concentrations listed above in 
figure 10. This suppression occurred despite IL-15-48 being able to bind to the IL- 
15 receptor. It is interesting to note that there is an analogous protein, IL-1 receptor 
antagonist (IL-IRa). This variant was found to have binding activity for the type 1 
Interleukin 1 receptor. However it was also discovered that IL-IRa could not
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activate the receptor and, furthermore was shown to have a suppressive effect in 
some murine models o f inflammatory disease. (83)
Finally, the testing o f semi-purified anti sera obtained from a rabbit previously 
inoculated with our murine recombinant IL-15 resulted in purification o f IgG enriched 
antibodies with anti-IL15 activity.
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Results for Murine models of Inflammation
3.10 Results observed in collagen induced arthritis, treated with murine IL-15 -  
48bp mutant and rabbit anti-mouse IL-15 antisera
Two experiments were set up to investigate the role o f IL-15 in inflammation. It was 
noted above that the recombinant IL -15-48 mutant exhibited binding to the IL-15 
receptor alpha sub-unit with similar affinity to the standard recombinant murine IL- 
15. It displayed no sign o f proliferative activity in the CTLL assay but did appear to 
act as an antagonist to IL-15 induced CTLL cell proliferation. In the light o f these 
characteristics, an experiment was set up to investigate the possibility that this IL-15 -  
48 mutant might modify the progress o f the Murine model for collagen induced 
arthritis. This model is described in chapter 1 section 1.4 and uses the protocol 
described in section 2.21 o f chapter 2. Briefly, 10, 9 week old, male DBA/1 mice 
were sensitised with 200pg bovine collagen suspended in lOOpl Freunds Complete 
Adjuvant (Difco, USA) injected intradermally on day 1. Subsequently, these mice 
were challenged with 200-pg collagen in Freunds incomplete adjuvant by 
intraperitoneal injection on day 21. Also on day 21, five o f the mice received a 
therapeutic dose o f IL-15-48 and five received a control dose of Human Serum 
Albumin (HSA). These injections were 300jug in 200pl PBS/Glycerol 40% and were 
given daily, starting on day 22 for 14 days. Measurement and observation o f the mice 
was carried out daily using the assessment code described in chapter 2 section 2.21 to 
define severity and incidence o f arthritis.
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3.11 Body weight measurement
Body weight was measured to 1/10* gram daily for IL-15-48 and control groups 
following collagen challenge on day 22. In fig 14 below, it can be seen that there was 
no apparent difference in the weight loss pattern between the two groups. Both groups 
lost weight at the same rate, indicating that the IL-15-48 molecule conferred no 
advantage compared to the HSA-control during the duration o f the experiment with 
respect to weight loss.
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Figure 14
Change of body weight expressed as % weight change per 
day per mouse.
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3.12 Severity of arthritis
The arthritis score o f  each mouse was determined by measuring footpad thickness by dial 
calliper (Kroeplin, Munich, Germany). As described previously in chapter 2, each limb was 
assessed for symptoms o f arthritis according to the scheme 0= no arthritis, l=Erythema 
(redness), 2=Erythema and swelling, 3=severe swelling and/or loss o f limb function.
In figure 15 below, it can be seen that initially the IL -15-48 treated group showed a 
lower average score over the first 5 days o f treatment, ranging 0.0-0.2 compared to 
the HSA control group with scores o f 0.2-1.0 for the same period. The difference, 
however, was very small and the two groups were not distinguishable after day 27. 
Even though there was an apparent difference at day thirty-four. When these results 
were tested by the Mann Whitney U test, there were no significant data at ant time 
point (p = >0.05).
♦ — Control —• — IL-1 5-48
Severity of Arthritis
25 28 31 34 37
D ays p o s t  c o lla g e n  c h a lle n g e
Figure 15
The mean arthritis severity score per group per day is presented 
here No statistical difference was demonstrated between the 
two groups
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Fig 16
Graph of the number of animals with symptoms of arthritis in each 
group per day A trend for lower incidence is consistant but no 
statistically significant data points demonstrated
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13.14 Treatment of Collagen arthritis mice with rabbit anti mouse IL-15 anti 
sera.
Targeting certain types o f immune-cell and soluble factors such as TNF-a has been 
shown to modify the CIA model, as discussed in the introduction section, 1.4.1.
Ruchatz et al successfully modified the progress o f the CIA by treatment with 
soluble, murine recombinant IL-15 receptor (Ruchatz 1998).
It follows that neutralisation o f endogenous IL-15 by anti-IL-15 antibodies 
might also modify the progress o f collagen induced arthritis. Therefore, in a similar 
experiment to that described above, fifteen, male, 12 week old, DBA1 mice were 
injected with collagen as in the previous experiment and as described in the materials 
and methods. These mice were challenged with a further collagen injection in the 
same manner as the experiment above (except the challenge was carried out on day 28 
not 21.) Following the collagen challenge, eight o f the mice were injected daily for 7 
days with polyclonal Rabbit anti-murine IL-15 serum which had been IgG enriched 
on a protein-A column The remaining 7 mice were injected daily with an irrelevant 
control antibody, normal Rabbit IgG, (Sigma). Both the anti-IL-15 and IgG control 
were injected intraperitoneally @ 250pg antibody in sterile PBS. Observations were 
recorded daily as in the previous experiment and are presented below in figures 17 & 
18
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13.15 Body weight measurement
Body weight was measured to 1/10* gram daily for both anti-sera and control 
groups following collagen challenge on day 28. The weight loss profile o f  this 
experiment was similar to the previous IL-15-48 collagen arthritis trial in that there 
was no apparent difference between the group treated with anti-IL-15 or the IgG 
control group. These data are shown below in figure 17.
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IL-15-48 — HAS-control
% weight loss in CIA mice
2 8  3 3  3 8
Day of experiment
Fig 17 Body weight was measured to l/10*h gram 
daily. There was no apparent difference in 
percentage weight-loss during the experimental 
period between the two groups.
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3.16 Severity of arthritis
The arthritis score for each mouse was determined by measuring footpad thickness by 
dial calliper (Kroeplin, Munich, Germany). As described previously, each limb was assessed 
for arthritis. At first a trend developed where the severity o f the arthritis was lower in 
the treatment group than the control group. This occurred at most time-points until 11 
days after the collagen challenge when the groups became indistinguishable. 
Although most data points demonstrate no significant difference, on day 32 and 36, 
the treated mice showed significantly less severe symptoms o f arthritis. These data are 
shown below in figure 18.
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day of experiment
Figure 18
The arthritis score of each mouse was determined. 
There was a trend for lower severity of arthritis in the 
anti-serum treated group and this attained statistical 
significance on days 32 and 36 (*). P = < 0.05 and 
p=<0.05 respectively, Mann W hitney U).
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13.17 Incidence of Arthritis
Using the scoring system for arthritis mentioned above, the number o f mice per group 
displaying any sign o f arthritis was calculated daily. The graph o f incidence o f 
arthritis is shown below in figure 19, expressed as a percentage. Initially, there was no 
difference between the mice treated with anti-IL-15 anti-sera and the incidence o f 
arthritis observed in the control group, although between the days 36 and 38, the anti- 
IL-15 treated group had a transiently lower incidence o f mice with arthritis than the 
control group. However there were no significant data points when tested by the Chi 
square test (p=>0.05), shown below in figure 19.
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Day of experim ent
• —Control —■—anti-IL-15
Fig 19
G raph showing the num ber of animals with symptoms 
of arthritis in each group per day. Figures are expressed 
as a percentage of the animals in the group. No 
significant data points are detectable. Measurements 
were not made prior to day 28.
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13.18 Assessment of footpad swelling as an indicator of severity of arthritis
As described previously, each footpad was measuring by paw thickness with a 
footpad dial calliper (Kroeplin, Germany). The measurements in mm for each limb 
were totalled per group per day and are presented here as a percentage increase or 
decrease over the initial measurement on day 28. The percentage increase or decrease 
in footpad size as an indicator o f severity and disease progress indicates that there was 
little or no difference between the placebo and the anti-IL-15 serum treated groups. 
There was no evidence o f any advantage conferred by the anti-serum. When the two 
groups were compared by Mann Whitney U analysis, there were no significant data 
points (P = >0.05). The significance o f the reduction in footpad thickness between day 
28 and 33, shown in figure 20, is unknown and highly likely to be due to 
measurement inconsistencies.
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Figure20
The increase of footpad size as a percentage of 
that measured at day 28. The footpad size of 
the anti IL-15 and the control groups increased 
but the significance of this is unclear.
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13.19 Summary of Collagen arthritis model experiments
The collagen induced arthritis experiments were carried out with the -48  IL-15 
mutant or with rabbit anti-sera enriched in anti-murine IL-15 antibodies raised against 
the recombinant IL-15 produced as described above. At no point in the weight loss 
data was there any suggestion that the administration o f either the IL-15 antagonist 
IL-15-48 mutant or the anti-IL-15 anti-sera modified the progress o f weight loss 
associated with collagen induced arthritis in mice.
When severity o f arthritis was determined by the scoring method referred to above, 
there was a transient trend for lower severity o f arthritis in the antagonist treated 
group compared to that o f the control group. The trend was reversed 5 days later and 
the antagonist treated group exhibited more severe arthritis than the control group 
until the end o f the experiment. However, no significant data points were observed.
A trend for lower severity o f arthritis was also demonstrated when mice were treated 
with the anti-IL15 anti-sera in the second experiment. This trend was sustained 
through the majority o f time-points until the end o f the experiment and obtained 
statistical significance on days 32 and 36.
The assessment o f footpad swelling as an indicator o f arthritis severity in the IL-15 
anti-sera experiment did not indicate any trend for reduced severity in the treatment 
group compared to the controls, but again, no statistically significant data points were 
observed.
The measurement o f incidence o f arthritis in mice treated with the -48  antagonist 
reveals a similar trend for lower incidence o f arthritis on 6 out of 16 days o f the 
experiment compared to the control. The same determination for incidence o f arthritis
1 0 2
in the experiment where mice were treated with IL-15 anti-sera also reveals a trend 
for lower arthritis incidence in the treated group compared to the controls. However, 
the trend is less defined here, becoming apparent only for three days at the end o f the 
experiment with no evidence o f statistically significant data points.
In summary, either the antagonist IL-15-48 mutant or the anti murine IL-15 anti-sera 
had theoretical potential to modify any inflammation characteristics associated with 
IL-15 in the CIA model. However, only non-statistically significant and very transient 
trends for lower arthritis symptoms were exhibited in mice treated with these 
compounds compared to their respective control animals.
The unknown nature o f the antagonist -48 mutant makes it difficult to speculate about 
the possible reproducibility or value o f the trend for lower arthritis incidence noted 
above.
The rationale for using the IL-15 anti sera as a treatment for CIA was based on its 
specific ability to bind IL-15 and not IL-18 (Figure 11). However, in a later analysis, a 
sample o f the Protein A purified antiIL-15 anti sera used in the experiment above was 
further purified by passing it through an immobilised E.coli lysate (Pierce USA). 
Much o f the IgG band seen after Protein A purification o f the serum was removed 
(data mislaid), indicating that the majority o f the IgG antibody recovered from the 
muIL-15 rabbit serum had anti-E.coli activity rather than the expected anti-IL-15 
component. The concentration o f specific anti-IL-15 antibody in the IgG fraction 
injected to the mice may therefore contribute to the inability o f the anti-IL-15 serum 
to modify the CIA and explain the weak trends exhibited here compared to that 
reported by Ruchatz (1998) when treating the CIA with soluble IL-15Ralpha.
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13.20 Conclusions
The problems associated with the purification o f murine IL-15 including its 
low solubility in any kind o f physiological solution and commensurate low 
proliferative activity in the CTLL bioassay rendered it unsuitable for use as a reliable 
agent in the investigation o f the role o f IL-15 in inflammation. The low activity per 
unit o f the recombinant murine IL-15 compared to the commercially prepared murine 
IL-15 indicated that it was unsuitable for use in meaningful in-vivo or in-vitro 
experimentation.
Treatment o f CIA mice with the antagonist IL-15-48 mutant established a 
transient, but non-statistically significant trend for lower incidence o f arthritis 
compared to the controls. A similar trend was also transiently exhibited for less severe 
arthritis in the treatment group.
Treatment o f CIA mice with anti-IL-15 enriched rabbit/anti-mouse anti-sera 
established a slightly stronger, but still non-statistically significant trend for lower 
incidence o f arthritis compared to control mice. A weak but more sustained trend was 
observed for less severe arthritis in the treatment group compared to the controls, this 
again not reaching statistical significance.
The slightly more robust trends for lower incidence o f and less severe arthritis 
in the anti-sera treated mice indicate that a statistically significant difference in 
arthritis severity and incidence might be observed if a more pure form o f anti-IL-15 
antibody could be administered to CIA mice in a similar experiment. Inclusion o f an 
affinity purification step using an immobilised E.coli lysate should be an integral part 
o f any future attempt to raise antibodies against a recombinant protein which itself 
had been cloned from an E coli expression system.
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The indifferent result using mutant IL-15-48 and the anti -IL-15 antiserum raised 
against the recombinant IL-15 in the rabbit also made it unlikely that these reagents 
would provide informative results for the other murine models o f inflammation 
planned for this thesis. The laboratory had recently cloned and expressed a soluble 
recombinant murine IL-15 receptor alpha molecule. This was readily purified from E 
coli and soluble in the near physiological solution 2mMNaCl/PBS. It was, therefore 
decided to use this receptor to further the investigation o f the role o f IL-15 in the LPS 
shock and the septic arthritis models o f inflammation, as previously described in 
materials and methods, chapter 2.
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Chapter 4
4.1 Treatment of LPS Shock with soluble murine IL-15 Receptor alpha protein
Chapter three described the treatment o f collagen-induced arthritis (CIA) with 
the recombinant IL-15^18 mutant and subsequently with rabbit anti-murine, 
polyclonal anti-IL15 antibodies. The results o f these two experiments implied a trend 
for less severe arthritis (figure 15) and a lower incidence o f arthritis (figure 16) and to 
some degree, similar trends in the IL-15 anti-sera treated groups. In order to 
investigate further the role o f IL-15 in murine inflammatory disease, further 
experiments in the septic shock (LPS) and septic arthritis models were set up (See 
Chapter 2, 2.22 & 2.23 for protocols). The active treatment was soluble, murine IL- 
15-Receptor alpha (IL-15Ra), recently cloned and expressed by Holger Ruchatz o f 
this laboratory. This molecule was shown to be readily purified from E.coli and 
soluble in the near physiological solution, 2mM NaCl PBS.
Ruchatz et al (43) reported that CIA was modified by both prophylactic and 
during-disease treatment with IL-15-receptor-alpha, providing strong evidence that 
IL-15 was an important cytokine in inflammatory disease and in particular, a disease 
model associated with tumour necrosis factor, is widely believed to be a pre-eminent 
cytokine in the pathogenesis o f LPS shock. (51) (55) (76) (77) (53). The importance 
and central role proposed by Freundenberg (52) o f macrophage action in LPS shock 
when considered alongside the role shown for IL-15 in inducing macrophage TNF-a 
production (35) suggest that IL-15 may have a role in LPS shock. The following 
experiments address that possibility.
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Three experiments were undertaken to see if the course o f LPS induced septic 
shock could be modified by neutralising endogenous IL-15 following injection o f 
recombinant soluble IL-15 receptor alpha post LPS injection.
In a preliminary experiment, 48 young adult (10-12 week old) healthy, female 
Balb/C (Harlan, UK) mice were divided to 4 groups. Groups 1 and 2 were injected 
intraperitoneally (IP) with 18mg/Kg lipopolysaccharide (LPS). (Sigma Poole, Dorset.) 
Groups 3 and 4 were injected with 20mg/Kg LPS. Half an hour post LPS injection 
groups 1 and 3 (controls) were injected (IP) with lOOpg Human Serum Albumin 
(HSA) suspended in lOOpl HS- PBS. Groups 2 and 4 were injected intraperitoneally 
at a similar time interval with lOOpg IL-15Ra suspended in lOOpl HS-PBS. The HSA 
and IL-15Ra injections were repeated at 24-hour intervals for a total o f three days. 
This protocol is summarised below in table 3.
Inject LPS 
(IP) 
In jectIL - 
15Ra or 
control as 
below (IP)
Inject IL- 
15Ra or 
control as 
below
InjectIL - 
15 R a  or 
control as 
below
Terminate 
all groups
OHours 12Hours 24Hours 36Hours 48Hours 60Hours 72 Hours
Group
No.
LPS
mg/Kg
IL-15Ra or PBS injections
l 18 lOOugHS A/PBS (Control)
2 18 3x40ug IL-15Ra (Treatment)
3 20 lOOug HS A/PBS (Control)
4 20 3x40ug IL-15Ra (Treatment)
Table 3 Table detailing groups receiving LPS at 0 hours and treatment with 
IL-15Ra or High salt-PBS control 24 and 48 hours. Observations of mice 
performed at 12-hour intervals. The experiment terminated at 72 hours.
4.2 Mortality in LPS shock mice
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With the exception o f 1 o f the mice in group 3, all the mice that had been injected 
with the greater dose (20mg/Kg) o f LPS (groups 3 & 4) succumbed to LPS induced 
shock within 72 hours. This indicated the maximal informative dose o f LPS was 
exceeded at 20mg/Kg.
The mice treated with 18mg/Kg showed different survival characteristics 
between the treatment and control groups in mortality at 72 hours post LPS injection. 
As can be seen in figure 21 below, the HSA treated control group exhibited 75% LPS 
induced mortality but the IL-15Ra treated group showed 25% mortality. P=0.013 
(Kruskal-Wallace) indicating that IL-15Raw as in this instance able to modify the 
ability o f mice to survive LPS induced shock mortality. This protective effect was not 
apparent when the LPS dose was at 20mg/Kg. with hindsight, it would have been 
useful to establish a dose response curve to determine LD 50 to set this experiment 
against other author’s work.
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UPS induced mortality
0  -----     p - ......----------------------------- r - -----------
0 12 24 36 48 eo 72
Hours post 18rn^Kg LPS injection
IL-15Ra
C c r tr d
Figure 2 l
Number of'mice surviving measured in hours following LPS injection. From 48 
hours. 8 mice survived in the II -15Ra treated group compared to 4 o f the control 
group P= 0.013 (Kruskal Wallace)
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Observations in the above experiment indicated that the effect o f LPS 
injection at 18mg/Kg when sustained over 5 days o f the experiment was deleterious to 
the welfare o f the mice leading to an extended period o f severe illness. After 
discussion with Home Office veterinary staff, it was suggested that this was not 
consistent with best practice. Furthermore, the high doses o f LPS used in the previous 
experiment and their associated morbidity prevented measurements other than 
mortality being made. One o f the features o f LPS shock is liver damage. In order to 
assess this useful biochemical indicator o f disease severity, blood samples must be 
taken and this had proved refractive in the mice treated with high doses o f LPS due to 
the hypotensive nature o f LPS shock pathogenesis (78). Many authors, including 
Smith SR. (79) and Tsutsui H (80) have used a priming injection o f heat killed G 
parvum  to sensitise mice to the effects o f LPS. Whereas many o f these experimenters 
were using lethal doses, the aim here was to reduce the dose o f LPS used to induce 
shock symptoms to an approximately sub-clinical level and therefore reduce the 
severity o f the LPS-shock symptoms and their associated high mortality. Therefore, 
the mice in the following experiment were injected intravenously with heat killed 
Corynebacterium parvum (C parvum) 1 mg/mouse. This new method was expected to 
allow symptoms o f LPS shock to develop at a lower severity induced by a 5 or 10 fold 
lower dose o f LPS. One week later LPS was injected at 0.0, 2.5 or 5mg/Kg.
Briefly, in this experiment, C parvum was injected into the tail vein o f 31 o f 
34 Balb/c mice. 7 days later, the mice were pre-treated with IL-15Ra, PBS-control or 
nothing, as described in materials and methods (section2.22) and summarised below 
in table 4. Furthermore, mice were also segregated to receive two different doses o f 
LPS in this dose ranging experiment and lastly, with or without C parvum priming.
I l l
Weight was monitored over the 24 hours post LPS challenge as an indicator o f shock.
Liver damage, amongst other major organ failures is a common feature o f the 
pathogenesis o f LPS shock. This has been observed in most species and is reviewed 
(for humans) by Parrillo (80).
Therefore, as described in the introduction, three biochemical indicators o f 
liver damage were assessed by measuring serum samples for evidence o f increased 
levels o f Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT) and 
Creatine Kinase. These enzymes were measured with the kind help o f Dr Dennis 
O’Reilly, Glasgow University Hospital trusts. A Kodak slide forms a biochemical test 
for these markers o f liver damage and whereas the role o f the liver breakdown 
enzymes AST and ALT are common indicators o f liver disease, the role o f CK is not 
understood however it does seem to fluctuate with AST and ALT in all these 
determinations as seen below. This experiment also addressed the question of 
whether IL-15Ra treatment could modify LPS shock when administered 
prophylactically compared to the therapeutic treatments o f the experiments described 
earlier.
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^  Inject IL—
:e l5R a or
lifofKa oeum
itrol
tow___________________________
Cparvum IL-15Ra or 
PBS injections
1 n=5
2 n=5
3 n=5
4 n=4
5 n=4
6 n=5
7 n=3
8 n=3
3x40mg IL15Ra 
3x40mg IL-15Ra 
3x40mg IL-15Ra 
100ml HS-PBS 
100ml HS-PBS 
100ml HS-PBS 
0 
0
Table 4.
Table detailing groups receiving C. parvum on day 1 and subsequent treatm ent 
with IL-15Ra or High salt-PBS control on days 1,3 and 5. LPS was administered 
IP to the groups described above on day 6 and following 24 hours observation, 
the experiment term inated on day 8.
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4.3 Mortality in C parvum treated LPS shock mice
As expected, and detailed in figure 22 below, mortality was not a major 
feature o f this experiment and only 3 mice succumbed to LPS shock. This distribution 
exhibits no differences between the groups and does not attain statistical significance 
(p=>0.05 Kruskal Wallace). It could be noted that all the dead mice were from groups 
treated with LPS. (One each from the groups o f mice treated with IL- 
15Ra+CP+5mgLPS, those treated with PBS+C/P+5mgLPS and those treated with 
PBS+C/P+2.5mgLPS). Although it was expected that the mortality amongst the 
control mice especially and the treated mice generally would be reduced compared to 
the earlier experiment, it must be noted that there is a possibility that variation in the 
weight for weight toxicity o f the batch o f LPS used could introduce another variable.
LPS induced mortality
6
5
4
3
2
1
0
24120
Hours post LPS
IL-15Ra+C/P+5mgLPS — PBS+C/P+5mgLPS 
IL-15Ra+C/P+2.5mgLPS PBS+C/P+2.5mgLPS 
 OK— 5mgLPS only
Figure 22
LPS induced mortality was exhibited in 3 mice, one from each group. 
There was no statistical difference indicating that mortality was not a 
reliable indicator o f LPS shock in C parvum primed mice.
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4.4 Weight loss in C parvum primed LPS Mice
Weight loss or gain was recorded as change in weight from the time o f LPS 
injection (base) and 18 hours later. Primed mice treated with IL-15Ra and receiving 
5mg/Kg LPS were compared to those receiving the same priming and LPS but PBS 
control instead o f IL-15Ra. There was no statistically significant difference between 
the two groups, (not shown; p=>0.05 Mann Whitney U). As indicated in figure 23 
below, when the weight-loss characteristics o f the control and treatment mice injected 
with the lower 2.5 mg o f LPS/Kg were compared, the IL-15Ra treated mice lost more 
weight in the 18 hours following LPS shock induction than the control mice o f group 
5 (p= <0.05, Mann Whitney U).
The significance o f difference in weight loss is not clear, although it infers that 
there is a greater weight loss in the presence o f IL-15Ra in the context o f therapy 
against LPS induced shock. The presence o f 5mg/Kg LPS may have overwhelmed 
any effect o f IL-15Ra operating in this model, resulting in no difference between the 
two groups.
116
W e i g h t  l o s s  in LPS m ice
2 0 .5  
20
19 .5
CD
1 8 .5
1 8 H rs0 Hrs
t i m e  from 2.5m g/Kg LPS in je c t io n
PBS C on tro lIL-1 5 R a t r e a t e d
Figure 23
Differential weight loss in the LPS shock model. D-15Ra treated mice lost 
more weight than PBS treated controls. (P=<0.05, M ann W hitney U)
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4.5 Biochemical Liver damage indicators in C parvum primed LPS shock mice
To test the independent effects o f C Parvum, IL-15soluble receptor and two 
different doses o f LPS, the following series o f experiments were devised. Serum 
samples were taken following exanguination o f the mice. As described in the 
materials and methods (section 2.22), serum samples were diluted 1/20 into 7% 
BSA/Saline (Sigma) and analysed on a photo assay device (Kodak, Ilford, Essex) and 
the numbers o f international units o f enzyme recorded per ml o f serum sample. These 
results are displayed below in figure 24. Georg Meflfert et al, (135) have very recently 
suggested that creatine kinase as a marker o f liver injury is very unreliable due to 
isoforms interering with assays. The creatine kinase measured in these experiments 
was done so because it was an assay included in the liver damage kit supplied by 
Kodak. This part o f the results may now not be relevant however AST and ALT are 
still perceived to be markers o f liver disease.
4.6 The effect of IL-15/C parvum on liver damage in the absence of LPS
As expected, in all three o f the liver enzyme measurements, control mice 
receiving neither LPS, C parvum or active treatment/placebo exhibited the lowest 
levels o f liver damage enzyme indicators. For the purposes o f this experiment, these 
must be considered as the base line
Five mice were also primed with C. parvum and 7 days later received the 
active, muIL-15 soluble receptor treatment, but were not challenged with LPS. As 
seen below in figure 24, there was a 3-6 fold increase in the serum levels o f the three 
measured liver damage enzymes detected, compared to the mice in the control group 
receiving no treatment or priming. A further group o f 5 mice were also primed with
C. parvum and was not challenged with LPS but received PBS placebo injections in 
place o f the IL-15Ra. The serum AST, ALT and CK levels detected were similar to 
the active treatment group described above. Thus it can be seen that merely priming 
the mice with C parvum has an effect and that there was no vast difference in the 
serum liver damage enzyme parameters between the active treatment and the PBS 
placebo groups. As these data are derived from pooled samples, no statistical analysis 
can be applied.
ControlPBS Control
serum ALT (average)
ControlPBS Control
Serum  CK (average)
PBS Control Control
Figure 24 Serum ALT, AST and CK determinations
IL-15Ra PBS-Control No C parvum control
C Parvum priming +++ +++ —
LPS — — —
PBS — +++ —
IL-15Ra +++ — —
Data derived from pooled samples.
The untreated C parvum controls showed less liver damage enzymes than the IL-15 or PBS 
treated mice which exhibited similar levels o f  serum liver enzymes.
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4.7 The effect of IL-15Ra on liver damage induced by 2.5mg/Kg LPS
Five mice primed with C parvum and then challenged with 2.5mg/Kg LPS received 
muIL-15 receptor active treatment. Four control mice were treated with PBS control 
instead o f IL-15Ra. With reference to figure 25 below, comparison o f the ALT, AST 
and CK levels indicate that the IL-15 treated group exhibited approximately 50% 
lower serum levels o f damage enzymes than the placebo controls. These lower levels 
detected in the IL-15 treated group were also similar to the group o f five 
primed+PBS-control mice that were not challenged with LPS. Thus, the presence o f 
soluble IL-15Ra appeared to reduce the level o f liver damage induced by 2.5mg/Kg 
LPS when compared to placebo.
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Serum AST(average)
2.5rrgLPS/C parvum 
control
PBS Control
Serum ALT<average)
2 5mgLPS/C parvum 
control
Serum CK (average)
PBS Control 25rrgLPS/C parvum 
control
Figure 25 Serum ALT, AST and CK determinations
IL-15Ra PBS-Control C parvum control
C Parvum priming +++ -H-f +++
LPS 2.5mg/Kg +++ +++ —
PBS — -H-+ +++
IL-15Ra 4-f-t- ---- —
Data derived from pooled samples.
The IL-15Ra treated C parvum-primed mice showed approx. 50% lower liver damage enzymes 
than the PBS treated control mice. The IL-15Ra treated mice serum levels o f liver damage 
enzymes were similar to those observed in the non-LPS challenged controls.
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4.8 The effect of IL-15Ra on liver damage induced bv 5mg/Kg LPS
Five mice primed with C parvum and then challenged with 5.0mg/Kg LPS received 
muIL-15 receptor active treatment. A control group o f four mice also primed with C 
parvum and injected with 5mg/Kg LPS were treated with PBS. A further control 
group o f 3 mice were not primed nor treated with either IL-15 or PBS placebo but 
were challenged with 5mg/Kg LPS. With reference to figure 26 below, comparison o f 
the ALT, AST and CK levels indicate that the IL-15 treated and the PBS-placebo 
treated group exhibited similar serum levels o f damage enzymes to that o f 
5mg/KgLPS only mice. These data suggest that in the presence o f 5mg/Kg LPS, there 
was no trend for the 11-15 treated mice for less liver damage compared to the PBS 
controls when observed in C parvum primed mice. However, the levels o f damage 
were similar to that observed to be induced by 5mg/Kg LPS alone in the absence o f C 
parvum. This was in contrast to the difference seen above in figure 25, where in the 
presence o f 2.5mg/Kg LPS, there was a trend for lower liver damage in the IL- 
15Ra treated group compared to the PBS control mice. No statistical analysis was 
possible to define these trends as the data was derived from pooled samples.
Serum AST(average)
PBS Control 5rngLPS Control
Serum ALT (average)
PBS Control 5mgLPS Control
PBS Control 5mgLPS Control
Figure 26 Serum ALT, AST and CK determinations
II^I5Ra PBS-Control C parvum control
C Parvum priming +++ +++ —
LPS 5mg/Kg +++ +++ +++
PBS — +++ —
IL-15Ra +++ — —
Data derived from pooled samples.
The IL-15Ra treated C parvum-pnmed mice showed similar serum levels o f  
liver damage enzymes to both the PBS treated control mice and the non­
primed controls. IL-15Ra showed no protective effect in terms o f  a trend for 
lower serum liver damage enzymes in the presence o f  5mg/LPS and priming.
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4.9 LPS model measurement using septic shock index
A further experiment was developed to examine the modification o f LPS 
shock by IL-15Ra based on the findings o f the two previous experiments. Further 
changes were sought to investigate ways o f improving the welfare o f the mice whilst 
gaining better quality data.
Some experimenters use a rectal probe to monitor core temperature in measurement o f 
septic shock. This was felt to be invasive and likely to be stressful for the mice. 
Others, often in nutrition fields, use a blood pressure cuff around the tail vein. As LPS 
shock features hypotension with blood supply tending to be restricted to core regions, 
this was also felt to be impractical. The Morton-Griffith index (84) provides a 
framework for assessment o f animal welfare during experiments such as LPS induced 
shock. Based on these papers, a scoring index was devised allowing a detailed 
assessment o f LPS shock features and enabling prediction o f lethal shock. The aim for 
this was to prevent dead or very sick mice being found in cages, as this prevented 
serum sampling and subsequent biochemical analysis.
The index functions by “0” being scored for each “healthy-parameter”. However if a 
mouse showed signs o f an unhealthy parameter then a negative score was given, as 
shown in table 5 below. If any mouse scored “-7 ” it was humanely killed as 
experience from the experiments above indicated that this score predicted death.
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Healthy Unhealthy
Actively running around 0 Moving slowly -1
Inquisitive 0 Not Inquisitive -1
React to touch 0 No reaction to touch -1
Moving around at 60 hours 0 No spontaneous movement at 60 
Hours
-4
Normal stools 0 Diarrhoea -1
Clear eyes 0 Encrusted eyes -1
Skin warm to touch/relaxed 0 Skin cold/Hunched aspect -1
Weight loss <30% 0 Weight loss >30% -7
No shivering when picked up 0 Shivers uncontrollably on picking 
up
-5
Mobile at 72 hours 0 Immobile at 72 Hours -7
Table 5 Table o f  scoring system  used to monitor mice during this experiment based 
on previous results and Morton-Griffith index and the Rodent Protection Docum ent. 
All animals scoring - 7  were humanely killed
Using the above table (as described in the methods and materials section 2.22), 27 
Balb/C mice (Harlan Olac, Cambridge) were primed with 1 mg/mouse C parvum IV 
route. The protocol is summarised in table 6 below. These mice were injected with 
2.5mg/Kg LPS and segregated randomly to receive either IL-15Ra or PBS control 
immediately post LPS injection and at 24 hours later.
Dayl Day 7 (0 
hours)
Day 8 (24 
Hours)
Day 9 (48 Hours)
Prime Mice Inject LPS as 
below & 
Inject IL- 
15 R a or 
control
Inject IL- 
15 R a or 
control
Terminate
Experiment
Group
No.
C.parvum
mg/mouse
IL-15Ra or 
PBS injections
LPS mg/Kg
1 n=14 1 2x40mg IL15Ra 2.5
2 n=13 1 2x100ml HS-PBS 2.5
Table 6 Table detailing groups receiving IV C. parvum on day 1 LPS was 
administered on day 7 and immediate treatment with IL-15 receptor or High 
salt-PBS control at t=0 and t=24. All animals were terminated at t=36 hours
4.10 Analysis of Weight data in mice assessed by septic shock index
As noted in the materials and methods, weight was recorded at 0, 12, 24 and 36 hours 
post LPS challenge. The body masses recorded are shown below in figure 27.
Both the treated and placebo groups lost weight over the course o f the experiment. 
When individual weight changes o f the mice were compared across the two groups, 
Mann Whitney U analysis shows that, although there was no difference between the 
groups at 0, 24 and 36 hours (p=>0.05), at 12 hours the Il-15receptor treated group 
lost less weight than the controls (P=<0.011). The significance o f this differential 
weight loss data is unknown and was only exhibited transiently. Mortality was only 
by termination.
W e i g h t l o s s  d u r i n g  L P S  s h o c k
22
2 1 . 5
2 0 . 53■f 2 0
1 9  5
19
» 1 8 . 5
1 7 . 5
0 1 2 2 4 3 6
Figure 27
Weight loss measure in mice following LPS shock.
Mice treated with EL-15Ra exhibited less weight loss at 12 hours than 
controls (p= 0.011, Mann Whitney U analysis), however at 24 and 36 hrs, 
there was no significant difference
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4.11 Biochemical Liver damage indicators in mice assessed by septic shock index
Serum samples were taken at termination o f  each mouse, diluted into 7% BSA 
and assayed for serum levels o f ALT, AST and Creatine Kinase as indicators o f 
severity o f septic shock, induced by 2.5mg/Kg LPS challenge. These results are 
shown below in figure 28 .
There was a significant difference found when the IL-15Ra treated group was 
compared to the control group in the assay for both ALT and AST (P=0.0011 Mann 
Whitney U, respectively). However, there was no statistical difference between the 
two groups demonstrated by the assay for Creatine Kinase (P >0.05 Mann Whitney 
U), although the trend is for lower liver damage as indicated by the lower serum level 
o f Creatine Kinase in the receptor treated group.
In the previous experiment, (figures 24, 25 &26), analogous assays were 
made for these enzymes and similar differences were shown for IL-15Ra treated mice 
receiving 2.5mg/Kg LPS, but the former serum samples were grouped blood as 
opposed to the latter samples which allowed statistical analysis, as they were derived 
from individual mice. The other difference between these two experiments is that the 
former was sampled at 24 hours compared to 48 in the latter. The average AST 
enzyme unit levels were much higher in the second experiment (average range 178 to 
360) compared to (average range 27to 61) in the previous determination. The 
significance o f this difference is unknown and may be due to sampling error or the 
longer elapsed sampling time. In summary, there was a trend for lower liver damage 
enzymes in IL-15Ra treated mice in the 2.5mg/Kg LPS group o f the first experiment 
shown in the pooled samples. This trend is further confirmed by the lower serum
levels o f  AST, ALT and CK in the IL-15Ra treated, 2.5mg/Kg LPS group o f the 
second experiment when compared to the control mice. (ALT p= < 0.0011, AST p=< 
0.0011 and CK p= > 0.05 respectively Mann Whitney U analysis.)
P= <0.0011 
Mann Whitney-U 
Error bar = Std Dev
P= <0.0011 
Mann Whitney-U 
Error bar =  Std Dev
+/-6239
P = >0.05 
Mann Whitney-U 
Error bar =  Std Dev
Figure 28
Serum levels of AST, ALT and Creatine Kinase following LPS shock. Sampling 
at 48 hours post LPS injection. The data indicate lower liver damage enzyme 
levels in the LL-15Ra group compared to the controls with P=0.0011 in AST and 
ALT (M ann W hitney U) tests. The difference in CK  is not significant P=>0.05) 
But the trend is maintained for lower serum -CK in the IL-15Ra treated group .
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4.12 Septic shock index
As mentioned in the text above, an index was devised to measure the severity 
o f LPS-induced septic shock during this experiment. Assessments were made at 0, 12, 
24, 36 and 48 hours following LPS injection. These data are presented below in figure 
29. Comparison o f IL-15Ra treated groups and the control reveals that there were less 
severe features o f septic shock in the receptor treated group at all time points. At 12 
hours and at the end o f the experiment at 48 hours, these differences are statistically 
significant (P= 0.0011 Mann Whitney U test). The dead mice scored -7  and continued 
to be included at each time point on the basis o f intention to treat.
Index for LPS induced septic shock
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Figure 29
Graph of severity of septic shock measured by arbitrary score 
index. The symptoms of shock were less severe in the IL-15Ra 
treated group at 12 and 48 hours (P = <0.0011 Mann Whitney U) 
The trend for less severity was maintained at all time points.
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4.13 Summary of results from the experiments im LPS induced shock
In the preliminary LPS induced shock experiment, it was shown that injecting 
3x40ug doses o f IL-15Ra reduced mortality o f Balb/C mice by 40% when compared 
with controls. (P= <0.013 Kruskal-Wallace test) This modification o f mortality was 
demonstrated when the initiating dose o f LPS was 18mg/Kg but in the presence o f 
20mg/Kg LPS dose all the mice succumbed to LPS shock.
Although this was informative in that IL-15Ra was seen to have a protective effect, 
the severity o f the illness o f the mice was unacceptable and furthermore, dead mice in 
cages prevented any further observations being made. Therefore, in the second 
experiment, C. parvum priming was used to reduce the amount of LPS needed to 
induce disease and to shorten the duration o f  the LPS induced septic-shock 
experiment. Mortality and morbidity were markedly reduced, with only three mice 
succumbing to shock, distributed amongst control and treatment groups. The lower 
overall severity o f the septic shock in this experiment allowed serum sampling of the 
mice and therefore analysis o f biochemical indicators o f LPS shock: serum liver 
enzyme levels. Unfortunately, in the first o f the C parvum primed experiments, the 
samples from most informative groups IL-15Ra and controls injected with 2.5 or 
5mg/KgLPS) were insufficient for individual mouse levels to be assayed. Therefore 
group data was derived without statistical analysis being possible. However these 
results showed approximately 50% lower serum levels o f liver damage enzymes in the 
receptor treated group compared to the control where LPS shock had been initiated by 
a 2.5mg/Kg mouse bodyweight dose. Interestingly, this was not observed in the IL- 
15Ra treated group injected with 5mg/Kg LPS, This reflected the finding o f the first
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experiment where the protective effect o f IL-15Ra treatment did not enhance survival 
in mice with shock induced by 5 mg/Kg LPS, as noted above.
The final experiment was again carried out with C parvum primed Balb/C 
mice. These were injected with LPS. Shock symptoms were induced by a dose o f 
2.5mg/Kg LPS- mouse weight. During 48 hours observation following induction o f 
LPS shock, there was a trend for greater weight loss in the control group compared to 
the controls, this transiently attaining statistical significance at 12 hours. In this 
experiment, it was possible to extract serum samples from each mouse at 48 hours and 
assess the serum concentrations o f ALT and AST and Creatine Kinase. The mice 
treated with IL-15Ra showed significantly lower levels o f serum ALT and AST than 
the control group, (P=<0.0011 for both, (Mann Whitney-U)). There was also a trend 
for lower Creatine Kinase in the sera o f the receptor treated group compared to the 
controls. This result reflects the trend for a protective effect o f IL-15Ra treatment 
demonstrated by the lower serum enzyme levels o f ALT and AST (and CK) in the 
first C parvum primed LPS experiment. In addition to the above indication that 
IL-15Ra was able to modify the response to LPS induced septic shock in the mice, 
the septic index o f severity also demonstrated that there was reduced severity o f shock 
features in the receptor treated mice. The graph o f severity (figure 29) shows that this 
was maintained at all time points and statistically significant at two time points 
(P=<0.0011 at 12 and 48 hours Mann Whitney U).
In conclusion, soluble-recombinant IL-15Ra was able to protect mice 
following induction o f septic shock by administration o f low doses o f LPS both with 
or without priming with C. parvum. This protective effect was seen when IL-15Ra 
was introduced prophylactically and as an active treatment post LPS induction o f 
shock. The nature o f this protection was exhibited by reduction in mortality, as
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disclosed by the first experiment and features o f liver damage, and demonstrated by 
the lower serum levels o f enzyme indicators described in the latter two experiments. 
Weight loss, if considered as an indicator o f disease severity, was also attenuated 
(transiently) in the IL-15Ra treated mice o f the second C parvum primed experiment. 
Furthermore, the general features o f morbidity were less severe in the IL-15Ra 
treated mice as demonstrated by the lower septic-shock severity scores in the latter 
experiment. These data show a robust indication o f the trend for reduced disease 
severity in mice treated with IL-15 antagonists, demonstrated in the collagen induced 
arthritis model o f inflammation in the previous chapter. In addition to demonstrating 
IL-15Ra modification o f LPS shock, using the C parvum priming o f the mice, 
priming o f mice in this way can increase the response o f mice to subsequent injection 
o f LPS shock (55). This increases TNFa production in response to LPS challenge as 
shown by Rossol (81). Here, they reported that in general, C parvum primed mice 
began to die within 6 hrs of LPS (20ug/mouse) challenge, in contrast to the majority 
o f mice they had pre-treated with either anti-TNFa or IFNy antibodies. In the context 
o f this experiment, priming enabled a more humane, shorter time scale to be followed 
for the LPS model experiment. However, although shorter in time, this enhanced the 
usefulness of the model, because serum is more readily available from less severely ill 
mice therefore allowing a greater chance o f success in obtaining serum for cytokine 
ELIS As and other biochemical tests. The establishment o f a scoring system for 
pathological data derived from liver and kidney sections might also be a good 
indicator o f disease severity. This too would drive the focus away from mortality as a 
de facto end-point in this animal model o f inflammatory disease.
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Chapter 5 
5.1 Treatment of septic arthritis mice with IL-15R<x recombinant protein
In chapter 3, the Collagen Induced Arthritis model (CIA) was used to see if 
the treatment with antagonists o f murine IL-15 could modify this disease. Although 
there was no statistically significant difference between the disease progression 
between the two groups, a trend was recognised where the group treated with the 
recombinant IL -15-48 mutant molecule exhibited lower incidence and severity o f 
arthritis in the early stages o f the disease. This was shown to be transient and after a 
few days, there was no difference between the control and treated groups. A second 
experiment treating collagen arthritis with polyclonal anti-sera (Chapter 3, section 
3.10) failed to support this trend. However, treatment o f collagen induced arthritis 
with recombinant IL-15Ra, reported by Ruchatz et al (1998), indicated that a strong, 
down-regulatory response occurred, induced by IL-15 receptor therapy. In chapter 4, 
the IL-15Ra molecule was used to treat LPS induced shock. The symptoms o f this 
acute inflammatory response were modified by IL-15Ra therapy. These mice 
exhibited a lower incidence and severity o f arthritis and furthermore, less liver 
damage than the control animals.
The two experimental diseases discussed above demonstrate the effect o f IL- 
15Ra in disease models that are initiated by a single dose o f defined antigen, against 
which the host makes a vigorous inflammatory response. It was felt to be o f interest to 
see if the same trends might exist in a disease model that was induced by a live 
pathogen. In order to investigate this, two experiments were devised using the septic 
arthritis Model. In one experiment, a bolus dose o f therapeutic IL-15Ra concurrent
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with induction o f septicaemia and a second therapeutic bolus on day three. The 
second experiment featured a prolonged treatment o f IL-15Ra, which was initiated 
following induction o f septicaemia. The progression o f clinical symptoms o f the 
induced disease was measured in groups treated with either with recombinant IL- 
15Ra or a control substance. The results are described below in section 5.5, an 
experiment extending over 7 days and section 5.6, a further experiment extending 
over 14 days.
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5.2 Induction of septic arthritis
Murine IL-15Ra was prepared and purified according to the protocol set out 
in chapter two, diluted to a working stock of400pg/ml and tested by ELISA for IL-15 
binding activity which was found to be equivalent to that obtained in previous 
preparations. The methods for this are described in chapter 2, but briefly here: E. coli, 
transformed with the gene for murine IL-15Ra, was incubated in shaken suspension. 
Production o f IL-15 was induced by IPTG and following expression, muIL-15 was 
affinity purified on a nickel-agarose column. The purified protein was resuspended 
into high salt PBS.
5.3 Animals
30, female Swiss mice, 4-6 weeks old were segregated into 4 groups. Mice were 
segregated into 5 per cage and fed on standard laboratory diet and water ad-libitum. 
Twenty o f the mice (groups 1 and 2) were injected with 5x107 live Staphylococcus 
aureus (S. aureus) by intravenous injection via the tail-vein. The 10 remaining mice 
o f groups 3 and 4 were injected in the same manner with lxlO7 heat killed S. aureus.
Shortly after the S. aureus inoculation, the mice o f group 1 and 3 were injected 
intraperitoneally with 40pg murine IL-15Ra suspended in lOOpl PBS. Groups 2 and 4 
were injected with an equivalent volume o f PBS control solution. The injection o f IL- 
15Ra or control PBS was repeated on day three after the S. aureus injection. This 
protocol is summarised in Table 7 below.
The mice were monitored for any symptoms o f septicaemia from day one and 
arthritis from day three and onwards. Previous studies had shown symptoms of 
arthritis were most likely to appear, (67). At day seven the mice were euthanased and
examined at post-mortem. Septicaemia was assessed daily by observation o f coat 
condition, body stance, eye discharge and spontaneous movement. Body mass was 
measured every second day.
The presence o f joint disease was assessed by the scale o f clinical scores used 
for collagen induced arthritis. Mice were monitored on days 1, & 3-7 for symptoms o f 
septic arthritis and assigned severity scores according to the index described in 
materials and methods section 2.21, but briefly: 0 = no swelling or red colour; 1= 
erythema or slight swelling; 2= marked swelling or erythema; and 3 = severe swelling 
and or loss o f limb function. Each limb was examined daily by a blinded observer. Each 
limb o f each animal was assessed daily by this method.
Day 1 20 mice 5xl07 live aureus (TSST+ye)(IVroute) &. 10 mice 5xl07 heat killed S. aureus 
(TSST+VC)(I V route)
lOeach mice 40mg IL-15Ra or equivalent volume of High-Salt PBS (IP route)
Monitoring for sepsis and arthritis 
Day 2 Monitoring for sepsis and arthritis
Day 3 25 mice 40mg IL-15Ra or equivalent volume of High-Salt PBS. Monitoring for sepsis and 
arthritis.
Day 4 Monitoring for sepsis and arthritis 
Day 5 Monitoring for sepsis and arthritis 
Day 6 Monitoring for sepsis and arthritis
Day 7 Monitoring for sepsis and arthritis All mice from each group terminated.
Table 7 Summary of schedule for bolas injection septic arthritis model experiment.
Features of Septicaemia
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5.4 Mortality
There was no evidence o f  mortality in either o f the groups treated with heat killed 
bacteria (data not shown). In the groups treated with live S. aureus, there was 30% 
mortality in the PBS control group at one week, but 0% in the receptor treated group. 
The occurrence o f this mortality is shown below in figure 30 and there was no 
significant difference in the two groups (p=>1.0, Kruskal-Wallace test).
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Figure 30
Mortality data for the receptor and PBS control treated groups 
that had previously been inoculated with live S. aureus bacteria 
LS-1 strain. There was no significant difference in mortality
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5.5 Incidence of septicaemia
The incidence o f septicaemia was calculated daily and expressed below in figure 31. 
A trend for lower sepsis incidence in the receptor treated group was seen, but the 
difference between the two groups was not statistically significant. (p>0.05 chi 
squared)
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Figure 31
Incidence of septicaemia in receptor and PBS control treated group 
inoculated with 5x107 live S. aureus.
Chi square test indicates no significant data points i.e. p=>0.05.
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5.6 Weight loss data
The body-mass o f the mice was recorded on days 3, 5 and 7. Figure 32 below 
indicates the change as percentage difference to the previous day’s weight. The 
greater weight loss in the control group data reflected the incidence o f sepsis data, 
shown above in figure 31. However, no statistical significance was demonstrated 
when these data were compared by the Mann Whitney U test p>0.05.
Two groups o f mice (1&2) inoculated with heat-killed S. aureus showed no features 
o f septicaemia. Both the receptor and the control treated groups (1&2) had gained 2% 
body weight by the end o f the experiment. (Data not shown)
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Figure 32 
The body 
weight of each 
mouse was 
measured on 
days 3,5 & 7. 
The actual 
change in 
grams from 
the previous 
days reading is 
presented here 
as a
percentage.
5.7 Severity of septiceamia
The severity o f sepsis over time was also determined according to the scoring system 
described in the materials and methods (section 2.22, table 2), by a blinded observer 
on days 1, 3 and 7. The mice that succumbed were counted as scoring 4: from the day 
o f death until the end o f the experiment, (i.e. analysis was on an intention to treat 
basis.) Briefly, Starey-coat, hunched aspect, lack o f spontaneous movement and 
mucotaneous eye secretion, each scored one index point. The average score was 
calculated daily for each mouse with a maximum score o f four. These data are shown 
below in figure 33. This figure shows that as with the septicaemia incidence and 
weight loss data above, there was a trend for lower severity o f septicaemia in the 
receptor treated group when compared to the control. This difference reached 
statistical significance on day five where p= <0.02. (Mann Whitney U analysis), 
emphasising the strength o f the trend.
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Figure 33 
The severity' of 
septicaemia yvas 
assessed by the septic 
index described in the 
text above.
The difference between 
the two groups reached 
statistical significance 
on day 5(*) (p=>0.02) 
(Mann Whitney U) A 
trend for low er sepsis 
severity was 
maintained on all other 
days of the experiment.
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Arthritis
The animals were also monitored for evidence o f arthritis. Mice were monitored by a 
blinded observer on days 1, & 3-7 inclusive for symptoms o f septic arthritis and 
assigned severity scores according to the index in materials and methods section 2.21. 
Briefly: 0 = no swelling or red colour; 1= erythema or slight swelling; 2= marked 
swelling or erythema; and 3 = severe swelling and or loss o f limb function. The 
severity o f arthritis is shown later in figure 35.
5.8 Incidence of septic arthritis
The incidence o f arthritis was calculated by expressing the percentage o f mice in each 
group with arthritis at each time point. Analysis by Mann Whitney-U indicated that 
there was no significant difference in the incidence o f arthritis between the two 
groups (p=>0.05) as shown immediately below in Figure 34. However, a trend for 
lower incidence o f arthritis in the receptor treated group compared to the control 
group is apparent.
Incidence of arthritis
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Figure 34
Incidence of arthritis No significant difference was demonstrated but the 
receptor treated group initially exhibited less incidence of arthritis.
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5.9 Severity of septic arthritis
Severity o f arthritis was also calculated using the arthritic index described. The mean 
score per mouse was calculated daily and is presented below in figure 35. As with the 
incidence o f arthritis, there was a clear trend in which the receptor treated group 
incurred less severe arthritis than the control group. When these data were compared 
by the Mann Whitney U test with statistical significance was attained on day six 
(P=<0.05). However, by day seven, there was no difference between the two groups.
Arthritis severity sco re
p = <0.05
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Figure 35
The severity of arthritis is assessed by the arthritic index described in the text 
above.
The difference between the two groups reached statistical significance on day 6 
(p=<0.05)
(Mann Whitney U) The IL-15Ra group trend for lower arthritis severity was 
maintained on all other days of the experiment until day 7.
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Severity o f arthritis was also calculated in terms o f the average number o f arthritic 
limbs per group o f mice at each time point. This is illustrated below in figure 36. A 
trend existed with fewer limbs involved per mouse in the receptor treated group 
compared to the control group. The difference was statistically significant on days 5 
and 6 (p= <0.05 and <0.03 respectively. (Mann Whitney U). This reflected the 
severity and incidence data presented above.
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The number of limbs with arthritis was calculated and is expressed here as 
mean limbs involved per mouse
I* p=<0.05 
2* p= <0.03
(Mann Whitney U) all other data points not significant
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There was no evidence o f septic arthritis in the groups inoculated with heat 
killed S. aureus. This is in contrast to the groups treated with IL-15 receptor or the 
PBS control that were inoculated with live S. aureus.
The trend for reduced septicaemia and lower arthritis severity and incidence 
suggests that the IL-15Ra may act in mice to reduce the symptoms o f septicaemia and 
arthritis associated with the septic arthritis model, caused by inoculation with live S. 
aureus. Furthermore, this trend was reinforced by statistical significance at several 
time points.
The experiment above can be described as bolus administration o f the 
receptor. A further experiment was designed to see if prolonging the IL-15Ra 
treatment would identify more clearly, any modification o f septic arthritis progression 
by IL-15Ra administration. The following experiment features 7 daily injections o f 
IL-15Ra (or control) and the observation period was extended to two weeks.
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5.10 The effect of prolonged injection of IL-15Ra in the septic arthritis model
In a second experiment, 50 female Swiss mice, 4-6 weeks old, were 
segregated into 4 groups, 5 mice per cage and fed on standard laboratory diet and 
water ad-libitum.
All o f the mice were injected with 5x107 live Staphylococcus aureus (S. 
aureus) by intravenous injection via the tail-vein, as shown below in table 8.
Shortly after this inoculation, 25 o f the mice were injected intraperitoneally, 
with 40mg murine IL-15-receptor alpha suspended in lOOplPBS and the remainder 
with an equivalent volume and concentration o f murine serum albumin (MSA) 
(Sigma) suspended in PBS. The injection o f IL-15Ra or control PBS was repeated 
daily at 24-hour intervals for seven days after the S. aureus injection.
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D ayl All mice 5x107 live S. aureus (TSST+ve)(IVroute) then 25 mice 40mg IL-15 
R a  / High-Salt PBS (IP route).and 25 mice equivalent volume o f High-Salt 
PBS.
Assessment o f sepsis and arthritis.
Day 2 as day 1 for IL-15Ra or control injection with assessment o f sepsis and 
arthritis. (No further S. aureus inoculation) and continue until day 7
Day 3 
Day 4 
Day 5 
Day 6 
Day 7^  
control
10 mice from each group terminated. Cease injection o f receptor and
Day 8 Monitoring for sepsis and arthritis and continue until day 14 
Day 9 
Day 10 
Day 11 
Day 12 
Day 13
Day 14^ remaining 15 mice per group terminated
Table 8,
Summary of schedule and reagents used during an experiment in prolonged 
injection of therapeutic soluble IL-15Ra/control in the septic arthritis model 
experiment.
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The mice were monitored for symptoms o f septic arthritis and septicaemia 
from day one, as described in the materials and methods section 2.23. Therapeutic 
injection o f IL-15Ra and control ceased on day 7 and 10 mice from each treatment 
group euthanased for analysis.
Subsequently, this group was referred to as the “1 week group”. The 
remaining 15 were monitored for a further 7 days before euthanasia and these mice 
were subsequently known as the “2 week group”.
The occurrence o f septicaemia was assessed by a blinded observer using the 
septicaemia index, described in section 2.22, table 2. Body mass was measured every 
day and coat condition, body stance, eye discharge and the presence or absence o f 
spontaneous movement were also assessed. At post-mortem, organs, blood and joints 
were examined for live colony forming units o f S. aureus. Spleen cells were also 
taken at post-mortem to examine proliferative activity against a range o f cellular 
mitogens.
The presence o f joint disease was assessed by the scale o f clinical scores used 
for collagen-induced arthritis described in materials and methods section 2.21, 
materials and methods
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5.11 Mortality during IL-15Rq prolonged therapy
There were four deaths among the 50 inoculated mice. One mouse in the 
control group died on day 5 and two further mice died in the control group on day 11, 
as did one mouse in the receptor group. This is shown in figures 37 & 38 below where 
the surviving animals are plotted as a function o f time. When these data were 
compared, there was no statistical difference in the two treatment groups for 
mortality. (Kruskal-Wallace test)
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Figure 37 M ortality described as % mice surviving 
in week ONE. 25 mice per group. No statistical 
difference was demonstrated.
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Figure 38 M ortality described as % mice surviving in 
week TWO. 15 mice per group. No statistical difference 
was dem onstrated.
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5.12 Incidence of septicaemia during IL-15Ra prolonged therapy
The status o f four symptoms o f bacterially induced septicaemia was monitored daily 
and recorded for each mouse, as described for LPS induced septicaemia in section 
2.22, materials and methods. The presence o f any one or more or these symptoms was 
recorded daily and the percentage o f mice in either treatment group exhibiting 
septicaemia at each time point are presented in figure 39 below. Dead mice continued 
to be included as scoring “4” because assessment was carried out on an intention to 
treat basis as before.
The incidence o f sepsis was observed to be lower in the receptor treated group 
on days 1-4, but none o f these data points reached statistical significance (p=>0.05 
Mann Whitney U). After day four, there was no obvious difference between the two 
groups.
Incidence of seticaenria
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Figure 39
The actual number of mice expressed as a percentage of mice 
in each group with symptoms of sepsis over time. No 
significant data points were recorded
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5.13 Changes in body mass during IL-15Ra prolonged therapy
In figure 40 below the daily change in weight was plotted against time. The 
general pattern indicated that both groups lost body mass initially and from day seven 
(coinciding with cessation o f injection therapy), both treatment and control arms o f 
the two week group began to gain weight. At no point during the experiment did the 
data attain statistical significance (p=>0.05 Mann Whitney U).
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Figure 40
The actual body weight for all the mice in each group presented as 
change in grams from the previous day’s total weight over time. No 
significant data points were demonstrated
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5.14 Severity of septicaemia during IL-15Ra prolonged therapy
The severity o f septicemia was calculated at each time point for the two 
groups. This was achieved using the mean septic score per mouse derived from the 
index described in section 2.22, materials and methods. The data shown in Figure 41 
below indicated that between day 1 and day 8, the receptor group consistently 
appeared to exhibit less severe sepsis than the control group. After day 8, (1 day after 
cessation o f receptor treatment), the difference in severity o f septicaemia was less 
apparent between the two groups. There were no significant data points when the two 
groups were compared using the non-parametric test; Mann-Whitney U (p=>0.05).
Se
pt
ic
ae
m
ia
 
ind
ex
 
sc
or
e
159
m
 - ______________.... .
severity of septicaemia
o 5 10
time (days)
15
IL-15Ra Control
Figure 41. The mean septicaemia score shown in this table 
was calculated as the average score of the surviving mice in 
each group per day. In spite of the early trends for 
difference, No significant data points were recorded.
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5.15 Incidence of Arthritis during IL-15Ra prolonged therapy
Both the receptor and control groups o f mice in this septic arthritis model were 
assessed for clinical signs o f arthritis using the arthritic-index and by incidence o f 
arthritic animals in each group over time and finally, the mean number o f limbs with 
arthritis per mouse as a function o f time.
In figure 42 below, the incidence o f arthritis is described by the percentage o f 
surviving animals in each group showing any signs o f arthritis at each daily time 
point.
'■y
Statistical analysis o f this data by Chi test reveals that the lower incidence o f 
arthritis in the receptor group illustrated in figure 42 below, was significant (p= 
<0.0002) on day two. This data indicated there was a delay in the incidence o f 
arthritis in the earlier stage o f the disease when the receptor group was compared to 
the controls. There is no difference between the groups after day five (p=>0.05).
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Figure 42
There are fewer incidences of arthritis in the receptor group on 
days 2,3 &5 compared to the control group. Day 2(1*) p=<0.0002 
Day 3 (2*) p=>0.05. Following day five, there are no statistically 
significant data points
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5.16 Severity of Arthritis during IL-15Ra prolonged therapy
Figure 43 below shows the mean arthritic index score calculated from the sum o f the 
individual daily index scores o f each mouse divided by the number o f surviving mice 
to give the mean on each day o f the experiment. Although there was a trend whereby 
the severity o f arthritis was lower in the receptor group compared to the control on 
days 2 and 3 (accurately reflecting the data in figure 42 above) , statistical analysis 
using the Mann Whitney U test fails to show statistical significance. (P>0.05)
------
5 10
tVTB(cfe^ G}
Figure 43
The severity of arthritis was measured by the index described on page 
147. There was initially a transient trend for lower severity in the 
receptor group compared to the control No statistically significant data 
points were observed
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5.17 Severity of Arthritis defined as limbs involved during IL-15Ra prolonged 
therapy
Severity o f  arthritis was also assessed by calculating the mean number o f 
limbs involved per mouse at each time point. This is illustrated below in figure 44. 
Concurring with the graphs o f arthritic incidence (figure 42) and severity ( figure 43), 
the data in figure 44 indicated that there were initially, less limbs involved per mouse 
in the receptor group compared to the number o f  limbs involved in the control. This 
difference was statistically significant on day 2 (p=< 0.0035 Mann Whitney U). On 
day three there was less difference (p= >0.05) and from day 4 onwards there was no 
difference between the groups.
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Figure 44
Average limbs per mouse per group 
The difference on day two (*) was 
significant at p=<0.0035 but there were no 
significant differences after day 3.
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5,18 Bacteriological observations in septic arthritis model mice during prolonged 
therapy with IL-15Ra
In addition to clinical indicators o f infection, the presence o f S. aureus -colony 
forming units (CFUs) was also investigated by culture o f various tissues at post 
mortem, as described in section 2.23 o f materials and methods, chapter 2. Briefly, 
following euthanasia o f the 1 and 2 week groups o f mice on day 7 and 14 
respectively, samples o f tissue and blood were taken from 10 mice in the treatment 
and control groups at both time points. These tissues were then pooled. 
Homogeneous, single cell suspensions were made from kidney, spleen and liver, lg 
samples o f each tissue were diluted in 10ml sterile PBS and then serially diluted to
7 71x10" through to 1x10" . lOOjul o f whole blood was obtained by tail bleeding 
immediately prior to euthanasia. This was diluted as above into 900pl sterile PBS and 
then serially to 10"7 as above. lOOpl o f each dilution o f tissue or blood was then 
spread over a pre-incubated blood-agar plate (Oxoid UK).
To estimate the presence o f S. aureus CFUs in joints, the whole foot below the 
knee was removed at euthanasia and stored on ice. Using a sterile scalpel, a fresh cut 
was made through the forefoot o f each hind limb. The exposed bone surface was then 
streaked across a pre-incubated blood agar plate (Oxoid UK) in a regular pattern.
The agar plates were incubated overnight at 37°C and colonies identified with 
the kind assistance o f Dr Curtis Gemmell o f the Department o f Microbiology of 
Glasgow Royal Infirmary. The colonies positively identified as S. aureus were 
counted. These results are presented below in figure 45 -  49. In whole blood (figure 
45), Kidney (Figure 46) Liver (figure 47) and spleen (figure 48), there is a trend for 
higher S. aureus CFUs in the receptor treated group compared to these tissues in the
control group. Furthermore, this trend continues into the second week for the blood 
and kidney compartments, albeit at lower CFU levels than the day seven analysis. The 
CFUs present in the joints assessed offer no support to any trend seen in the other 
tissues and the significance o f this observation is unclear.
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Figure 45 S. aureus colony-forming units in lOOpl pooled, whole blood taken at 7 and 
14 days after S. aureus inoculation from 10 mice per group. (I.e. not individual mice) 
In both week one and two groups, more bacteria were observed in the receptor treated 
mice than the control
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Figure 46 S. aureus colony-forming units in lg  combined kidney cells (I.e. 
not individual mice) from 10 mice per group. There were far greater numbers of 
CFUs in the receptor treated week 1 group compared to the control group. A similar 
observation of lower magnitude is seen in the results o f the two week group
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Figure 47 S. aureus colony-forming units in lg combined liver cells (I.e. not 
individual mice) from 10 mice per group. The One week receptor treated group 
demonstrated increased CFUs compared to the control group. There were no evident 
CFUs in the two week group. Treated or control arms
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Figure 48 S. aureus colony-forming units in lg combined spleen cells (I.e. not 
individual mice) from 10 mice per group. Increased CFUs were only observed in the 
One week Receptor treated mice.
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Figure 49 S. aureus colony-forming units in freshly cut joints at seven and 14 days 
post infection. In week one there were more CFUs isolated from the control mice than 
the receptor treated mice. In contrast, the opposite was observed in the two week 
group.
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5.19 Stimulation of Spleen cells
The spleens o f ten mice from each group were collected on days seven and 
fourteen. These were processed into a single cell suspension according to the method 
described in the methods and materials section (2.23). Briefly, spleen cells were re­
suspended in RPMI at 1x10^ cells /ml and plated out in a round bottomed 96 well 
culture plate. Spleen cells were stimulated with serial dilutions o f Staphylococcal 
Enterotoxin-A (SEA) (Sigma), Concanavalin-A (Sigma) or medium alone. 
Incubations were for 24 or 48 hours at 37°C. Detection o f proliferation was by 
3hThymidine pulse 6 hours prior to cell harvesting followed by scintillation counting 
on a Wallac Beta counter. (Wallac, USA).
The counts per minute induced by spleen cell proliferation in response to 
exogenous SEA or the mitogen: CON-A were plotted as a function o f concentration.
Figures 50 - 53 below indicate that there was a reduction in the ability o f the 
spleen cells o f the receptor-treated group to proliferate in response to both the Non­
specific T cell mitogen CON-A and the S. aureus specific molecule, Staphylococcal 
Enterotoxin-A (SEA), when compared to the control group. The receptor group’s 
lower spleen cell proliferation was marked in the day 7 spleens. This pattern was 
reversed in the day 14 spleen cells; Approximately 50% lower in SEA and 30% lower 
in CON-A week 1 and changing to approximately 10% higher in SEA and 12% higher 
in CON-A at the end o f week two.
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Figure 50 There was a trend for lower in-vitro Spleen cell activation in 
mice treated with IL-15Ra when pooled spleen cells from the one week group of 
septic arthritis mice were challenged with SEA
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Figure 51 At low concentrations of SEA, there was a trend for lower in- 
vitro Spleen cell activation in mice treated with IL-15Ra when pooled spleen 
cells from the two week group of septic arthritis mice were challenged with SEA. 
However, this was not confirmed at higher concentrations of SEA where the 
opposite was observed.
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Figure 52 There was a trend for lower in-vitro Spleen cell activation in 
mice treated with IL-15Ra when pooled spleen cells from the one week group of 
septic arthritis mice were challenged with CON-A This trend was observed 
continuously across the range of CON-A used to stimulate the cells.
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Figure 53 There was a trend for lower in-vitro Spleen cell activation in 
mice treated with IL-15Ra when pooled spleen cells from the one week group of 
septic arthritis mice were challenged with CON-A This trend was observed most 
strongly at a range of l-2ng/ml CON-A but the difference was not so apparent at 
the extreme concentration range used to stimulate the cells.
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5.20 Summary of bolus and prolonged IL-15Rq septic arthritis model
experiments
A trend for reduced symptoms o f septicaemia and arthritis was demonstrated 
in mice treated with 2 bolus injections o f IL-15Ra when compared to those treated 
with the carrier control. The incidence o f septicaemia was decreased at every time 
point in the receptor treated group when compared to that o f the control group. 
Although this difference did not attain statistical significance, the observations o f 
severity o f sepsis also exhibited the same trend with the receptor group exhibiting 
fewer features o f septicaemia at each time point throughout the experiment when 
compared to the controls. Furthermore, the difference between the two groups did 
attain statistical significance on day 5 (p=<0.02, Mann Whitney U analysis).
The arthritis associated with the model was also reduced in the receptor treated 
group. The incidence o f arthritis was reduced on all days o f the experiment in the 
receptor treated group when compared to the controls. Although the trend was 
consistent, there were no significant data points. The severity o f arthritis measured 
both by the arthritic index and the number o f limbs involved per mouse, again 
exhibited a clear trend: less severe arthritis and less limbs involved per mouse in the 
receptor treated group contrasting with those observed in the control group. 
Furthermore, the data for arthritic severity was significantly different on day 6 (p= 
<0.05, Mann Whitney U analysis) and also for the number o f limbs involved on day 
5(p= <0.05) and day 6 (p= <0.03) when subject to Mann Whitney U analysis.
In the experiment featuring prolonged therapy with IL-15Ra, similar trends 
were exhibited during the first few days o f the experiment to those described in the 
bolus experiment summarised above. There was a trend for lower incidence o f
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septicaemia in the receptor treated group on days 1-4 compared to the controls. A 
similar trend was observed for reduced severity o f septicaemia in the receptor treated 
group compared to the controls, until day 7 after which no difference was seen.
Furthermore, reduced incidence o f arthritis, severity o f  arthritis and o f  mean 
number o f limbs involved with arthritis was observed in the IL-15Ra therapy group 
compared to the control group between days 3-6. Although not statistically 
significant, on the days 2, 3 and 5, there was less severe arthritis in the receptor 
treated group when compared to the controls. There was also lower incidence o f 
arthritis in the receptor treated group on days 3, 4 and 6, with day 3 (p= <0.0002) and 
day 4 (p=< 0.05) attaining statistical significance. The mean number o f limbs 
involved was also less in the receptor treated group on days 2, 3 and 5 and the 
difference on day 3 was statistically significant (p= <0.0035).
In summary, it can be seen that the administration o f IL-15Ra to mice with 
septic arthritis reduced the incidence and severity o f septicaemia and arthritis 
associated with the septic arthritis model in the first 3-7 days o f the disease. This 
implies that the IL-15Ra may act to modify host response to the S. aureus, resulting 
in less inflammatory disease.
Two interesting features can be discerned from this data. In the experiment, 
where two doses o f IL-15Ra were administered, a sustained difference was seen 
between the two groups with a trend for lower sepsis and arthritis extending over the 
7 days o f the first experiment. In the experiment featuring prolonged injection o f IL- 
15Ra, a similar trend was seen but observations o f lower severity/incidence o f 
symptoms associated with this model did not generally extend beyond the first few 
days o f the experiment. A second feature is that the lower incidence/severity o f sepsis
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and arthritis was not apparent following the cessation o f treatment. This might 
indicate that the host response to S. aureus was being suppressed by the 
administration o f IL-15Ra and that this effect was lost on cessation o f treatment.
The clinical observations described above for the two experiments represent a 
repetitive trend for reduced inflammatory response leading to manifestation o f 
septicaemia and septic arthritis when mice were treated with IL-15Ra. The results for 
the non-clinical parameters investigated, S. aureus colony forming unit numbers and 
spleen cell proliferation, may also be reflective o f this trend. (These measurements 
were derived from pooled samples and as a consequence, statistical analysis is 
impossible.) The S. aureus bacterial load was found to be greater in blood, kidney, 
liver and spleen at the end o f week one in the therapy group compared to the control 
group. In the septicaemia and arthritis measurements, the receptor treated mice 
generally exhibited less severe symptoms o f septicaemia and arthritis during the time 
that blood bacterial load was higher. In the second week following cessation o f IL- 
15Ra therapy, bacterial loads between the two groups became essentially identical. 
This “normalisation” o f bacterial load, however, is demonstrated at a time point where 
there was no longer any evidence o f lower arthritis or septicaemia in the receptor 
treated group.
These results may suggest that IL-15Ra treatment transiently reduced 
inflammation (manifest as symptoms o f septicaemia and arthritis), but concomitantly 
may have suppressed the ability o f the mice to clear the infecting S. aureus or perhaps 
modified the distribution pattern o f the bacteria in some way.
If the host response to S. aureus was indeed impaired by the IL-15Ra, then 
further evidence for this hypothesis might be expected in the form of reduced spleen 
cell proliferation in the receptor treated mice.
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To investigate this, spleen cells were pooled from 10 mice per group 
and their proliferative response against SEA and Con-A was measured. Figures 50 
and 51 showed that in the One Week groups, that the spleen cell proliferative 
response o f the receptor treated mice was reduced by 40 - 50% compared to the 
controls at the end o f the treatment period (day 7). In the Two Week group, (figure 52 
& 53) the reduced proliferative responses o f the receptor treated group were observed 
to have similar or equal levels o f response to SEA and CON-A to the controls by the 
end o f week two, 7 days after the last IL-15Ra injection. This data does not contradict 
the trends exhibited for septicaemia or arthritis. The proliferative ability o f the spleen 
cells was reduced in the receptor group at the 7 day time point when the CFUs o f the 
therapeutic group were markedly higher than the CFUs found in the control group. 
This coincides with the increase o f inflammation and o f reduction o f bacterial load in 
this group to levels seen in the control group. As with the bacteriology data, the 
spleen samples used in these preliminary experiments were pooled from 10 mice and 
no statistical analysis can be applied. This preliminary CFU and proliferation data 
appears consistent with the modification o f the host response to S. aureus by 
therapeutic injection o f IL-15Ra.
In conclusion, the administration o f IL-15Ra to mice with septic arthritis 
seems to modify host response to S. aureus, manifest by reduced symptoms o f sepsis 
and arthritis. The reduction in inflammatory response demonstrated by the severity 
and incidence data was co-incident with the highest bacterial load. This point also 
coincided with a reduced ability o f the spleen cells to proliferate in response to the
pathogen’s antigen in-vitro. Cessation o f treatment restored the proliferative response 
o f the spleen cells resulting in reduced bacterial load and a restoration o f the 
inflammatory response indicated by levels o f sepsis and arthritis indistinguishable 
from control mice.
Mclnnes (68) examined the blood/organ bacterial load and spleen-cell 
proliferation profile o f mice infected with the same strain o f S. aureus used here. The 
experimental mice were genetically deficient in inducible NO Synthase (iNOS), an 
enzyme that produces Nitric Oxide. In their experiment, they found that the deficiency 
o f NO production led to increased colony forming units (S. aureus) in blood, spleen 
and kidney compared to control mice, reflecting the pattern seen above in figures 45- 
49. In contrast to these experiments described above, Mclnnes et al found increased 
proliferation o f spleen cells from the iNOS deficient mice in response to SEA when 
compared to control mice.
There is no relationship implied here between NO action in inflammatory 
response to live pathogens such as S. aureus and that o f IL-15. However, it is possible 
to see that the bacterial profiles demonstrated by the removal o f the pro-inflammatory 
Nitric Oxide are similar to the bacterial seen above in response to the removal o f the 
pro-inflammatory murine IL-15 by administration of the IL-15-receptor. Comparison 
o f the graphs o f Severity of Sepsis in the first (fig 41) experiment and that o f Mclnnes 
(1998 fig 2b) reveals a startlingly similar pattern o f sepsis over seven days in both the 
wild type mice and the experimental groups. These similarities with the NO deficient 
model o f Septic arthritis strengthen the possibility that the results are likely to be 
reproducible and informative, if repeated in a more robustly designed experiment.
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Some logical steps to investigate the trends and patterns presented here would be to 
increase the dose o f IL-15Ra and to extend the observation period to 21 days to study 
the long term effect ofgreater bacterial load. The use o f single spleens for proliferation 
and bacteriological assays would allow statistical calculations to be carried out.
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Chapter 6
Discussion and Conclusions
This project investigated the possibility that IL-15 might play a modifying role 
in three murine models o f  human inflammatory disease; collagen induced arthritis, 
septic shock and septic arthritis, models for the human diseases o f rheumatoid 
arthritis, septic shock and septic arthritis respectively. The possibility that IL-15 is 
implicated was based on the premise that IL-15 influences the production o f 
TNFa. TNFa in turn being documented as a major cytokine component in 
pathogenesis o f the diseases and/or their murine models investigated here.
Initially, the experimental design was to generate murine IL-15 and then 
derive monoclonal antibodies against IL-15 and use these as a neutralising agent in 
the murine models. Generation o f a murine IL-15cDNA was achieved from J774 cells 
resulting in the cloning o f a cDNA with a sequence homologous to that published by 
Anderson et al (17). Furthermore, a mutant form o f IL-15 was cloned from the same 
culture o f J774 cells.
6.1 Recombinant murine IL-15 deletion mutant
When analysed, this alternative cDNA contained the same sequence as the 
wild type murine IL-15 cDNA but was deficient in 16 codons translating to an in­
frame deletion mutant o f 16 hydrophobic amino acids. The significance o f the 
presence o f this mutant in the total RNA of the J774 cells is unclear. It may be an 
artefact o f either the cloning procedure or perhaps the nature o f the J774 cells that 
their continued culture may have generated mutations over time. However it is 
interesting in that the deletion is in frame and furthermore, deletes codons for a series
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o f predominantly hydrophobic amino acids from the secondary structure o f murine 
IL-15. The deletion mutant, here named IL-15-48, was also tested for characteristic 
IL-15 T cell stimulating activity. It was found that this mutant was able to bind IL-15 
receptor alpha with similar coefficient to the purified recombinant murine IL-15. 
However it did not activate CTLL cells. This suggests that the deleted 16 amino acids 
were not in binding to the IL-15Ra but are important in generating the necessary 
signals to activate the T cell. Taking advantage o f this unexpected phenomenon, the 
mutant was also used in a CIA experiment as a therapeutic antagonist to IL-15.
Another cytokine deletion mutant is well documented in the literature (85) IL- 
lR a  is a naturally occurring mutant form o f IL-1, which amongst other cells, is 
produced by macrophages (86). This mutant shares amino acid homology to IL-1 a  
and IL-1 (3 however, IL -IR a lacks one receptor binding motif compared to IL-1 a  & p 
which have two. The omission o f the motif in IL -IR a seems to prevent signal 
transduction when IL -IR a is bound (87). Therefore as IL -IR a has relatively similar 
affinity for the receptor as that o f the IL-1 a  & p (88) its binding can be seen to have 
an antagonistic effect on IL-1 activity in a cell system.
There is also evidence o f alternative IL-15 splicing mutants in the literature. 
Meazza et al found splice variant IL-15 cDNA in the majority o f small lung cell 
cancer cells that they examined. Meazza (19) discovered that there was an alternative 
exon, which coded for a shorter signal peptide when the IL-15 RNA was translated. 
The effect o f the shorter leader sequence was not determined. It did not up-regulate 
expression or secretion o f bioactive IL-15 in these cells. It is interesting to note that 
IL-15 RNA can be transcribed by cells such as T cells which do not secrete IL-15, 
demonstrating that the IL-15 control mechanisms are likely to be at a 
translation/secretion level rather than transcriptional (89).
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The Immunex Corporation (Seattle, USA) has extensively tested PEGylated 
and mutein forms o f IL-15. They found that targeting lysine residues adjacent to 
amino acids crucial for interaction with the IL-15p subunit might account for the 
antagonist activity exhibited by PEG-IL-15. They concluded that there was scope for 
therapeutic molecules against inflammatory disease to be generated in this manner 
(90)
If  however, IL-15-48 were a natural mutant, then it too would have a similar 
theoretical antagonist potential to that o f the muteins above. However, the addition 
o f PEG is known to have the effect o f reducing immunogenicity and enhancing 
physiological half-life. It is not known that IL-15-48 is a naturally occurring mutant, 
neither is it known what function if any the deleted hydrophobic residues would 
have had within the tertiary structure o f the mature protein if it had been produced. 
However, it can be seen that the binding function was not affected by the deletion 
and therefore it might be speculated that the IL-15-48 mutant might exist naturally 
as some form o f regulatory agent for IL-15. The deletion sequence itself may be o f 
interest to those who have insight into protein structure as it would define an area 
involved in the function o f IL-15 but not related in any meaningful way to its 
capacity to bind IL-15Ra. Since completion of the experimental section o f this 
thesis, no studies have been published too offer any evidence that the IL-15-48 
mutant observed here was anything other than an artefact. Recent work using site 
directed mutagenesis by Harb et al, (110) has elucidated amino acid sequences in 
several portions o f the native human IL-15 poly peptide which interact in some way 
with the human soluble IL-15Ra. Notwithstanding the lack o f sequence homology 
between human and murine forms o f IL-15, there is no obvious homology between 
the amino acids identified by Harb as being involved in the interaction between IL-
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15 and its receptor. The hydrophobic nature o f the IL-15-48 deletion mutant is not 
reflected in Harbs’ sequences nor is the numerical position within the polypeptide 
chain. More analysis could be done here but the lack o f other reports o f any such 
similar molecule spontaneously arising in the 5 years since the first observation o f 
IL-15-48 in this experiment would suggest that it was indeed an artefact o f the J774 
cells used for culture. However, the possibility o f artificially constructing a similar 
mutant as a research tool, i.e. a molecule that binds its receptor and acts as an 
antagonist remains open as an alternative should an experiment require a non­
antibody based protocol.
Although functional/non-functional mature protein IL-15 isoforms have been 
conspicuous by their absence, pre translation Isoforms have been observed. Recent 
research into IL-15 mRNA isoforms centre around 5’ upstream modifications 
allowing eventual direction o f mature IL-15 protein to different cellular 
compartments, leading to soluble or membrane bound isoforms. This has informed 
the debate around the discrepancies between IL-15 mRNA and mature protein in 
various tissues (such as macrophages where constitutive expression o f IL-15 mRNA 
but little protein) has often been seen in the IL-15 literature. Musso et al (111) 
investigated this and show that monocytes do indeed have a membrane bound form 
of IL-15 but did not observe this form in the T and B cell subsets. It can be seen that 
a culture medium of macrophages might not exhibit much or any evidence o f IL-15 
activity even where there was evidence for mRNA however the role o f macrophages 
and monocytes in immune responses may well be driven by cell-cell contact or 
soluble forms o f IL-15R alpha.
The activities o f IL-15 as a promoter o f TNFa immune systems may be 
controlled by a soluble receptor acting as an antagonist. I.e. a differential in
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concentration o f IL-15 soluble receptor may allow or disallow interaction between 
membrane bound receptors on target cells with which for example macrophages 
displaying IL-15 might wish to activate. In 2004, Mortier et al (112), demonstrated a 
proteolytic release mechanism for soluble IL-15 in human cell lines and COS7 cells. 
This demonstrates a possible control mechanism for IL-15 activity and perhaps 
suggests a reason as to why the soluble receptor was so successful in the work o f 
Ruchatz et al (43) in ameliorating the proposed IL-15 driven pathology o f the 
collagen arthritis model. This regulation o f pro-inflammatory cytokines is reflected 
in the homologous IL-2/IL-2Ra system where spontaneous IL-2Ra is cleaved 
leading to soluble antagonism to IL-2 activity (113). The difference here is that the 
IL-2/IL-2Ra interaction is o f low affinity and non-physio logical concentrations 
must be generated to induce antagonism. In contrast, Mortier (112) proposes that the 
IL-15/IL-15 sSoluble receptor alpha interaction is o f very high affinity and as such 
may be an example o f a physiological control mechanism.
6.2 Recombinant Murine IL-15
Murine IL-15 cDNA was cloned and protein expression was induced 
according to the expected mobility on SDS-PAGE analysis. However, the protein
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produced was highly insoluble and had very low bioactivity. It was not soluble in PBS 
and could therefore only be re-suspended in PBS with high concentrations o f salt and 
glycerol present. The presence o f these additives engendered great difficulty in 
pursuing meaningful experiments for activity and cell culture bioassays. Low 
bioactivity o f the protein might be due to the presence o f these additives and/or the 
harsh purification/resuspension steps needed to elute the murine IL-15 protein from 
the expression system. A more fundamental reason may be that the regulation o f IL- 
15 secretion, widely acknowledged to be complex, suggests that using a prokaryotic 
expression system was possibly disadvantageous. In any future attempts to derive 
bioactive recombinant IL-15 an eukaryotic cell expression system such as drosophila 
cells could be used. However, since the completion o f this thesis, several companies 
now offer commercial recombinant murine IL-15, including Cedarlane Laboratories, 
(USA), who now market an E. coli derived, recombinant murine IL-15 with 98% 
purity and an ED50 value o f <20ng/ml (CTLL assay), giving a specific activity o f 
>5xl04units/mg. They also state an endotoxin value o f <0.1ng/pg. Although these 
units o f measurement are not available for our recombinant muIL-15, it would be 
interesting in any future attempts to repeat this work to compare and refer to the 
activity data of the Cedarlane muIL-15 product. It would also seem from these data 
that purification with immobilised anti E. coli media might be essential in gaining a 
purified and active protein. It had been suggested above that using an Eukaryotic 
recombinant protein system (such as bacculo/drosophila) to produce active muIL-15 
might overcome stability, activity and solubility problems: the fact that the Cedarlane 
recombinant muIL-15 product was soluble in water when reconstituted from lOmM 
Tris at pH8 would suggest that there might not be such an advantage. (Data sheet 
available in the appendix). In spite o f the low bioactivity, some o f the recombinant
murine IL-15 protein was used to induce polyclonal rabbit anti-murine IL-15 
antibodies. These were purified to a relative binding affinity o f 1/32000 following 
protein-A enrichment o f the IgG fraction and then used in the CIA experiment 
described in chapter 3.
As the conditions and reagents used in the purification o f recombinant murine 
IL-15 were virtually incompatible with the in-vivo and in-vitro experimental use, it 
was decided to use the soluble form o f murine IL -15R a. This protein was eluted 
from the Qiagen expression system and had activity in PBS at a physiological 
concentration. Therefore, the experiments within the LPS and the septic arthritis 
models were undertaken using IL-15Ra a natural antagonist.
6.3 Collagen Induced Arthritis model
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Previously, Ruchatz et al (43) reported modification o f the symptoms o f  CIA 
when treating DBA1 mice with soluble IL-15Ra. In the experiments described in 
chapter 3, neither the IL-15 mutant antagonist nor the purified IL-15 anti-sera 
demonstrated such a clear improvement in the symptoms o f mice suffering from CIA. 
These experiments were carried out using the same strain o f mice DBA/1 and welfare 
conditions and diet etc.
In terms o f arthritis severity, the mice treated by placebo were reflective o f 
placebo treated mice o f the Soluble IL-15Ra experiment by Ruchatz et al. There was 
a common pattern for a more rapidly increasing severity in the beginning o f the 
second week o f treatment.
The mice treated with IL-15-48 initially exhibited a flat curve for arthritis 
severity, however this trend was not statistically different from the placebo treated 
mice. This is in contrast to the mice treated with soluble IL-15Ra, which showed a 
marked and increasing difference from those treated with placebo. The initial trend 
for reduced arthritis severity in IL-15-48-mutant treated mice may be o f interest in the 
light o f other score/observations shown in the anti-body treated CIA (below) and the 
effect that IL-15Ra had on LPS shock and Septic arthritis. However, there was no 
statistical difference demonstrated by the therapeutic intervention o f IL-15-48 
compared to placebo.
In addition to severity, incidence o f arthritis was also measured there was a 
trend for lower incidence initially but not statistically significant. Although not 
directly comparable, this is in contrast with the data for number of arthritic paws
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shown by the soluble IL-15Ra mice o f Ruchatz et al who reported almost complete 
abrogation o f arthritis incidence.
In a subsequent CIA experiment, rabbit anti-IL-15 polyclonal antiserum was 
also used. Similar to the IL-15-48 experiment, there were no statistical differences in 
any o f the parameters measured between anti-IL-15 and placebo treated mice except a 
transient reduction o f severity o f arthritis in the anti-IL-15 treated group suggesting a 
trend for mice treated with anti-IL-15 to show less severe signs o f arthritis than the 
placebo group.
Considering the ability o f IL-15Ra to abrogate almost completely the 
symptoms and signs o f collagen induced arthritis, it was disappointing that there was 
such a weak trend for improvement when the IL-15-48 and anti-IL-15 were used 
under such analogous conditions. Endogenous IL-15 was again the presumptive target 
and it can really only be concluded that the therapeutic agents trialed here were o f 
insufficient concentration or quality to neutralise any IL-15 pro-inflammatory activity.
The slightly stronger trend for lower severity in the anti-IL-15 treatment 
experiment indicates that there may be a mild abrogation o f arthritis. The generation 
of a substantially more potent preparation o f anti-IL-15 antibody might be a usefiil 
experiment and would possibly demonstrate a level o f abrogation o f collagen induced 
arthritis symptoms similar to that shown by the soluble IL-15Ra. A sample o f the 
polyclonal IL-15 anti-serum was run through an E. coli affinity purification column. 
The filtered eluate was found to have a much lower IgG concentration than prior to 
filtration (data not shown). This implies that the anti-sera used could have partly been 
comprised by anti-E. coli antibodies rather than the anti-IL-15 activity first supposed. 
The inclusion o f an immobilised E. coli lysate step should be an integral part o f any
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future preparation o f recombinant protein and antibody from an E. coli based 
expression system.
Any future experiments with anti-IL-15 or the mutant antagonist might also 
benefit from more extensive dose ranging trials, as toxicity at the doses used here was 
not seen to be a problem.
It is interesting to speculate that a crossover trial with both anti-IL-15 and anti- 
TNFa would be interesting with respect to any synergy arising in symptom 
abrogation. Interestingly, Williams et al (42), describe a dose dependent effect o f anti- 
TNFa on CIA, suggesting that a higher concentration o f neutralising, anti-IL-15 
antiserum might be more effective in any future work. It would have been helpful to 
analyse cytokines by ELISA at early time points to generate more and comparable 
data in any repetition o f these experiments. It is not possible to demonstrate how 
intervention o f anti-IL-15 reduced (transiently) the severity o f arthritis symptoms.
If  IL-15 is important here, it may be through its ability to modify T cell 
activation and attraction (33). Thus it could be proposed that neutralising IL-15 
reduced chemoattraction o f T cells into the joint hence less arthritis. Less arthritis 
because removal o f IL-15 could reduce expression o f TNFa both by failing to induce 
T cell secretion o f TNFa and reduction in T cell activation o f Macrophages to 
produce TNF. Again, Fluorescence Activated Cells Sorting (FACS) analysis might 
illuminate more o f the precise role o f IL-15 in the pathogenesis o f the CIA model. IL- 
15 is also reported to induce B cells to mature (13). Therefore as anti CD40 treatment 
has shown to reduce arthritis, then in addition to the reduction o f TNFa production 
and T cell recruitment, B cell activation may also be reduced when IL-15 is 
neutralised. In addition, IL-15 has been shown to upregulate Neutrophil activity (91) 
If this were reduced by neutralisation o f IL-15, then the pro-inflammatory effect of
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neutrophils in the CIA model, as demonstrated by Schrier et al (92) in rats, might also 
be less severe.
From the above, the effects o f IL-15 can be seen to be pleiotropic and its 
neutralisation might reduce the severity o f symptoms in the CIA model. In relation to 
this project, that IL-15 can modify the symptoms o f arthritis in this model is hinted at 
by the transient reduction seen in the results section. ‘Transient action” may be 
suggested by the results but the end o f protective effect when the therapeutic 
injections ceased in the prolonged septic arthritis experiment results in chapter 5, 
would suggest the contrary. Dividing the study o f effects o f IL-15 into time sections 
in the arthritis model may also be helpful and informative in future experiments.
The fact that there was such a marked reduction in the symptoms with the sIL- 
15Ra is interesting and points to the sIL-15Ra as a more stable and effective trial 
molecule. Human trials are about to commence in Rheumatoid Arthritis patients to 
evaluate the therapeutic benefit o f neutralisation o f human IL-15 (134). All o f the 
above points to implicit activity o f IL-15 in arthritic disease and the cascade o f 
activity where IL-15 activated T cells cause migration o f active immune cells to the 
site o f synovitis has been discussed in the literature search earlier. The most effective 
confirmation o f the role o f IL-15 in arthritis will be seen in the results o f the 
forthcoming human IL-15 modulation trials.
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6.4 LPS Shock model
In the original experimental design, anti-IL-15 anti sera would have been used 
in therapeutic intervention in the LPS shock model to elucidate any effects mediated 
by the neutralisation o f endogenous IL-15. Because o f the poor definition o f any 
effect seen in the CIA experiment described above and the difficulties involved in 
production o f murine recombinant IL-15 for testing such anti-bodies, soluble IL-15Ra 
was used as the therapeutic agent in the septic arthritis and LPS experiments.
In a preliminary experiment, a highly significant difference was seen in the 
BALB/c mice treated with sIL-15Ra (33% mortality compared to placebo treated 
mice: 85%) following insult with 18mg/Kg LPS. This was a highly significant 
difference (p=<0.013 Kruskal Wallace).
It was decided to pursue LPS challenge experiments using lower doses o f 
LPS, (5 - 2.5 mg/Kg) in combination with C. parvum priming. This was in order to 
gain information through biochemical analysis of the liver damage enzymes in 
experiments with shorter duration and lower severity.
As expected, these mice exhibited no significant difference in mortality 
whether treated with srIL-15Ra or placebo. The most informative results were 
derived from measurements o f the liver damage associated with C. parvum primed 
mice, challenged with LPS. Serum levels o f aspartate-aminotransferase (AST), 
alanine-aminotransferase (ALT) and creatine kinase (CK) were assessed as indicators 
o f liver damage. The samples were pooled due to small blood volumes eluted from 
the tail vein. Several observations can be made from the results. Firstly the priming o f 
the C. parvum does affect the level o f liver damage indicators in its own right. 
Secondly, the placebo was comparable to the C. parvum alone treatment in its effect
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on liver damage enzymes, lending credibility to the actual liver damage parameters 
observed in the active srIL-15Ra treatment group in spite o f the impossibility o f 
statistical analysis o f pooled samples. The reduction o f serum levels o f liver damage 
indicators in the IL-15Ra treated mice; suggest that IL-15 is associated with liver 
damage and hence its use may be indicated in preventing acute hepatic injury
In the active-treatment or placebo mice, the results segregated to the mice 
insulted with 5mg/Kg LPS and those with 2.5mg/Kg LPS. There was no apparent 
difference between the PBS control and the active sIL-15Ra treatment in the 5mg/Kg 
but in the 2.5mg/Kg experimental set, the sIL-15Ra treated mice showed 
approximately 50% lower serum levels o f all three indicators o f liver damage 
indicators. This suggests that future experiments might need greater concentration o f 
sIL-15Ra in order to show a protective effect at 5mg/Kg but more importantly that 
the experiment was informative at 2.5mg/Kg LPS.
A further experiment sought to describe the clinical signs o f non-lethal levels 
o f LPS shock and to generate serum samples suitable for statistical analysis o f serum 
liver damage levels.
The results showed that there was a significant protective effect against 
symptoms o f septicaemia when IL-15Ra was administered compared to placebo PBS 
(p=<0.0011) because the mice in the IL-15Ra group consistently exhibited less severe 
symptoms of sepsis at all points in the duration o f the experiment. As with the 
previous experiment, serum liver enzymes were measured, this time at 48 hours post 
LPS challenge. As a consequence o f  later sampling, one would expect higher serum 
enzyme activity due to the prolongation o f the model. The serum enzyme levels were 
increased according to this expectation.
195
The trend for lower sepsis score in sIL-15Ra treated mice, measured by the 
septic index mirrored the enzyme determinations; AST, ALT were reduced by 50 -  
60% compared to the control mice levels (p=<0.011). The CK level was also reduced 
in the treatment group by about 33% compared to the control (p=<0.05).
As there was no ELISA assay to determine any serum cytokine changes 
occurring during the experiment, it is hard to determine how IL-15 might actually be 
influencing this apparent reduction in mortality, liver damage and signs o f sepsis. It 
could be proposed that IL-15 following LPS injection acted to cause mortality at high 
LPS doses and merely liver damage at low LPS doses, through induction o f TNFa. 
TNFa is implicated in liver injury, as shown by Ming et al (93) who concluded that 
TNFa was essential in the pathology o f liver damage.
Taguchi et al (94) used very similar methodology to that used here, when they 
primed BALB/c mice with 1 mg/mouse P acnes (C. parvum) and challenged with LPS 
(lpg/m l IV tail vein) 7 days later. At 24 hours blood sampling showed that control 
mice exhibited similar resting serum levels o f AST and ALT to the placebo/non-LPS 
mice o f the experiments described here.
Following LPS challenge Taguchi et al demonstrated a 15-50-fold increase in 
serum liver damage enzymes in their mice. When Taguchi administered Rolipram, 
(an antidepressant phosphodiesterase inhibitor, known to cause liver damage in mice) 
these serum damage indicators were reduced for ALT and AST. In our experiments 
treatment by IL-15Ra reduced ALT and AST, indicating an abrogation o f the liver 
injury induced by LPS by treatment with sIL-15Ra.
Taguchi also measured the levels o f macrophage derived, in-vitro TNFa. This 
was reduced by 40% in the Rolipram treated group. It would be o f great interest to 
investigate the effect o f IL-15Ra on in-vitro TNFa levels in analogous experiments to
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Taguchi to see if similar reductions in liver injury might be related to a cascade effect 
o f IL-15. I f  so, then treatment with anti-IL-15 in acute hepatitis may be beneficial.
It is believed that macrophages infiltrate the liver tissue several days after C. 
parvum priming. (95) These macrophages express the mac-2 activation marker 7 days 
following priming. Taguchi (94) showed that in a time course, cultured macrophage- 
TNFa production began within 2 hours o f the LPS challenge. This reflected earlier 
work by Nagakawa (96) which showed that TNFa was transiently elevated and also 
that the amino-transferase enzymes measured here too, were also elevated in tandem 
with the rise in TNFa. TNFa neutralisation was found to be protective. Tiegs et al 
(97) in another experiment, link TNFa production and raised serum liver damage 
enzymes. Here, TNFa production is followed by increased AST and ALT serum 
levels. Tiegs demonstrated a dose dependant relationship between the treatment o f 
mice with Ebselen, (a selenium based immune-suppressive compound, synthetic 
antioxidant inhibitor o f free-radical induced apoptosis) and TNFa production and the 
activity o f the liver enzymes, AST and ALT. The AST and ALT again followed a 
decrease in concentration as TNFa decreased. This was in the presence o f increasing 
Ebselen levels.
The experiments in the literature indicate that TNFa has a direct effect on 
liver injury as shown by serum levels o f AST and ALT. Removal o f TNFa or use of 
TNFR1 receptor knockout mice shows a protective effect, underlining the importance 
o f TNFa in liver injury. Macrophages may well be the source o f the increased TNFa 
concentrations in inflammatory situations. The events or mediators influencing the 
increase in concentration o f TNFa are likely to occur within 2 hours following LPS 
challenge. The findings in the author’s experiments suggest that IL-15 may contribute 
to mortality and liver injury after the mice are challenged with LPS. At a high dose o f
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LPS, the presence o f sIL-15Ra conferred a protective effect against mortality 
compared to placebo. At a much lower dose o f LPS, liver injury was observed in the 
mice treated with placebo however the mice treated with sIL-15Ra exhibited much 
reduced levels o f liver damage enzymes. This indicates that endogenous IL-15 might 
be acting to induce liver damage but neutralisation o f IL-15 by the presence o f sIL- 
15Ra led to a protective effect. As no other cytokine determinations were made 
during the above experiments, it is a matter o f speculation as to how the protective 
effects o f sIL-15Ra were acting in what can be seen from the literature quoted above, 
is widely acknowledged to be a primarily TNFa driven process.
For the future, evidence for any pro-TNFa production up-regulation by 
endogenous IL-15 might be sought out in the time preceding the first 2 hours 
following LPS insult in C. parvum primed mice. A natural progression might be to 
examine real time levels o f TNFa. The recently developed “Real Time PCR” (98) 
could be an informative technique here. Then it might be possible to establish any 
connection with the reduced serum AST and ALT levels, modified by the presence of 
sIL-15Ra and the TNFa influence on LPS induced liver damage. To investigate this 
area further, experiments might be informative when measuring TNFa levels in a 
time course concomitantly with the treatment with IL-15Ra. The results reported here 
indicate that future experiments might be most informative at doses o f 2.5mg/Kg or 
less.
The trend for lower liver damage and reduced symptoms of sepsis reported 
above provide a strong indication that removal o f IL-15 does indeed modify the LPS 
shock process.
It is interesting to speculate on the nature of a possible link between IL-15 and 
TNFa in the LPS shock pathogenesis. The liver tissues are highly enriched in an LPS
receptor called SR-A. (99) These receptors may be highly prevalent in this organ in 
order to remove LPS from the bloodstream as it flows along the portal vein from the 
gut. It is further believed that LPS Binding Protein (LBP) transfers the LPS to CD 14, 
either soluble form or membrane bound to liver macrophages. At these macrophages, 
LPS then interacts with TOLL like receptors and this interaction in turn leads to 
eventual elimination o f the LPS in combination with HDL molecules. In the mouse, 
TLR4 is believed to be the TOLL Like Receptor responsible for LPS metabolism 
(100). This is demonstrated by the observation that TLR4 deficient mice are more 
susceptible to gram -ve  infection. TLRs may have a central role in promogulating the 
inflammatory reaction. Signalling through these receptors has been associated with 
release o f TNFa, IL-1, 6, 8 and 12. TLRs have been shown to be essential for LPS 
responsiveness in mice.
Does IL-15 have a role, synergistically or otherwise, in the pathway from LPS 
binding, TOLL up-regulation and TNFa production by liver macrophages, leading to 
LPS induced liver damage? IL-15 upregulates TOLL 2 in cell lines as does LPS 
(100). Therefore might IL-15 be acting synergistically with LPS by up-regulating 
TNFa via a TOLL related cascade. This may explain the reason why, in Ruchatz’ 
work, sIL-15Ra was able to almost totally abrogate the inflammation resulting in 
arthritis in response to collagen challenge and mediated by TNFa, pointing to a direct 
and possibly exclusive influence o f IL-15 in TNFa expression. However, in the case 
o f LPS shock, although biochemical indicators o f liver damage were reduced, the 
symptoms o f sepsis were reduced but not abrogated. This may be because TNFa 
driving liver damage was under the direct influence o f IL-15 but the TNFa inducing 
the wider signs o f sepsis was in fact being partly driven by signalling via LPS induced 
TOLL receptors or some other unknown system, independent o f IL-15. Thus,
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neutralisation o f IL-15 might for instance, have reduced only activation o f the TOLL 
2 but not TOLL 4 for example. The possibility that TOLL proteins were in involved 
in the pathogenesis o f sepsis and associated liver injury might be investigated further 
in similar experiments to those o f chapter 4 using mice deficient in the different 
TOLL receptors. The consensus o f the literature indicates that the symptoms o f LPS 
shock are driven by TNFa. The role o f TNFa and IL-15 in LPS induced liver damage 
and shock symptoms might also become clearer if mice deficient in TNFa were used, 
either by pre-treatment with neutralising antibodies or genetic knockout. In a recent 
paper, Ajuwon et al (114), discover that following LPS insult o f primary pig 
adipocytes, IFNy induces IL-15 production. Interestingly, TNFa was not induced 
until at least 8 hours by the LPS. Where as the significance o f this is unclear, it 
implicates upregulation o f IL-15 in a LPS affected cell type yet without a direct link 
to TNFa production. Another recent study by Yajima et al (115), looks at the effect o f 
over expression o f IL-15 in BCG primed mice when exposed to LPS. The mice 
became more susceptible to liver injury when IL-15 was over expressed an example 
of an opposite situation to that seen in the experiment here when liver injury was 
reduced by the reduction o f endogenous IL-15 by sIL-15 receptor therapy, supporting 
the observation o f IL-15 involvement in LPS shock pathogenesis.
In 2002, Biber et al (116) demonstrated a lethal systemic inflammatory 
response in ice co-inoculated with IL-15 and IL-12. NK cells were activated into 
apoptosis and severe shock symptoms were induced. Subsequent blockade of 
interferon gamma and TNFa or IL-16 did not alter this response. Only the depletion 
of NK cells modified the shock response. They proposed that IL-15 and IL-12 were 
synergistically inducing lethality via a TNFa and IFNy independent mechanism, via
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the NK cells. Cooper et al (117) demonstrated how IL-15 deficient mice do not 
develop NK cells. It is odd that when IL-15 was co-injected with IL-12 NK cell 
apoptosis was induced. Many studies suggest that IL-15 has a central role in NK cell 
development.
The mode o f IL-15 driven activation and development o f NK cells has been further 
explored by Wary et al (118) who showed evidence o f NK cell activation through the 
ERK 1 / 2 signal transduction pathway. Immune cell developmental effects o f IL-15 
were also reported by Hiromatsu et al (119). Apoptosis in liver, kidney, lung and 
spleen cells was significantly reduced in mice transgenically over expressing IL-15. 
These mice were resistant to induced E. coli shock and interestingly their TNFa 
levels were the same as non-transgenic IL-15 mice. Hiromatsu suggested that the 
over expression o f IL-15 somehow reduced TNFa induced apoptosis. The protective 
effect o f IL-15 exhibited here seems somewhat at odds with the protective effect o f 
neutralising IL-15 in the LPS experiments reported here. It may be that some 
feedback loop becomes established where IL-15 reduced either TNFa or some other 
disruption in receptor activity trafficking.
In another twist o f the story, Yajima et al (115) demonstrate an increased 
susceptibility to LPS induced liver injury using similar IL-15 transgenic mice when 
the mice were primed with BCG and insulted with LPS. The number o f CD8 T cells 
in the livers o f the IL-15 TG mice was elevated following LPS inoculation. However 
depletion o f the cells saw complete abrogation o f the TG mice’s susceptibility to LPS 
shock. This work suggests a central role for CD8 T cells in the mechanism o f IL-15 
activity in LPS shock.
In the experiments here, almost complete resistance to lethal shock was 
observed in the non-BCG primed mice following insult with LPS. In the latter
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experiments when BCG priming was used, the IL-15Ra therapy again conferred 
protection from LPS induced liver injury and shock symptoms. In reference to the 
work o f  Yajima et al (115) , it may be suggested that the susceptibility o f the mice to 
LPS induced liver damage is mediated by an IL-15 driven CD 8 T cells infiltration. In 
Yajima’s experiment, the depletion o f these cells abrogated the liver damage; 
likewise, it is possible to speculate that following the therapeutic administration o f 
soluble IL-15R alpha, an endogenous IL-15 driven migration o f CD8 T cells was 
averted leading to the observed reduction in liver damage and associated sepsis 
symptoms. With this in mind, future experiments exploring the role o f IL-15 in Shock 
may be served by using IL-15 -/- mice to see if there is a difference in the CD8 T cell 
infiltration as reported by Yajima. In addition, the apoptosis rate o f NK cells, the 
levels o f TNFa and IL-12 could be measured in IL-15 -/- mice. If  exogenous IL-15 
were administered it may be informative to see if the reported reduction o f NK cell 
apoptosis and LPS shock susceptibility were restored to wild type responses.
If it could be confirmed that IL-15 was in fact able to reduce the severity o f LPS 
induced liver injury, it may be that endogenous IL-15 be a possible therapeutic target 
in human incidence o f septic shock. However as a caution, LPS shock model is a 
bolus insult with non-repeating assault on the immune system. The results o f the 
septic arthritis model where the live pathogen was able to colonise far more 
effectively the essential organs o f the mouse in the situation o f reduced endogenous 
IL-15 following therapeutic inoculation o f soluble IL-15 receptor.
It is also worth noting that alongside the research into IL-15, IL-17 has been identified 
as a possible therapeutic target alongside IL-15. Ferretti et al (120) showed that 
following LPS induced lung inflammation in mice, separate infiltrations of
Neutrophils and lymphocytes were observed at days +1 and +2. These immune 
infiltrations were accompanied by increased IL-17. The IL-17 pulse was however 
preceded by increased IL-15 messenger RNA, immediately after the LPS insult. This 
observation lead Ferretti et al to propose that the IL-15 triggers IL-17 which in turn 
drives the neutrophilia leading to the observed airway inflammation. Thus another 
therapeutic target is presented in the inflammatory cascade and a suggestion that 11-15 
may play just a brief transitory role in the pathway to the immune response.
6.5 Septic arthritis Model
The LPS shock model is based on a bolus insult o f LPS. In the final 
experiments conducted in the preparation o f this thesis, the septic arthritis model was 
investigated. Here the initial insult is generated by the injection o f S. aureus, however, 
unlike the “single shot” LPS model, the insult continues and extends as the 
bacteraemia progresses.
Unlike the protective effect against septicaemia observed when therapeutic 
sIL-15Ra was used in the LPS model, there was no evidence o f any similar effect 
here. As the S. aureus infection was not calculated to be a lethal dose (range 1-5 
xlO7), a separate experiment would be required to quantify any effect on mortality 
associated with S. aureus induced sepsis. There were no dramatic differences in either 
symptoms o f sepsis or arthritis following sIL-15Ra therapy compared to placebo. 
This was the case for both the bolus sIL-15Ra therapy and the prolonged sIL-15Ra 
therapy. The summary table (table 9) below compares each o f the results for the two 
experiments. A swift glance indicates that in the absence o f distinct differences, there 
is evidence o f a trend running throughout, indicating a partial abrogation o f arthritis 
and sepsis. However, like the results for the LPS experiments, there is no complete 
abrogation o f sepsis, leading to the possibility that endogenous IL-15 has a brief but 
not exclusive role in the pathogenesis o f sepsis caused by S. aureus infection. This 
may suggest that in this model that the presumptive TNFa driving symptoms o f sepsis 
is not exclusively under the influence o f endogenous IL-15. This is similar to the 
hypothesis for incomplete abrogation o f sepsis in the LPS shock model. Biochemical
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parameters were informative in the LPS experiments above; it may therefore be 
profitable to make similar investigations in a future repetition o f the Septic arthritis 
model too.
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Symptom Bolus (LPS) Prolonged (S. aureus)
Mortality NS NS
Incidence o f Sep NS NS Weak trend
Weight change NS NS
Severity Sep Trend one day sig NS Initial trend
Incidence arth NS Weak trend NS Initial trend
Severity Art Sig Weak trend No trend
Ave limbs inv’d Sig Trends Sig Initial trend
CFUs N/A CFUs higher in IL-15Ra 
except joint tissue.
SEA wk 1 N/A Initially reduced in IL-15Ra
SEA wk 2 N/A Initially reduced in IL-15Ra
Con a wk 1 N/A Reduced in IL-15Ra
Con a wk 2 N/A No trend NS
Table 9
Table comparing overall results in the various parameters investigated in the 
Bolus and the prolonged IL-15Ra therapy experiments in the septic arthritis 
model.
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It is interesting to consider the almost complete abrogation o f arthritis induced 
by endogenous collagen in the CIA experiment o f Ruchatz et al (43) in relation to the 
severity o f arthritis demonstrated in the septic arthritis model here. In spite o f the use 
o f the same therapeutic agent at a similar dose and dosing regimen, there was little or 
no effect on the severity o f  symptoms o f arthritis compared to placebo. One can only 
speculate that there is a separate system driving this damage that is related to the 
bacteria and their antigens. Bremmell (66) reports that S. aureus could bind directly to 
a bone protein called bone sialoprotein in the septic arthritis model. Furthermore, S. 
aureus strains have been shown to bind directly to collagen (102) and fibronectin 
(103). Bremmell suggests that it may be the direct binding o f the bacteria to the 
joint/bone interfaces which directs the arthritis.
In 1994, Abdelnour et al (104) characterised the cell types found at the site o f 
synovitis seen in the septic arthritis model. They reported that initially, Macrophages 
and Granulocytes, staining positively for production o f TNFa and IL-1, had colonised 
the synovium. Later a population o f CD4+ T cells were distinct in the synovium, 
some of which stained positively for IL-2. There was also very little histochemical 
evidence o f MHC class II expression. Abdelnour et al also observed that if they 
depleted the CD4+ T cell population, then the synovitis was reduced in severity 
although not abrogated. They concluded that the appearance o f the cellular infiltration 
o f the septic model caused by injection o f S. aureus was not dissimilar to the infiltrate 
known to be present in non-infectious arthritis disease models.
It is therefore very interesting to ask why the abrogation o f arthritis was 
possible in the CIA model following sIL-15Ra treatment and yet, using the same 
therapeutic agent in the septic arthritis model, there was no abrogation o f the arthritic 
symptoms? There is o f course the fact that the CIA is a bolus challenge o f collagen
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and the septic model there is an active and regenerating live bacterial challenge. 
However, if the pathogenic mediators o f arthritis are proposed to be the same in both 
the septic and CIA models, would it not follow that there would be some greater 
modulation o f the arthritis in the septic model by sIL-15Ra?
The direct binding o f the S. aureus to the bone and joint components may be 
significant in driving a different sort o f response to that seen in CIA and LPS shock 
leading to sepsis and synovitis respectively. The differences in cytokine induction by 
S. aureus derived SEA and LPS were examined by Bjork et al (105). They discovered 
that in-vitro; LPS induced predominantly four cytokines; IL-1 a  and p, TNFa and IL- 
8 . Peak levels o f TNFa occurred within 4 hours. When SEA was used to induce 
cytokines, TNFa was not amongst the dominant cytokines induced by SEA. T-cells 
eventually produced TNFa but this was between 12 and 48 hours following the SEA 
stimulation. This differential expression pattern o f cytokines in response to gramm 
positive and gramm negative toxins is suggested by Bjork et al to be a possible 
explanation o f the differences seen in the speed o f onset in the diseases (and models) 
that arise in response to either E. coli / LPS and S. aureus/SEA infection. Might this 
also be a clue to why the sIL-15Ra was able to abrogate the liver damage o f the LPS 
model but not the sepsis o f the septic arthritis model? Interestingly, IL-2 was not 
found to feature in the LPS induced cytokine pattern but did in the cytokines induced 
by SEA. Perhaps again, in reference to the redundancy o f IL-2 and IL-15, the immune 
response to SEA/S. aureus induced disease is focussed more on the release o f IL-2 
than IL-15. Hence, the neutralisation o f IL-15 would have little effect as demonstrated 
by the results here.
Although removal o f IL-15 by administration o f sIL-15Ra seems to have had 
little effect on the outcome o f arthritis and sepsis with the exception o f a non­
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significant trend for slightly less severe symptoms o f both, there is one aspect o f the 
results that stands out and that is the presence/absence o f S. aureus CFU and the in- 
vitro reactivity o f the splenocytes to exotoxin (SEA and synthetic CON-A).
The presence o f raised CFU levels has been previously reported: Mclnnes et al 
(6 8 ) also reported increased CFUs in the septic arthritis model following IV injection 
o f S. aureus in iNOS knockout mice. In the experiment here, as with the iNOS 
deficient mice, the numbers o f S. aureus colony forming units were markedly 
increased in blood, spleen and kidney tissues compared to both the placebo treated 
mice.
Takano et al (106) neutralised IL-15 using anti-IL-15 monoclonal antibodies. 
They showed that in mice treated with anti-IL-15-mab, there was a significant 
increase in E. coli CFUs in liver spleen and peritoneal cavities. Also they showed that 
there was a reduced proliferation o f y5T cells in response to IL-15 neutralisation. The 
higher numbers o f CFUs indicated a reduced ability o f IL-15 deficient mice to clear S. 
aureus. The presence o f higher S. aureus CFUs indicate that endogenous IL-15 has a 
role in the immune response leading to the clearance o f bacteria from the blood and 
organs. The question remaining regards the exact role o f IL-15 in the clearance 
process.
The spleen cells removed from sIL-15Ra treated mice were less reactive to 
SEA and CON-A than spleen cells from placebo treated mice. It is interesting that 
Gerwein et al (107) reported that the IL-15 driven T cell mitogenesis was down 
regulated by SEA. Not all T cells respond to SEA only previously activated T cells. 
However in the presence o f an experimental dose of IV injected S. aureus, one would 
expect there to be a sizeable population o f activated T cells. The suggestion o f 
Gerwein’s results is that the ability o f T cells to react to SEA was reduced by the
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neutralisation o f IL-15. This may indicate that the presence o f endogenous IL-15 
would normally be synergistic in either the activation o f T cells or by promoting the 
high affinity MHC co-expressed SEA receptors which allow APC independent 
activation o f  the T cells. Gerwien et al had also shown that pre-treatment o f  T cells 
reduced the activation o f Janus Kinase 3 (JAK 3) which is integral to IL-15 signalling.
It is also known that the presence o f IL-15 upregulates IL-2Ra receptor and 
down regulates the IL-15Ra (108). It may be that the role o f IL-15 in septic arthritis is 
very distinct from that suggested by the CIA and LPS shock models. From the results 
in chapters 3, 4 & 5, there seems to be some inconclusive pro-inflammatory action in 
general sepsis and arthritis but nothing as inflammatory as that seen in the liver 
damage o f the LPS model or the mortality protection also exhibited there. 
Furthermore, the septic arthritis results in chapter 5 do not suggest that IL-15 is so 
fundamentally involved as it would appear to be in the arthritis o f the collagen 
induced arthritis model. However, what can be proposed is that there is a role for IL- 
15 in the clearance o f bacteria in gram-positive infections. The nature o f this role is 
unclear. With reference to the differential cytokine pattern reported by Bjork et al 
(105), it may be that IL-15 exerts its effect through up-regulation o f high affinity IL-2 
receptors (Kumaki et al 108) and therefore has only a transitory role before IL-2 itself 
takes over the driving o f the immune response to the pathogen. Also Takano’s 
demonstration (106) o f reduced y5T-cells proliferation may indicate that the role o f 
these T cells might not so much to do with the pathogenesis o f the arthritis but in fact 
to be associated with the normal clearance o f invading bacteria. Hence the 
neutralisation of IL-15 might have been significant in the increased CFUs found in the 
tissues.
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Whereas the LPS model literature showed a possible CD8 T Cell/IL-15 link, 
suggesting a mechanism for the observed protection from the LPS induced symptoms 
o f shock, there was no such clear result or outcome in the two septic arthritis 
experiments; only that there was a slightest trend for amelioration o f synovitis and 
sepsis and possibly o f greater interest, the observed lack o f bacterial clearance o f S. 
aureus from the tissues o f the mice in the therapy groups and the subsequent lack o f 
reactivity o f the spleen cells to bacterial toxins. At the time o f the original write up o f 
this project, all that could be surmised was that the IL-15 somehow could influence 
bacterial clearance.
In recent papers several other aspects o f the bacterial proteins and host 
immune modulators have been examined for a role in the pathogenesis o f sepsis and 
arthritis associated with the septic arthritis model. For example Calander et al (121), 
examined a group o f staphylococcal proteins called exoproteases. When a S. aureus 
strain deficient in these proteases and lysins was tested in the septic arthritis model, 
there was no difference to the wild type control. Similarly, Gjertysson, Nitschke & 
Tarkowski (122) (investigated the possibility that polyclonal B cell and Ig humoural 
responses was important to the resolution o f sepsis and arthritis in the event o f septic 
arthritis. To investigate this they depleted the entire B cell complement. The 
pathogenesis o f sepsis and arthritis was unchanged in spite o f this when compared to 
the controls. The sialic acid binding protein CD22 was also tested for a role in the 
pathogenesis o f septic arthritis but it’s presence or absence was found not to signify 
any difference to the controls.
Two studies have looked at other S. aureus characteristics that can affect 
virulence. In 2002 Jonsson et al (123) studied the influence o f sortase A, a 
staphylococcal coat protein which catalyses cell/bacterial attachment. Using a sortase
deficient mutant o f S. aureus (S. aureus newman SMK3) in the septic arthritis model, 
they demonstrated that a mild response in both sepsis and arthritis compared to the 
wild type S. aureus newman controls.
Interestingly, the authors describe a rapid blood clearance o f the sortase 
mutant in comparison to that o f the control wild type bacterial clearance. They 
furthermore suggest that neutrophils are essential to the clearance because following 
depletion o f neutrophils a severe systemic infection (in spite o f which, the sortase 
mutants were unable to induce any great degree o f septic arthritis!) Jonsson et al 
conclude that the sortase mutant was less virulent. In a later paper Jonsson et al (124) 
describe two distinct sortases; Srt A and Srt B. using mutants, they assigned Srt B as 
having a role in pathogenesis o f infection and Srt A as being a critical virulence factor 
for the induction o f septic arthritis.
So in summary, although recent research has shown that some virulence 
factors endogenous to the S. aureus species, are involved in the pathogenesis o f sepsis 
and arthritis in the septic arthritis model, it is difficult to see exactly what if any 
influence the administration o f soluble receptor had on the observed accumulation o f 
colony forming units in the mice’s tissues following therapeutic intervention.
In an analogous experiment to those these, Takano et al (106) used anti IL-15 
antibodies to deplete endogenous IL-15 in the septic arthritis model. As here, they 
reported increased S. aureus colony forming units and interestingly also reduced 
SEA/T- cell reactivity.
One possible mode of action may depend on the bacteria subduing T cell 
activity allowing direct attachment o f S. aureus to sialic acid residues (via CD22) and 
therefore directly initiating arthritis, furthermore, less reactivity o f T cells to bacterial
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toxins to SEA/TSST etc may allow faster and more effective infection o f tissues and 
organs leading to greater sepsis such as that observed here. As these possible host 
immune defence reactions are exacerbated by administration o f anti IL-15 antibodies 
it may also be worth investigating the possibility that persons succumbing to S. aureus 
infection and septic shock exhibit any polymorphism in their ability to generate 
endogenous IL-15. With respect to IL-15/bacterial interactions, the differential 
activities o f  Srt A and Srt B in sepsis and arthritis in the septic arthritis model, might 
be profitably investigated alongside presence or absence o f IL-15 effect o f soluble IL- 
15R alpha on levels o f activity.
Following the septic arthritis experiment, the role o f IL-15 in septic arthritis 
remains unclear. In collagen arthritis a repetition o f experiments with better quality 
reagents might be informative and possibly mirror the effects o f the receptor seen in 
the experiment o f Ruchatz et al (44). In the case o f LPS shock, there were 
observations of IL-15 acting in a pro-inflammatory role and concomitant abrogation 
or amelioration o f the effects o f LPS was observed following S IL-15 receptor 
therapy. In addition, these observations were not discordant with the literature. In 
summary, the role of IL -15 will be further explored by the results o f ongoing phase 
two pharmaceutical trials o f anti IL-15 therapy in human rheumatoid arthritis. In 
recent reviews, several authors have described many disease states in which IL-15 is 
suspected o f having a contributing, pathogenic role including rheumatoid Arthritis, 
transplant rejection, cancer, irritable bowel disease, dermatitis, pulmonary 
inflammation and AIDS, (125) (126).
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However it can be clearly seen that IL-15 lies to a greater or lesser degree 
deep within the complex cascades o f immune regulators fundamental to the normal 
mammalian response to infection. Depletion o f IL-15 in situations such as LPS shock 
models where the insult is non-repeated is informative however care should be taken 
when knowing out a pro-inflammatory protein that the host doesn’t become subject to 
greater risk o f infection such as evidenced here in the septic arthritis model and 
elsewhere as shown in the literature above. A consideration o f the success o f the anti 
TNFa therapies now commercially being used in inflammatory disease suggests there 
may be a cost/benefit analysis to be considered. Whilst the success is striking there 
are reports o f unusual opportunistic infections in patients receiving these therapies. 
This should not reduce interest in elucidating the role o f IL-15 and other pro- 
inflammatory cytokines and there pursuit as therapeutic targets, merely a caution that 
they were there for some reason and although this project has not uncovered any exact 
role it has shown that there are positive and negative effects to depletion o f IL-15 in 
the LPS and septic arthritis models respectively. The most promising tools that may 
elucidate further the role o f IL-15 in all these disease areas are the emergent 
techniques o f proteomics and genomics, allowing real time visualisation o f 11-15 
genetic and protein products in their sites o f activity and production.
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6.6 Conclusions
In conclusion, the neutralisation o f IL-15 with the mutant IL-15-48 antagonist, 
anti murine IL-15anti serum and sIL-15Ra seems to have a varied potential for 
modulation o f the pathogenesis o f all three models. However in each case there seems 
to be different pathways by which this modulation could be occurring. In future 
experiments, repetition o f the above experiments using IL-15, TNFa and T cell knock 
out mouse strain might be informative. However it is worth paying considerable 
attention to the redundancy o f IL-2 and another recently discovered cytokine IL-21 
which are now defined as members o f the same family o f 4 alpha helix cytokines 
(109) and possible induction o f IL-17 as a mediator o f IL-15 presumptive functions.
215
References
1 Janeway & Travers 1996, Reviewed by Janeway & Travers, Immuno-Biology, 2nd 
edition, Current Books
2 Shimizu Y, van Seventer GA, Horgan KJ, Shaw S. Immunol Rev 1990 Apr;
114:109-43. Roles of adhesion molecules in T-cell recognition: fundamental 
similarities between four integrins on resting human T cells (LFA-1, VLA-4, 
VLA-5, VLA-6 ) in expression, binding, and costimulation
3 Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA, 1991, J 
Exp. Med. Mar 1; 173(3):721-30 Binding of the B cell activation antigen B7 to 
CD28 costimulates T cell proliferation and interleukin2 mRNA accumulation
4 Abbas AK, Murphy KM, Sher A. 1996 Nature Oct 31; 383 (6603): 787-93, 
Functional diversity of helper T lymphocytes.)
5 Salgame P, Abrams J.S., Clayberger C., Goldstein H, Modlin R L, Convit J and 
Bloom B.R, 1991, Science, 254:279-282, Differing lymphokine profiles of 
functional subsets of human CD4 and CD8 T cell clones
6 Parker DC, 1993 Annual Rev. Immunol; 11:331-60, T Cell dependent B cell 
activation)
7 Abbas AK, 1988,Immunol Today, Mar; 9(3): 89-94, A reassessment of the 
mechanisms of antigen-specific T-cell-dependent B-cell activation
8 Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J,
Roessler E and Waldmann TA, 1994, Proc. Natl. Acad. Sci. USA. Vol. 91, 
pp4935-4939, May. A lymphokine, provisionally designated interleukin T and 
produced by a human adult T-cell leukemia line, stimulats T-Cell proliferation 
and the induction of lymphokine-activated killer cells
9 Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, Brennan J,
Roessler E & Waldmann TA, 1994, Proc. Natl. Acad. Sci. USA, Vol. 91 ,pp4940- 
4944, The Interleukin IL(2) receptor □ chain is shared by IL-2 and a cytokine 
provisionally designated IL-T that stimulates T-cell proliferation and the 
induction of lymphokine-activated killer
216
10 Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers 
C, Richardson J, Schoenbom MA, Ahdieh A, Johnson L, Alderson MR, Watson 
JD, Anderson DM, GiriJG, 1994, Science, Vol. 264, 13th May, p965-968; 
Cloning o f a T-cell growth factor that interacts with the b chain o f the interleukin - 
2  receptor.
11 Dirk M Anderson, Lisabeth Johnson, Moira B Glaccum, Neal G Copeland, Debra 
J Gilbert, Nancy A Jenkins, Virginia Valentine, Mark N Kirstein, David N 
Shapiro, Stephan W Morris, Kenneth Grabstein & David Cosman, 1995, 
Genomics 25, p701-706, Chromosomal assignment and genomic structure of IL- 
15) Restriction and linkage data analysis in human and murine DNA indicate that 
IL-15 is located in the central region of chromosomes 4 and 8 respectively.
12 Krause (12) Krause H, Jandrig B, Wernicke C, Bulfone-Paus S, Pohl T, 
Diamantstein T, 1996, Cytokine, Vol. 8 , No. 9, pp667-674. Genomic structure 
and chromosomal localisation of the human IL-15 gene.
13 Armitage RJ, Macduff BM, Eisenman J, Paxton R,and Grabstein KH, 1995, 
Jounal o f Immunology, 154: pp483-490. IL-15 has stimulatory activity for the 
induction of B 11 proliferation and differentiation.
14 (14) (Carson WE, Giri JG, Linndemann J, Linett ML, Ahdieh M, Paxton R, 
Anderson D, Eisenmann J, Grabstein K,and Caligiuri MA. 1994, J. Exp Med. Vol. 
180, October 1994, pp 1395-1403, Interleukin 15 is a novel cytokine that activates 
Human Natural Killer cells via components of the IL-2 receptor
15 Leonard WJ, Noguchi M, Russel, SM, McBride OW, 1994, Immunol. Review, 
Apr: 138:61-86, The molecular basis ofX-linked severe combined 
immunodeficiency and the role of the interleukin-2 receptor gamma chain as a 
common gamma chain, gamma c.
16 Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, 
Park LS, Cosman D and Anderson D, 1994, EMBO, Vol 13, No. 12, pp 2822- 
2830, Utilization of the □ and □ chains ofthe IL-2 receptor by the novel cytokine 
IL-15.
17 Dirk M Anderson, Satoru Kumaki, Minoo Adieh, Jeanette Bertles, Mark 
Tometsko, Aaron Loomis, Judith Giri, Neal G Copeland, Debra J Gilbert, Nancy 
A Jenkins, Virginia Valentine, David N Shapiro, Stephen W Morris, Linda S Park 
& David Cosman, 1995, J Biol. Chem, Vol 270, No 50, December 15, p29862- 
29869. Functional characterization ofthe human interleukin-15 receptor □ chain 
and close linkage ofIL-15RA and LL-2RA genes.
217
18 Richard N Bamford, Andrew P Battiata, Jack D Burton, Harmesh Sharma & 
Thomas A Waldmann, 1996, Proc. Natl. Acad. Sci. USA, Vol 93, pp2897-2902, 
Interleukin 15/(IL-T) prodution by the adult T-cell leukaemia cell line HuT-102 is 
associated with a human T-cell lymphotrophic virus type IRregion/DL-15 fusion 
message that lacks many upstream AUGs that normally attenuate IL-15mRNA 
translation.
19 Raffaella Meazza, Simonetta Verdiani, Roberto Biassoni, Massimiliano 
Coppoleccia, alessia Gaggero, Anna Maria Orengo, Mario P Colombo, Bruno 
Azzarone, Silvano Ferrini, 1996, Oncogene 12, p2187-2192, Identification o f a 
small novel interleukin 15 (IL-15) transcript isoform generated by alternative 
splicing in human small cell lung cancer cell lines.
20 Nishimura H, Washizu J, Nakamura N, Enomoto A and Yoshikai Y, 1998, J.
Immunology, 160: 936-942, Translational Efficiency is upregulated by alternative 
exon in murine EL-15mRNA.
21 Klippel J H, & Crofford L, 1997, Primer on the Rheumatic Diseases, Arthritis
Foundation, USA
22 Ishikawa H & ZiffM, 1976: Arthritis Rheum. 1976Jan-Feb; 19(1): 1-14, Electron 
microscopic observations o f immunoreactive cells in the rheumatoid synovial 
membrane.
23 Buchan G, Barrett K, Turner M, Chantry D, Maini RN,and Feldmann M, 1988; 
Clin. Exp. Immunol: Sep; 73(3): 449-55; Interleukin-1 and tumour necrosis factor 
mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha
24 Xu W.D. Firestein GS, Taetla R, Kaushansky K, and Zvaifler, 1989: J. Clin. 
Invest. Vol. 83, March ; 876-882; Cytokines in chronic inflammatory arthritis
25 Hirano T, Matsuda T, Turner M, Myasaka N, Buchan G, Tang B, Shimizu M, 
Maini R, Feldmann M et al; 1988 Eur J Immunol. Nov; 18(11): 1797-80; 
Excessive production o f interleukin 6 /B cell stimulatory factor-2 in rheumatoid 
arthritis.
26 Brennan FM, zachariae CO, Chantry D, Larsen CG, Turner M, M Matsushima K, 
Feldmann M 1990, Eur J Immunol. Sep; 20(9): 2141-4; Detection o f interleukin 8 
biological activity in synovial fluids from patients with rheumatoid arthritis and 
production of interleukin 8 mRNA by isolated synovial cells and TNF-a
218
27 Chu CQ, Field M, Feldmann M, and Maini RN, 1991 Arthritis and Rheumatism, 
Vol. 34: No. 9, 1125-1132; Localization of Tumour Necrosis Factor a in synovial 
tissues and at the Cartilage-Pannus junction in patients with rheumatoid arthritis
28 Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, brennan 
FM, Walker J, Bilj H, Ghrayeb J, Woody JN, 1993; Arthritis Rheum.
Dec;36(l 2):1681-90; Treatment o f rheumatoid arthritis with chimeric monoclonal 
antibodies to tumor necrosis factor alpha
29 Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN, 1992: Br. J 
Rheumatology, 31, p653-661; Detection of cytokines at the cartilage/pannus 
junction in patients with rheumatoid arthritis; Implications for the role of 
cytokines in cartilage destruction and repair.
30 Firestein GS, Xu WD, Townsend K, Brodie D, Alvaro-Gracia J, Glasebrook A, 
ZvaiflerNJ, 1988, J. Exp. Med. November 1988; 1573-1586; Cytokines in 
chronic Inflammatory arthritis
31 Panayi GS, Lanchbury JS, and Kingsley GH, 1992, Arthritis and Rheumatism, 
Vol. 35 No 7:729-735: The importance ofthe T cell in initiating and maintaining 
the chronic synovitis o f Rheumatoid Arthritis.
32 Komfeld H, Berman JS, Beer DJ & Centre DM, 1985, J. Immunol. 134:3887- 
3890. Induction of human T lymphocyte motility by IL-2.
33 Wilkinson PC & Liew FY, 1995, J. Exp. Med. Vol. 181: 1255-1259, 
Chemoattraction o f human blood T lymphocytes by Interleukin-15.
34 Mclnnes IB, AlMughales J, Field M, Leung B, Huang FP, Dixon R, Sturrock RD, 
Wilkinson PC & Liew FY, 1996 Nature Medicine, 2:175; The role of IL-15 in T 
cell migration and activation in Rheumatoid arthritis.
35 Mclnnes IB, Leung B, Sturrock RD, Field M and Liew FY, 1997 Nature 
Medicine, 3:189; Interleukin-15 mediates T cell dependent regulation ofTNFD 
production in RA.)
36 Feldmann M, Brennan FM & Maini RN, 1996, Ann. Rev. Immunol. 14:397; Role 
of cytokines in Rheumatoid Arthritis.
37 Trentham DE, Townes AS and Kang AH, 1977, J. Exp. Med., 146: 857; Auto­
immunity to type II collagen: an experimental model of arthritis
219
38 Sewell KL, Trentham DE Pathogenesis of rheumatoid arthritis Lancet. 1993 Jan
30;341 (8840)283-6
39 Staines NA, Wooley PH, Collagen arthritis—what can it teach us? Br J 
Rheumatol. 1994 Sep;33(9):798-807
40 Trentham DE.; Novel immunomodulating and immunotherapies, and novel 
therapies and strategies for inflammatory arthropathy. 1992, Curr. Opin. 
Rheumatol. Jun; 4(3): 322-4
41 Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of 
collagen-induced arthritis with an antibody to gp39, the ligand for CD40. 1993, 
Science Sep 3;261(5126):1328-30;
42 Williams RO, Feldmann M, Maini RN, 1992; Proc. Natl. Acad. Sci. USA, Vol. 89 
pp 9784-9788; Anti-tumour necrosis factor ameliorates joint disease in murine 
collagen induced arthritis
43 Ruchatz H, Leung BP, Wei XQ, Mclnnes IB, LiewFY, 1998 J Immunol. 1998 
Jun 1; 160(11): 5654-60. Soluble IL-15 receptor alpha-chain administration 
prevents murine collagen-induced arthritis: a role for IL-15 in development of 
antigen-induced immunopathology
44 Guyton Arthur C, 1986, Textbook of medical physiology, WB Saunders 
company, Philadelphia, USA.
45 Tracey KJ, Fong Y, Hesse D, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami 
A, 1987, Nature, Vol. 330:662; Anti-cachetin/TNF monoclonal antibodies 
prevent shock during lethal bacteraemia
46 Standiford, TJ, Stieter RM, Lukacs NW, Kunkel, 1995 J Immunol. 155:2222- 
2229; neutralization of IL-10 increases lethality in endotoxemia
47 Glauser MP, Zanetti G, Baumgartner Cohen J, 1991; The Lancet, Vol. 338, p 732; 
Septic Shock: pathogenesis
48 Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello C, 
Cerami A, Wolff SM, Wilmore DW; 1988 N Engl J Med. 1988 Jun 9; 318(23):
220
1481-6; Detection of circulating tumor necrosis factor after endotoxin 
administration
49 Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer 
JW, Endres S, Lonnemann G, Corsetti J, Chemow B, et al. J Infect Dis 1990 Jan; 
161(1): 79-84 Circulating interleukin-1 and tumor necrosis factor in septic shock 
and experimental endotoxin fever
50 Tracey KJ, Beutler B, Lowry SF, Menyweather J, Wolpe S, Milsark IW, Hariri 
RJ, Fahey III TJ, Zentella A, Albert JD, Shires T, Cerami A; 1986, Science Vol. 
234, p470; Shock and Tissue injury induced by recombinant human cachetin
51 Beutler B, Milsark IW, Cerami AC 1985 Science Aug 30;229(4716):869-71 
Passive immunization against cachectin/tumor necrosis factor protects mice from 
lethal effect of endotoxin
52 Freudenberg MA, Keppler D, Galanos C, 1986 Infect Immun Mar;51 (3):891 -5 
Requirement for lipopolysaccharide-responsive macrophages in galactosamine- 
induced sensitization to endotoxin
53 Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM 1997 J Endocrinol 
Apr;153(l):l 15-22 (1997) Immunoneutralization o f interleukin-1, tumor necrosis 
factor, interleukin-6  or interferon does not prevent the LPS-induced sick 
euthyroid syndrome in mice
54 Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser 
MP, Baumgartner JD 1992, J. Immunol Mar 15; 148(6): 1890-7;Cytokine 
production after intravenous or peritoneal gram-negative bacterial challenge in 
mice. Comparative protective efficacy o f antibodies to tumor necrosis factor- 
alpha and to lipopolysaccharide
55 Lehmann V, Freudenberg MA, Galanos CJ 1987 Exp. Med. Mar 1; 165(3): 657- 
63 Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and 
D-galactosamine-treated mice
56 Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA
1992 J Immunol Sep 1 ;149(5):1666-70 Evidence for IFN-gamma as a mediator 
of the lethality of endotoxin and tumor necrosis factor-alpha
57 Smith SR, Calzetta A, Bankowski J, Kenworthy-Bott L, Terminelli C, 1993; J 
Leukoc Biol Jul;54(l):23-9 Lipopolysaccharide-induced cytokine production and 
mortality in mice treated with Corynebacterium parvum
221
58 Amiot F, Fitting C, Tracey KJ, Cavaillon JM, Dautry F, 1997; Mol Med 
Dec;3(12):864-75 Lipopolysaccharide-induced cytokine cascade and lethality in 
LT alpha/TNF alpha-deficient mice
59 Smith SR, Terminelli C, Denhardt G, Narula S, Thorbecke GJ; 1996 Cell 
Immunol Nov 1; 173(2):207-l 4; Administration of interleukin-10 at the time o f 
priming protects Corynebacterium parvum-primed mice against LPS- and TNF-a- 
induced lethality
60 Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P, Trinchieri G, 
1995: Eur J Immunol. Mar; 25(3): 672-6; Interleukin-12 is required for interferon- 
gamma production and lethality in lipopolysaccharide-induced shock in mice
61 Shalaby MR, Halgunset J, Haugen OA, Aarset H, Aarden L, Waage A, 
Matsushima K, Kvithyll H, Boraschi D, Lamvik J, et al 1991, Clin Immunol 
Immunopathol Oct;61(1 ):69-82; Cytokine-associated tissue injury and lethality in 
mice: a comparative study
62 Doherty TM, Seder RA, SherA, 1996; J Immunol Jan 15; 156(2): 735-41 
Induction and regulation of IL-15 expression in murine macrophages
63 Goldenberg DL, 1998; Lancet, 351:197-202; Septic Arthritis [review]
64 Goldenberg DL. Arthritis Rheum 1989 Apr;32(4):496-502; Infectious arthritis 
complicating rheumatoid arthritis and other chronic rheumatic disorders.
65 Ostensson A, Geborek P. 1991; Br J Rheumatol Feb;30(l):35-8; Septic arthritis 
as a non-surgical complication in rheumatoid arthritis: relation to disease severity 
and Therapy.
66  Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A. 1991, Infect Immun 
Aug;59(8):2615-23 Experimental Staphylococcus aureus arthritis in mice
67 Bremell T, Abdelnour A, Tarkowski A. 1992; Infect Immun Jul;60(7):2976-85 
Histopathological and serological progression of experimental staphylococcus 
aureus arthritis
222
68  Mclnnes IB, Leung B, Wei XQ, Gemmell CC, Liew FY 1998; J Immunol Jan 
1; 160(1 ):308-l 5 Septic arthritis following Staphylococcus aureus infection in 
mice lacking inducible nitric oxide synthase
69 Zhao YX, Ljungdahl A, Olsson T, Tarkowski A. 1996, Arthritis Rheum 
Jun;39(6):959-67 In situ hybridization analysis o f synovial and systemic cytokine 
messenger RNA expression in superantigen-mediated Staphylococcus aureus 
arthritis
70 Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, 
Kox W. 1997 Nat Med. Jun; 3(6): 678-81 Monocyte deactivation in septic 
patients: restoration by IFN-gamma treatment
71 Sambrooke, Fritsch & Maniatis, (1989) Molecular Cloning, Cold spring Harbour 
laboratory press.
72 Hans Krause, Burkhard Jandrig , Catrin Wernicke, Silvia Bulfone-Paus, Thomas 
Pohl, Tibor Diamantstein 1996, Cytokine, Issue 9 p667-674; Genomic structure 
and chromosomal localization ofthe human interleukin 15 gene (il-15).
73 Sanger F, Nicklen S, Coulson AR. Proc Natl Acad Sci U S A  1977 
Dec;74(12):5463-7DNA sequencing with chain-terminating inhibitors.
74 Sedmak JJ, Grossberg SE. 1977, Anal. Biochem. May 1 ;79(l-2):544-52. A rapid, 
sensitive, and versatile assay for protein using Coomassie brilliant blue.
75 Wooley PH, Luthra HS, Stuart JM, David CS. 1981, J Exp Med Sep 
1 ;154(3):688-700Type II collagen-induced arthritis in mice. I. Major 
histocompatibility complex (I region) linkage and antibody correlates.
76 Cerami A Beutler B, 1988, Immunology Today, Vol. 9, No 1, The role ofTNF in 
endotoxic shock and cachexia
77 Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF & 
Cerami A, 1987, Nature, 330 17 Dec p 662; Anti Cachetin/TNF monoclonal 
antibodies prevent septic shock during lethal bacteraemia
78 Colman RW, 1989, N Eng J Med. May 4; 329(18) 1207-9, The role of plasma 
proteases in septic shock
223
79 Smith SR, Manfra D, Davies L, Terminelli C, Denhart G, Donkin J, 1997 J 
Leucocyte Biology, Vol. 61, p 24-32; Elevated levels of NO in both unchallenged 
and LPS challenged C parvum primed mice are attributable to the activity o f a 
cytokine induced isoform of inos.
80 Parrillo, JE, 1993, N Eng J Med, Vol.238 No 20, p 1471. Pathogenetic 
mechanisms of septic shock.
81 Rossol S, Voth R, Brunner S, Muller WE, Gallati H, Meyer zum Buschenfelde 
KH, Hess G, 1990, Eur J Immunol. Aug; 20 (8) 1761-5; C Parvum; An inducer of 
TNF □ in humans
82 S. Gillis K.A. Smith, Nature 268. 154, 1977
83 Reviewed by C A Dinarello, 1991 Blood 77, 1627 and animal models Ohlsson K 
et al, 1990, Nature, 348, 550
84 Morton and Griffiths (1985), Veterinary Record 116:431 -43 Morton Griffiths 
index
85 Carter DB, Deibel MR Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, 
Berger AE, Bienkowski MJ, Sun FF, McEwan RN, et al. Nature. 1990 Apr 
12;344(6267):584 Purification, cloning, expression and biological 
characterization of an interleukin- 1 receptor antagonist protein
86  (Janson RW, Hance KR, Arend WP J Immunol 1991 Dec 15;147(12):4218-23 
Production of IL-1 receptor antagonist by human in vitro-derived macrophages. 
Effects of lipopolysaccharide and granulocyte-macrophage colony stimulating 
factor
87 Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP J Biol Chem 1991 Jun 
5;266(16):10331 -6  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa 
IL-1 receptor but does not initiate IL-1 signal transduction.
88 Granowitz EV, Clark BD, Mancilla J, Dinarello CA J Biol Chem 1991 Aug 
5;266(22):14147-50 Interleukin-1 receptor antagonist competitively inhibits the 
binding of interleukin-1 to the type II interleukin-1 receptor
89 Onu A, Pohl T, Kause H, Bulphone-Paus S, 1997, J. Immunology, 158, 255-262; 
Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms
224
90 Pettit DK, Bonnert TP, Eisenman J, Srinivasan S, Paxton R, Beers C, Lynch D, 
Miller B, Yost J, Grabstein KH, Gombotz WR 1997; J Biol. Chem. Jan 24; 
272(4): 2312-8; Structure-function studies of interleukin 15 using site-specific 
mutagenesis, polyethylene glycol conjugation, and homology modelling.
91 Cassatella MA, McDonald PP Curr Opin Hematol 2000 May;7(3):l 74-7; 
Interleukin-15 and its impact on neutrophil function
92 Gilbertsen RB, Lesch M, Fantone J : Am J Pathol 1984 Oct;l 17(1 ):26-9 The role
of Neutrophils in type II collagen-induced arthritis in rats
93 (Ming Yin, Micheal D Wheeler, Hiroshi Kono, Blair U Bradford, andle M 
Gallucci, Micheal D Luster and Ronald G Thurman 1999, Gasteroenterology,
117:942-952, Essential role of TNFa in Alchohol-induced liver injury in mice
94 Taguchi I, Oka K, Kitamura K, Sugiura M, Oku A, Matsumoto M. 1999, Inflamm 
Res. Jul;48(7):380-5.Protection by a cyclic AMP-specific phosphodiesterase 
inhibitor, rolipram, and dibutyryl cyclic AMP against Prop ion ibacterium acnes 
and lipopolysaccharide-induced mouse hepatitis
95 Ferluga J, Allison AC. 1978 Lancet Sep 16;2(8090):610-1 Role of mononuclear 
infiltrating cells in pathogenesis o f hepatitis.
96 Involvement of tumor necrosis factor-alpha in the pathogenesis of activated 
macrophage-mediated hepatitis in mice. Gastroenterology. 1991 Apr; 100(4): 
1153-4 Nagakawa J, Hishinuma I, Hirota K, Miyamoto K, Yamanaka T, 
Tsukidate K, Katayama K, Yamatsu I.
97 Tiegs G, Kusters S, Kunstle G, Hentze H, Kiemer AK, Wendel A. 1998 : J 
Pharmacol Exp Ther Dec;287(3):l098-104; Ebselen protects mice against T cell- 
dependent, TNF-mediated apoptotic liver injury
98 Kim DW Exp Mol Med 2001 Apr21;33(l Suppl):101-9 Real time quantitative 
PCR
99 Review by Anthony L Defranco, Locksley and Robertson, 2001 Immunity, The 
Immune response to Infection, New Science Press Ltd, London W IT 4LB.
100 Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, 
Akira S 1999; J Immunol Apr 1 ;162(7):3749-52 : Toll-like receptor 4 (TLR4)- 
deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as 
the Lps gene product
225
101 Musikacharoen T, Matsuguchi T, Kikuchi T, Yoshikai Y 2001; J Immunol Apr 1; 
166(7): 4516-24: NF-kappa B and STAT5 play important roles in the regulation 
o f mouse Toll-like receptor 2-gene expression
102 Holderbaum D, Spech RA, Ehrhart LA Coll Relat Res 1985 Jun;5(3):261-71 
Specific binding of collagen to Staphylococcus aureus
103 Kuusela P 1978. Nature 1978 Dec 14;276(5689):718-20 Fibronectin binds to 
Staphylococcus aureus.
104 Abdelnour A, Bremell T, Holmdahl R, Tarkowski A Scand J Immunol 1994 
Apr;39(4):403-8 Role of T lymphocytes in experimental Staphylococcus aureus 
arthritis
105 Bjork L, Andersson J, Ceska M, Andersson U Cytokine 1992 Nov;4(6):513-9 
Endotoxin and Staphylococcus aureus enterotoxin A induce different patterns of 
cytokines.
106 Takano M, Nishimura H, Kimura Y, Mokuno Y, Washizu J, Itohara S, Nimura Y, 
Yoshikai Y: 1998; Infect Immun Jul;66(7):3270-8 Protective roles o f gamma 
delta T cells and interleukin-15 in Escherichia coli infection in mice
107 Gerwein J, Kaltoft K, Neilson M, Neilson M, Svejgaard A, Geisler C, Ropke C 
and Odum N: 1998 Tissue Antigens: 51 164-173 Staphylococcus enterotoxin A 
modulates il-15 induced signaling and mitogenesis in humans
108 Kumaki S, Armitage R, Ahdieh M, Park L, Cosman D, 1996, Eur J Immunol 26: 
1235-1239.
109 Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, 
Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt 
C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, 
Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, 
Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, 
Kaushansky K, Holly RD, Foster D Nature 2000 Nov 2;408(6808):57-63 
Interleukin 21 and its receptor are involved in NK cell expansion and regulation 
o f lymphocyte function
110 Harb, 2004 J Biol Chem, 2004 Jun 4; 279(23): 24313-22 Identification o f an 
Interleukin-15a Receptor-binding Site on Human Interleukin-15
J. Biol. Chem., Jun 2004; 279:24313 - 24322
226
111 Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, 
MalavasiF, Ponzi AN, Paus R, Bulfone-Paus S.
Human monocytes constitutively express membrane-bound, biologically active, 
andinterferon-gamma-upregulated interleukin-15.Blood. 1999 May 
15;93(10):3531-9.
112 Erwan Mortier, Jerome Bernard, Ariane Piet, and Yannick Jacques
Natural, Proteolytic Release of a Soluble Form of Human IL-15 Receptor a-Chain 
That Behaves as a Specific, High Affinity EL-15 Antagonist 
J. Immunol., Aug 2004; 173:1681 - 1688
113 Nelson et al, 1998 Adv Imunnology 70:1
114 Ajuwon KM, Jacobi SK, Kuske JL, Spurlock ME Interleukin-6  and interleukin-15 
are selectively regulated by lipopolysaccharide and interferon-gamma in primary 
pig adipocytes. Am J Physiol Regul Integr Comp Physiol. 2004 
Mar;286(3):R547-53. Epub 2003 Dec 04
115 Toshiki Yajima,1,2* Hitoshi Nishimura,1 Kimika Saito, 1 Hiroyuki Kuwano,2 and 
Yasunobu Yoshikai1 Overexpression of Interleukin-15 Increases Susceptibility to 
Lipopolysaccharide-induced Liver Injury in Mice Primed with Mycobacterium 
bovis Bacillus Calmette-Guerin Infection and Immunity, July 2004, p. 3855-3862, 
Vol. 72, No. 7
116 Biber JL, Jabbour S, Parihar R, Dierksheide J, Hu Y, Baumann H, Bouchard P, 
Caligiuri MA, Carson WAdministration o f two macrophage-derived interferon- 
gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic 
inflammatory response in mice that is dependent on natural killer cells but does 
not require interferon-gamma.
Cell Immunol. 2002 Mar-Apr;216(1-2):31-42
117 Megan A. Cooper, Jennifer E. Bush, Todd A. Fehniger, Jeffrey B. VanDeusen, 
Ross E. Waite, Yang Liu, Hector L. Aguila, and Michael A. Caligiuri In vivo 
evidence for a dependence on interleukin 15 for survival o f natural killer cells. 
Blood, 15 November 2002, Vol. 100, No. 10, pp. 3633-3638
118 Wary et al, haematological 2004, 89:101-103
12 3 1 1119 Takashi Hiromatsu, ’ Toshiki Yajima, Tetsuya Matsuguchi, Hitoshi Nishimura, 
Worawidh Wajjwalku,4Toshiyuki Arai,2 Yuji Nimura,2and Yasunobu Yoshikai 
Overexpression of Interleukin-15 Protects against Escherichia coli-lnduccd Shock 
Accompanied by Inhibition of TumorNecrosis Factornnr-Induced Apoptosis The 
Journal of Infectious Diseases 2003; 187:1442-1451
227
120 Stephane Ferretti, Olivier Bonneau, Gerald R. Dubois, Carol E. Jones and 
Alexandre Trifilieff4 EL-17, Produced by Lymphocytes and Neutrophils, Is 
Necessary for Lipopolysaccharide-induced Airway Neutrophilia: IL-15 as a 
Possible Trigger. The Journal o f Immunology, 2003,170:2106-2112
121 Calander AM, Jonsson IM, Kanth A, Arvidsson S, Shaw L, Foster SJ, Tarkowski 
A Impact of staphylococcal protease expression on the outcome of infectious 
arthritis Microbes Infect. 2004 Feb;6(2):202-6
122 Gjertsson I, Nitschke L, Tarkowski A The role of B cell CD22 expression in 
Staphylococcus aureus arthritis and sepsis Microbes Infect. 2004 Apr;6(4):377-82
123 Jonsson IM, Mazmanian SK, Schneewind O, Verdrengh M, Bremell T,
Tarkowski A On the role o f Staphylococcus aureus sortase and sortase-catalyzed 
surface protein anchoring in murine septic arthritis J Infect Dis. 2002 May
15;185(10):1417-24. Epub 2002 Apr 22
124 Jonsson IM, Mazmanian SK, Schneewind O, Bremell T, Tarkowski A The role o f 
Staphylococcus aureus sortase A and sortase B in murine arthritis Microbes 
Infect. 2003 Jul;5(9):775-80
125 Waldmann T. IL-15 in the life and death of lymphocytes: immunotherapeutic 
implications Trends Mol Med. 2003 Dec;9(12):517-21
126 Mclnnes and Gracie, Current Mclnnes IB, Gracie JA Interleukin-15: a new 
cytokine target for the treatment of inflammatory diseases Curr Opin Pharmacol. 
2004 Aug;4(4):392-7
127 Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, Malavasi 
F, Ponzi AN, Paus R, Bulfone-Paus S Human monocytes constitutively express 
membrane-bound, biologically active, and interferon-gamma-upregulated 
interleukin-15 Blood. 1999 May 15;93(10):3531 -9
128 Kurowska M, Rudnicka W, Maslinska D, Maslinski W Expression of IL-15 and 
IL-15 receptor isoforms in select structures of human fetal brain Ann N Y Acad 
Sci. 2002 Jun;966:441-5
129
Gupta MN, Sturrock RD, Field MA prospective 2-year study of 75 patients with 
adult-onset septic arthritis.
Rheumatology (Oxford). 2001 Jan;40(l):24-30
130 Gupta MN, Sturrock RD, Field M.
Prospective comparative study of patients with culture proven and high suspicion 
of adult onset septic arthritis.
Ann Rheum Dis. 2003 Apr;62(4):327-31.
228
i  +
131 Olof Hultgren3'*, Hans-Pietro Eugster , Jonathon D. Sedgwick , Heinrich Komer§ 
and Andrzej Tarkowski TNF/Lymphotoxin-Or Double-Mutant Mice Resist Septic 
Arthritis but Display Increased Mortality in Response to Staphylococcus aureus 
The Journal o f Immunology, 1998,161: 5937-5942
132 Kimura M.; Matsukawa A.; Ohkawara S.; Takagi K.; Yoshinaga MBlocking of 
TNF-alpha and IL-1 Inhibits Leukocyte Infiltration at Early, but Not at Late Stage 
of S. aureus -Induced Arthritis and the Concomitant Cartilage Destruction in 
Rabbits Clinical Immunology and Immunopathologv. January 1997, vol. 82, no. 
l,p p . 18-25(8)
133 Margareta Verdrengh, Andrej Tarkowski Role of macrophages in Staphylococcus 
aureus-induced arthritis and sepsis Arthritis & Rheumatism Volume 43, Issue 10, 
Pages 2276 - 2282
134 IB Mclnnes, Abstract, ACR, September 2004
135 Georg Meffert, Frank N Gellerich , Raimund Margreiter and Markus Wyss. 
Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC 
Gastroenterology 2005, 5:9
VList of Abbreviations
5-Bromo-4-Chloro-3-indolyl-P-galactopyranoside..............................................X-GAL
Adenosine triphosphate............................................................................................ ATP
Adenosine...................................................................................................................A
Alanine-amino transferase.......................................................................................ALT
Alkaline phosphotase buffer.....................................................................................CIP
Antigen presenting cell.................................................................................APC
Aquired immume deficiency syndrome............................................................ AIDs
Aspartate-amino transferase................................................................................AST
Base pairs (bp)......................................................................................................bp
Bicinchoninic Acid assay....................................................................................BCA
Bovine serum albumin...................................................................................... BSA
Carbon dioxide...................................................................................................CO2
Collagen induced arthritis..................................................................................CIA.
Colony forming units......................................................................................... CFUs
Complementary DNA........................................................................................ cDNA
Concanavalin-A...............................................................................................CON-A
Copper suphate............................................................................................... CUSO4
Creatine Kinase............................................................................................... CK
Cytosine........................................................................................................... C
Cytotoxic T lymphocyte line.........................................................................CTLL
Dalton......................................................................................................................Da
Deoxynucleictriphosphate............................................................................... dNTP
Deoxyribonucleic acid............................................................................... DNA
Diethylpyrocarbonate......................................................................................DEPC
Dithiothreitol................................................................................................... DTT
Ethylenediaminetetracetic acid..................................................................... EDTA
Effective dose.................................................................................................. ED
Enzyme linked immunosorbent assay.......................................................... ELISA
Escherichia coli.............................................................................................. E. coli
Fetal calf serum...............................................................................................FCS
Granulocyte/monocyte colony stimulating factor........................................GMC-SF
Guanosine.........................................................................................................G
High salt-Phosphate buffered saline.......................................................... HS-PBS
Horse radish peroxidase.................................................................................HRP
Human lymphotrophic virus HTLV-1 ........................................................ HTLV-1
Human serum albumin................................................................................ HSA
Immunoglobulin..............................................................................................Ig
Inducible nitric oxide synthase...................................................................iNOS
Interferon gamma.......................................................................................... IFNy
Interleukin..................................................................................................... IL
Interleukin-15 receptor alpha......................................................................IL-15Ra
Interleukin-2 receptor alpha........................................................................ IL-2Ra
Intracellular adhesion molecule 1.............................................................. ICAM-1
Isopropyl-B-D-thiogalactopyranosamide................................................... IPTG
Janus kinase 3 .............................................................................................. JAK-3
Leucocyte Antigen-1...................................................................................LFA-1
Lipopolysaccharide.....................................................................................LPS
Litre............................................................................................................. L
Long terminal repeat.................................................................................LTR
LPS Binding Protein..................................................................................LBP
Lymphotoxin........................................................................................... LT
Magnesium chloride............................................................................... MgCh
Magnesium sulphate...............................................................................MgSCL
Major Histo-compatibility molecule.....................................................MHC
Messenger ribonucleic acid...................................................................mRNA
Microlitre.....................................................................................................ul
Micromolar.............................................................................................. uM
Milliliter................................................................................................... ml
Millimolar................................................................................................ mM
Murine.....................................................................................................mu
Nanometers............................................................................................ nM
Nitric oxide............................................................................................ NO
Optical density.......................................................................................OD
Phosphate buffered saline.  ................................................................ PBS
Pico gram ..............................................................................................pg
Potassium Chloride..............................................................................KC1
Potassium............................................................................................... K
Reverse transcriptase polymerase chain reaction...............................RT-PCR
Sodium carbonate.................................................................................NaC03
Sodium Chloride.................................................................................. NaCl
Sodium dodecyl sulphate polyacrylamide gel electrophoresis SDS-PAGE
Sodium hydroxide................................................................................NaOH
Staphylococcal enterotoxin-A.....................................................................SEA
Staphylococcus aureus........................................................................ S. aureus
T helper cell 2 .......................................................................................Th2
T-cell receptor....................................................................................... TCR
T-helper cell 1....................................................................................... Thl
Thymidine................................................................................................. T
TOLL like Receptor................................................................................ TLR
Toxic shock syndrome toxin....................................................................TSST
Transforming Growth Factor b e ta ..........................................................TGF-j3
Transgenic................................................................................................. TG
Tumour necrosis factor alpha...................................................................TNFa
Untranslated reg ion ...................................................................................UTR
Uracil........................................................................................................... U
